10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission File Number: 001-36316

AgroFresh Solutions, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	46-4007249
(State or other jurisdiction of incorporation)	(IRS Employer Identification Number)

One Washington Square

510-530 Walnut Street, Suite 1350

Philadelphia, PA 19106

(Address of principal executive offices)

(267) 317-9139

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	AGFS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act). ☐ Yes x No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

The number of shares of common stock outstanding as of October 22, 2020 was 53,054,960.

Table of Contents

TABLE OF CONTENTS

			Page
PART I - FINANCIAL INFORMATION
	Item 1. Condensed Consolidated Financial Statements (Unaudited)
		Condensed Consolidated Balance Sheets	3
		Condensed Consolidated Statements of Operations	4
		Condensed Consolidated Statements of Comprehensive Loss	5
		Condensed Consolidated Statement of Stockholders' Equity	6
		Condensed Consolidated Statement of Cash Flows	7
		Notes to Unaudited Condensed Consolidated Financial Statements	8
	Item 2. Management's Discussion and Analysis of Financial Condition and Result of Operations		25
	Item 3. Quantitative and Qualitative Disclosures About Market Risk		38
	Item 4. Controls and Procedures		38
PART II - OTHER INFORMATION			39
	Item 1. Legal Proceedings		39
	Item 1A. Risk Factors		39
	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		41
	Item 3. Defaults Upon Senior Securities		41
	Item 4. Mine Safety and Disclosures		41
	Item 5. Other Information		41
	Item 6. Exhibits		42
SIGNATURES			43

2

Table of Contents

PART I - FINANCIAL INFORMATION

AgroFresh Solutions, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share and per share data)

	September 30, 2020		December 31, 2019
ASSETS
Current Assets:
Cash and cash equivalents	$	25,149	$	29,288
Accounts receivable, net of allowance for doubtful accounts of $2,025 and $2,232, respectively	69,580		68,634
Inventories	24,444		22,621
Other current assets	17,265		11,802
Total Current Assets	136,438		132,345
Property and equipment, net	13,275		13,177
Goodwill	6,605		6,323
Intangible assets, net	599,236		631,369
Deferred income tax assets	10,502		10,317
Other assets	11,449		12,161
TOTAL ASSETS	$	777,505	$	805,692
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	13,784	$	15,105
Current portion of long-term debt	3,316		4,675
Income taxes payable	7,629		5,648
Accrued expenses and other current liabilities	26,665		24,350
Total Current Liabilities	51,394		49,778
Long-term debt	264,850		398,064
Other noncurrent liabilities	5,989		7,246
Deferred income tax liabilities	35,577		16,574
Total Liabilities	357,810		471,662
Commitments and contingencies (see Note 20)
Series B convertible preferred stock, par value $0.0001; 150,000 and 0 shares authorized, 150,000 and 0 shares designated and outstanding at September 30, 2020 and December 31, 2019, respectively	140,684		—
Stockholders’ Equity:
Common stock, par value $0.0001; 400,000,000 shares authorized, 53,054,960 and 51,839,527 shares issued and 52,393,579 and 51,178,146 outstanding at September 30, 2020 and December 31, 2019, respectively	5		5
Preferred stock, par value $0.0001; 1 share authorized and outstanding at September 30, 2020 and December 31, 2019, respectively	—		—
Treasury stock, par value $0.0001; 661,381 shares at September 30, 2020 and December 31, 2019, respectively	(3,885)		(3,885)
Additional paid-in capital	559,037		561,006
Accumulated deficit	(241,710)		(199,621)
Accumulated other comprehensive loss	(41,164)		(31,060)
Total AgroFresh Stockholders’ Equity	272,283		326,445
Non-controlling interest	6,728		7,585
Total Stockholders' Equity	279,011		334,030
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY	$	777,505	$	805,692

 See accompanying notes to unaudited condensed consolidated financial statements.

3

Table of Contents

AgroFresh Solutions, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except share and per share data)

	Three Months Ended September 30, 2020		Three Months Ended September 30, 2019		Nine Months Ended September 30, 2020		Nine Months Ended September 30, 2019
Net sales	$	52,770	$	48,972	$	105,775	$	109,095
Cost of sales (excluding amortization, shown separately below)	13,511		13,892		28,492		31,516
Gross profit	39,259		35,080		77,283		77,579
Research and development expenses	2,852		2,566		8,389		9,720
Selling, general and administrative expenses	13,494		14,998		39,925		47,044
Amortization of intangibles	10,973		11,754		32,866		35,136
Impairment of long lived assets	—		—		—		992
Change in fair value of contingent consideration	—		(229)		—		128
Grant income	—		—		(2,974)		—
Operating income (loss)	11,940		5,991		(923)		(15,441)
Other income (expense)	96		(81)		1,596		(119)
Debt modification and extinguishment expenses	(5,028)		—		(5,028)		—
Gain (loss) on foreign currency exchange	1,390		54		2,466		(2,884)
Interest expense, net	(4,922)		(8,606)		(18,401)		(26,021)
Gain (loss) before income taxes	3,476		(2,642)		(20,290)		(44,465)
Income taxes expense (benefit)	25,857		(5,653)		22,656		(12,530)
Net (loss) income including non-controlling interests	(22,381)		3,011		(42,946)		(31,935)
Less: Net loss attributable to non-controlling interests	(494)		(278)		(857)		(336)
Net (loss) income attributable to AgroFresh Solutions, Inc	(21,887)		3,289		(42,089)		(31,599)
Less: Dividends on convertible preferred stock	4,400		—		4,400		—
(Loss) income attributable to AgroFresh Solutions, Inc. common stockholders	$	(26,287)	$	3,289	$	(46,489)	$	(31,599)
Net (loss) income per share:
Basic	$	(0.52)	$	0.06	$	(0.92)	$	(0.64)
Diluted	$	(0.52)	$	0.06	$	(0.92)	$	(0.64)
Weighted average shares outstanding:
Basic	51,001,852		50,227,590		50,765,829		50,138,835
Diluted	51,001,852		50,288,304		50,765,829		50,138,835

See accompanying notes to unaudited condensed consolidated financial statements.

4

Table of Contents

AgroFresh Solutions, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(In thousands)

	Three Months Ended September 30, 2020		Three Months Ended September 30, 2019		Nine Months Ended September 30, 2020		Nine Months Ended September 30, 2019
Net (loss) income	$	(22,381)	$	3,011	$	(42,946)	$	(31,935)
Other comprehensive (loss) income:
Unrealized gain (loss) on hedging activity, net of tax of $61, $24, ($81) and $24, respectively	229		83		(304)		83
Recognition of gain on hedging activity reclassified to net loss, net of tax of ($239), ($78), ($398) and ($235), respectively	(857)		(278)		(1,411)		(834)
Foreign currency translation adjustments	296		(3,823)		(8,389)		(903)
Comprehensive loss, net of tax	$	(22,714)	$	(1,007)	$	(53,050)	$	(33,589)

See accompanying notes to unaudited condensed consolidated financial statements.

5

Table of Contents

AgroFresh Solutions, Inc.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share and per share data)

	Preferred Stock			Common Stock			Treasury Stock		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Non-Controlling Interest		Total Stockholders’ Equity
	Shares	Amount		Shares	Amount		Amount
Balances, December 31, 2019	1	$	—	51,839,527	$	5	$	(3,885)	$	561,006	$	(199,621)	$	(31,060)	$	7,585	$	334,030
Stock-based compensation	—	—		—	—		—		2,473		—		—		—		2,473
Issuance of stock, net of forfeitures	—	—		1,178,663	—		—		—		—		—		—		—
Shares withheld for taxes	—	—		(47,599)	—		—		(239)		—		—		—		(239)
Issuance of common stock under employee stock purchase plan	—	—		84,369	—		—		197		—		—		—		197
Convertible preferred dividend	—	—		—	—		—		(4,400)		—		—		—		(4,400)
Comprehensive loss	—	—		—	—		—		—		(42,089)		(10,104)		(857)		(53,050)
Balances, September 30, 2020	1	$	—	53,054,960	$	5	$	(3,885)	$	559,037	$	(241,710)	$	(41,164)	$	6,728	$	279,011

	Preferred Stock			Common Stock		Treasury Stock	Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Non-Controlling Interest		Total Stockholders’ Equity
	Shares	Amount		Shares	Amount	Amount
Balances, June 30, 2020	1	$	—	52,875,089	5	(3,885)	$	562,584	$	(219,823)	$	(40,831)	$	7,222	$	305,272
Stock-based compensation	—	—		—	—	—	872		—		—		—		872
Issuance of stock, net of forfeitures	—	—		187,302	—	—	—		—		—		—		—
Shares withheld for taxes	—	—		(7,431)	—	—	(19)		—		—		—		(19)
Issuance of common stock under employee stock purchase plan	—	—		—	—	—	—		—		—		—		—
Convertible preferred dividend	—	—		—	—	—	(4,400)		—		—		—		(4,400)
Comprehensive (loss) income	—	—		—	—	—	—		(21,887)		(333)		(494)		(22,714)
Balances, September 30, 2020	1	$	—	53,054,960	5	(3,885)	$	559,037	$	(241,710)	$	(41,164)	$	6,728	$	279,011

	Preferred Stock			Common Stock			Treasury Stock		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Non-Controlling Interest		Total Stockholders’ Equity
	Shares	Amount		Shares	Amount		Amount
Balances, December 31, 2018	1	$	—	51,071,573	$	5	$	(3,885)	$	535,819	$	(138,789)	$	(28,837)	$	8,263	$	372,576
Stock-based compensation	—	—		—	—		—		2,256		—		—		—		2,256
Issuance of stock, net of forfeitures	—	—		521,386	—		—		—		—		—		—		—
Comprehensive loss	—	—		—	—		—		—		(31,599)		(1,654)		(336)		(33,589)
Balances, September 30, 2019	1	$	—	51,592,959	$	5	$	(3,885)	$	538,075	$	(170,388)	$	(30,491)	$	7,927	$	341,243

	Preferred Stock			Common Stock			Treasury Stock		Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Non-Controlling Interest		Total Stockholders’ Equity
	Shares	Amount		Shares	Amount		Amount
Balances, June 30, 2019	1	$	—	51,620,770	$	5	$	(3,885)	$	537,259	$	(173,677)	$	(26,473)	$	8,205	$	341,434
Stock-based compensation	—	—		—	—		—		816		—		—		—		816
Forfeiture of stock, net of issuances	—	—		(27,811)	—		—		—		—		—		—		—
Comprehensive income (loss)	—	—		—	—		—		—		3,289		(4,018)		(278)		(1,007)
Balances, September 30, 2019	1	$	—	51,592,959	$	5	$	(3,885)	$	538,075	$	(170,388)	$	(30,491)	$	7,927	$	341,243

See accompanying notes to unaudited condensed consolidated financial statements.

6

Table of Contents

AgroFresh Solutions, Inc.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited)

(in thousands)	Nine Months Ended September 30, 2020		Nine Months Ended September 30, 2019
Cash flows from operating activities:
Net loss	$	(42,946)	$	(31,935)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	34,775		36,692
(Benefit) provision for bad debts	(124)		215
Stock-based compensation	2,473		2,256
Impairment of intangible assets	—		992
Amortization of deferred financing costs	2,342		2,032
Interest income on interest rate swap	(1,809)		(1,070)
Accretion of contingent consideration	—		2,669
Change in fair value of contingent consideration	—		128
Deferred income taxes	18,086		(14,499)
Loss on sales of property and equipment	155		2
Changes in operating assets and liabilities:
Accounts receivable	(4,297)		(1,499)
Inventories	(2,281)		(4,424)
Prepaid expenses and other current assets	(6,784)		(1,429)
Accounts payable	(1,274)		3,855
Accrued expenses and other liabilities	2,344		(2,958)
Income taxes payable	2,846		(95)
Other assets and liabilities	(3,865)		384
Net cash used in operating activities	(359)		(8,684)
Cash flows from investing activities:
Cash paid for property and equipment	(2,131)		(3,271)
Other investments	—		(250)
Net cash used in investing activities	(2,131)		(3,521)
Cash flows from financing activities:
Net proceeds from issuance of convertible preferred stock	145,490		—
Costs associated with issuance of convertible preferred stock	(7,006)		—
Payment of preferred dividends	(2,200)		—
Proceeds from long-term debt	2,042		—
Repayment of long-term debt	(131,599)		(5,056)
Payment of deferred financing costs	(7,988)		—
Proceeds from issuance of stock under employee stock purchase plan	259		—
Net cash used in financing activities	(1,002)		(5,056)
Effect of exchange rate changes on cash and cash equivalents and restricted cash	(1,176)		1,682
Net decrease in cash and cash equivalents and restricted cash	(4,668)		(15,579)
Cash and cash equivalents and restricted cash, beginning of period	29,817		34,852
Cash and cash equivalents, end of period	$	25,149	$	19,273
Supplemental disclosures of cash flow information:
Cash paid for:
Cash paid for interest	$	18,381	$	18,007
Cash paid for income taxes	$	1,733	$	2,469
Supplemental schedule of non-cash investing and financing activities:
Accrued purchases of property and equipment	$	146	$	62

See accompanying notes to unaudited condensed consolidated financial statements.

7

Table of Contents

AgroFresh Solutions, Inc.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1.    Description of Business

AgroFresh Solutions, Inc. (the “Company”) is a global leader in delivering innovative food preservation and waste prevention solutions for fresh produce. The Company is empowering the food industry with a range of integrated solutions designed to help growers, packers and retailers improve produce freshness and quality while preventing waste. The Company has an extensive portfolio of solutions to extend freshness across the produce supply chain from near-harvest up to the point-of-sale. These include HarvistaTM for near-harvest optimization and the SmartFreshTM Quality System, the Company's flagship post-harvest freshness solution. Additional post-harvest freshness solutions include fungicides that can be applied to meet various customer operational requirements in both foggable (ActiMist™) and liquid (ActiSeal™) delivery options. The Company has a controlling interest in Tecnidex Fruit Protection, S.A. (“Tecnidex”), a leading regional provider of post-harvest fungicides, waxes, disinfectants and packinghouse equipment for the citrus market. Beyond apples, SmartFresh technology can provide ready-to-eat freshness for other fruits and vegetables including avocados, bananas, melons, tomatoes, broccoli and mangos. Additionally, LandSpringTM eases transplant shock for higher potential yields. RipeLockTM is the Company's modified atmosphere packaging technology for fruits and vegetables. The Company has key products registered in over 50 countries and supports customers with over 25,000 storage rooms globally.

The end-markets that the Company serves are seasonal and are generally aligned with the seasonal growing patterns of the Company’s customers. For those customers growing, harvesting or storing apples and pears, the Company’s core crops, the peak season in the southern hemisphere is the first and second quarters of each year, while the peak season in the northern hemisphere is the third and fourth quarters of each year. Within each half-year period (i.e., January through June for the southern hemisphere, and July through December for the northern hemisphere) the growing season has historically occurred during both quarters. A variety of factors, including weather and fruit quality, may affect the timing of the growing, harvesting and storing patterns of the Company’s customers and therefore shift consumption of the Company’s services and products between the first and second quarters primarily in the southern hemisphere or between the third and fourth quarters primarily in the northern hemisphere.

2.    Basis of Presentation and Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. These financial statements include all adjustments that are necessary for a fair presentation of the Company's condensed consolidated results of operations, financial condition and cash flows for the periods shown, including normal, recurring accruals and other items. The condensed consolidated results of operations for the interim periods presented are not necessarily indicative of results for the full year. For additional information, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report filed on Form 10-K for the year ended December 31, 2019.

COVID-19

In March 2020, the World Health Organization characterized the coronavirus ("COVID-19") a pandemic, and the President of the United States declared the COVID-19 outbreak a national emergency. The rapid spread of the pandemic and the continuously evolving responses to combat it have had an increasingly negative impact on the global economy. During the three months ended September 30, 2020, as the Company’s primary sales regions moved to the northern hemisphere, the COVID-19 pandemic continued to not have a significant adverse impact on the Company’s results of operations. However, there were numerous obstacles presented and some localized financial impacts of the pandemic, including fluctuations in foreign currency exchange rates and customer demand and spending pattern changes. While the Company is following the requirements of governmental authorities and taking additional preventative and protective measures to ensure the safety of its workforce, including implementing remote working arrangements and varying procedures for essential workforce, the Company cannot be 100% certain there will not be any incidents across its global operations that may cause service interruptions. The rapid development and fluidity of this situation precludes any prediction as to the ultimate material adverse impact of the coronavirus outbreak, although the Company operates in an industry that thus far has not been as severely impacted as others. Nevertheless, the outbreak presents some uncertainty and risk with respect to the Company and its performance and financial results.

Adoption of Highly Inflationary Accounting in Argentina

GAAP requires the use of highly inflationary accounting for countries whose cumulative three-year inflation rate exceeds 100 percent. The Company closely monitors the inflation data and currency volatility in Argentina, where there are multiple data sources for measuring and reporting inflation. In the second quarter of 2018, the Argentine peso rapidly devalued relative to the

8

Table of Contents

U.S. dollar, which along with increased inflation, indicated that the three-year cumulative inflation rate in that country exceeded 100 percent as of June 30, 2018. As a result, the Company adopted highly inflationary accounting as of July 1, 2018 for its subsidiary in Argentina. Under highly inflationary accounting, the functional currency of the Company's subsidiary in Argentina became the U.S. dollar, and its income statement and balance sheet are measured in U.S. dollars using both current and historical rates of exchange. The effect of changes in exchange rates on Argentine peso-denominated monetary assets and liabilities are reflected in earnings. As the three-year cumulative inflation rate exceeded 100 percent as of September 30, 2020, there is no change to highly inflationary accounting. As of September 30, 2020, the Company’s subsidiary in Argentina had a net asset position of $3.0 million. Net sales attributable to Argentina were approximately 6% and 6% of the Company’s consolidated net sales for each of the nine months ended September 30, 2020 and 2019, respectively.

Disaggregation of Revenue

The Company disaggregates revenue from contracts with customers into geographic region, product and timing of transfer of goods and services. The Company determined that disaggregating revenue into these categories achieves the disclosure objective of depicting how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

Revenues for the three months ended September 30, 2020

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	17,122	$	28,906	$	845	$	1,165	$	48,038
Fungicides, waxes, coatings and disinfectants	534		3,011		575		—		4,120
Other*	190		115		210		97		612
	$	17,846	$	32,032	$	1,630	$	1,262	$	52,770
Pattern of Revenue Recognition
Products transferred at a point in time	$	17,663	$	31,921	$	1,420	$	1,165	$	52,169
Services transferred over time	183		111		210		97		601
	$	17,846	$	32,032	$	1,630	$	1,262	$	52,770

Revenues for the three months ended September 30, 2019

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	19,726	$	22,377	$	1,680	$	1,605	$	45,388
Fungicides, waxes, coatings and disinfectants	—		2,857		198		—		3,055
Other*	218		86		108		117		529
	$	19,944	$	25,320	$	1,986	$	1,722	$	48,972
Pattern of Revenue Recognition
Products transferred at a point in time	$	19,802	$	25,238	$	1,877	$	1,605	$	48,522
Services transferred over time	142		82		109		117		450
	$	19,944	$	25,320	$	1,986	$	1,722	$	48,972

9

Table of Contents

Revenues for the nine months ended September 30, 2020

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	19,264	$	37,223	$	23,217	$	11,538	$	91,242
Fungicides, waxes, coatings and disinfectants	534		9,650		1,750		—		11,934
Other*	722		700		938		239		2,599
	$	20,520	$	47,573	$	25,905	$	11,777	$	105,775
Pattern of Revenue Recognition
Products transferred at a point in time	$	19,823	$	46,887	$	25,338	$	11,538	$	103,586
Services transferred over time	697		686		567		239		2,189
	$	20,520	$	47,573	$	25,905	$	11,777	$	105,775

Revenues for the nine months ended September 30, 2019

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	23,084	$	31,965	$	27,503	$	11,287	$	93,839
Fungicides, waxes, coatings and disinfectants	—		11,365		1,458		—		12,823
Other*	954		927		381		171		2,433
	$	24,038	$	44,257	$	29,342	$	11,458	$	109,095
Pattern of Revenue Recognition
Products transferred at a point in time	$	23,380	$	43,374	$	29,159	$	11,309	$	107,222
Services transferred over time	658		883		183		149		1,873
	$	24,038	$	44,257	$	29,342	$	11,458	$	109,095

*Other includes FreshCloud, technical services and sales-type leases related to Tecnidex.

———————————————————————————————————

(1)            North America includes the United States and Canada.

(2)             EMEA includes Europe, the Middle East and Africa.

(3)             Latin America includes Argentina, Brazil, Chile, Costa Rica, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Peru and Uruguay.

(4)             Asia Pacific includes Australia, China, India, Japan, New Zealand, the Philippines, South Korea, Taiwan and Thailand.

Contract Assets and Liabilities

ASC 606 requires an entity to present a revenue contract as a contract asset when the entity performs its obligations under the contract by transferring goods or services to a customer before the customer pays consideration or before payment is due. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g., receivable), before the entity transfers a good or service to the customer. The following table presents changes in the Company’s contract assets and liabilities during the nine months ended September 30, 2020 and the year ended December 31, 2019:

10

Table of Contents

(in thousands)	Balance at January 1, 2020		Additions	Deductions	Balance at September 30, 2020
Contract assets:
Unbilled revenue	$	1,666	11,670	(9,423)	$	3,913
Contract liabilities:
Deferred revenue	$	1,175	4,437	(4,239)	$	1,373

(in thousands)	Balance at January 1, 2019		Additions	Deductions	Balance at December 31, 2019
Contract assets:
Unbilled revenue	$	1,956	10,029	(10,319)	$	1,666
Contract liabilities:
Deferred revenue	$	1,280	3,032	(3,137)	$	1,175

The Company recognizes contract assets in the form of unbilled revenue in instances where services are performed by the Company but not billed by period end. The Company recognizes contract liabilities in the form of deferred revenue in instances where a customer pays in advance for future services to be performed by the Company. The Company generally receives payments from its customers based on standard terms and conditions. No significant changes or impairment losses occurred to contract balances during the nine months ended September 30, 2020. Amounts reclassified from unbilled revenue to accounts receivable for the nine months ended September 30, 2020 and for the year ended December 31, 2019 were $9.4 million and $10.3 million, respectively. Amounts reclassified from deferred revenue to revenue for the nine months ended September 30, 2020 and for the year ended December 31, 2019 were $4.2 million and $3.1 million, respectively.

Recently Issued Accounting Standards and Pronouncements

In January 2017, the Financial Accounting Standards Board ("FASB") issued ASU No. 2017-04, "Intangibles - Goodwill and Other", which simplifies the test for goodwill impairment. The guidance was effective for the Company beginning in the first quarter of fiscal year 2020. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the condensed consolidated financial statements of the Company.

In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments”, which introduces a new

current expense credit loss model to measure impairment on certain types of financial instruments. This update requires an entity to use a forward-looking expected credit loss model for accounts receivable, loans, and other financial instruments. In addition, the FASB issued various amendments during 2018 and 2019 to clarify the provisions of ASU 2016-13. The standard was effective for fiscal years beginning January 1, 2020, including interim periods. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the financial statements of the Company.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify and add

certain disclosure requirements related to fair value measurements covered in Topic 820. The new standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the notes to condensed consolidated financial statements of the Company.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments simplify the accounting for income taxes by removing certain exceptions to the general principles of Topic 740, "Income Taxes" and also improve consistent application by clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted, with the amendments to be applied on a retrospective, modified retrospective or prospective basis, depending on the specific amendment. The Company is currently evaluating the impact of adopting this guidance.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments are intended to ease the potential burden in accounting for, or recognizing the effects of, reference rate

11

Table of Contents

reform on financial reporting. The new standard is effective on a date selected by the Company between March 12, 2020 and December 31, 2022. The Company is currently evaluating the impact of adopting this guidance.

3.     Business Combinations and Asset Acquisition

Business Combination with Dow

On July 31, 2015 (the "Closing Date"), the Company consummated a business combination (the “Business Combination”) pursuant to the Stock Purchase Agreement, dated April 30, 2015 (the “Purchase Agreement”), by and between the Company and The Dow Chemical Company ("Dow") providing for the acquisition by the Company of the AgroFresh business from Dow, resulting in AgroFresh Inc. becoming a wholly-owned, indirect subsidiary of the Company. Pursuant to the Purchase Agreement, the Company paid the following consideration to Rohm and Haas Company (“R&H”), a subsidiary of Dow: (i) 17.5 million shares of common stock and (ii) $635 million in cash.

Pursuant to a Tax Receivables Agreement among the Company, Dow, R&H and AgroFresh Inc. entered into in connection with the consummation of the Business Combination, as amended on April 4, 2017 (as so amended, the “Tax Receivables Agreement”), the Company was required to pay to Dow 50% of the annual tax savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realized as a result of the increase in tax basis of the AgroFresh assets resulting from a Section 338(h)(10) election that the Company and Dow made in connection with the Business Combination. In December 2019, the Tax Receivables Agreement was terminated, and the Company paid to Dow an aggregate of $16 million in settlement of all past and estimated future liabilities that would have been owed under the Tax Receivables Agreement. Based on this termination, the Company recorded a reduction of liabilities of $27.9 million. This reduction, net of deferred income taxes of $5.9 million, has been recorded to additional paid-in capital since the Tax Receivable Agreement was with a related party and is treated as a capital transaction.

Acquisition of Tecnidex

On November 7, 2017, the Company entered into a definitive agreement to acquire a controlling interest in Tecnidex. The transaction was closed on December 1, 2017. Tecnidex is a leading regional provider of post-harvest fungicides, waxes, coatings, and disinfectants for the citrus market, with clients in 18 countries. For over 35 years, Tecnidex has been helping fruit and vegetable producers offer clean, safe and high-quality products to their regional clients. The acquisition was accounted for as a purchase in accordance with ASC 805, Business Combination.

At the effective date of the acquisition, the Company agreed to pay holders of Tecnidex an estimated $25.0 million in cash for 75% of the outstanding capital stock, of which $20.0 million was paid on December 1, 2017. In 2018, the purchase price was finalized as $22.3 million after giving effect to working capital, net debt and other adjustments. The remaining $2.3 million was paid during 2018.

In accordance with the acquisition method of accounting, the Company has allocated the purchase price to the estimated fair values of the identifiable assets acquired and liabilities assumed, with any excess allocated to goodwill. The preliminary assessment of fair value of the contingent consideration payments on the acquisition date was approximately $0.7 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. During the year ended December 31, 2019 there was a final adjustment made to consideration payable to holders of Tecnidex which resulted in a fair value adjustment of $0.4 million.

4.    Related Party Transactions

The Company is a party to an ongoing transition services agreement with Dow, a related party. The Company incurred expenses for such transition services for the nine months ended September 30, 2020 and 2019 of $0.04 million and $0.09 million, respectively. As of September 30, 2020 and December 31, 2019, the Company had outstanding amounts payable to Dow of $0.0 million and $0.1 million, respectively.

On June 13, 2020, in connection with the execution of the Investment Agreement (as defined in Note 15- Series B Convertible Preferred Stock and Stockholders’ Equity), the Company, PSP AGFS Holdings, L.P. (the “Investor”) and R&H entered into a side agreement, pursuant to which the parties agreed that if the Investor or its affiliates has the right to designate at least 50% of the total directors on the Company’s board of directors pursuant to the Investment Agreement, so long as R&H or its affiliates beneficially owns at least 20% of the Company’s outstanding common stock (on a fully diluted, “as converted” basis), the Company and the board of directors will increase the size of the board of directors by one member and the board will elect a

12

Table of Contents

designee selected by R&H to fill the newly-created vacancy. Such right is in addition to any right that R&H has to appoint a member of the board pursuant to its ownership of the Company’s Series A preferred stock (see Note 15- Series B Convertible Preferred Stock and Stockholders’ Equity).

Refer to Note 3 - Business Combinations and Asset Acquisition regarding the contingent consideration owed to Dow as part of the Business Combination, as well as certain other agreements entered into in connection with the Business Combination, including the termination of the Tax Receivables Agreement in 2019.

During 2016, the Company made a minority investment in RipeLocker, LLC ("RipeLocker"), a company led by George Lobisser, a director of the Company. In February 2019, the Company made a further minority investment in RipeLocker. As of and for the nine months ended September 30, 2020, there were no material amounts paid or owed to RipeLocker or Mr. Lobisser.

5.    Inventories

Inventories at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Raw material	$	3,026	$	3,401
Work-in-process	8,575		7,278
Finished goods	11,619		10,974
Supplies	1,224		968
Total inventories	$	24,444	$	22,621

6.     Other Current Assets

The Company's other current assets at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
VAT receivable	$	7,627	$	4,925
Prepaid income tax asset	5,349		3,616
Prepaid and other current assets	4,289		3,261
Total other current assets	$	17,265	$	11,802

7.    Property and Equipment

Property and equipment at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands, except for useful life data)	Useful life (years)	September 30, 2020		December 31, 2019
Buildings and leasehold improvements	7-20	$	7,032	$	6,508
Machinery & equipment	1-12	11,953		10,954
Furniture	1-12	2,944		2,681
Construction in progress		1,149		902
		23,078		21,045
Less: accumulated depreciation		(9,803)		(7,868)
Total property and equipment, net		$	13,275	$	13,177

Depreciation expense was $0.7 million and $0.6 million for the three months ended September 30, 2020 and 2019, respectively, and $1.9 million and $1.6 million for the nine months ended September 30, 2020 and 2019, respectively. Depreciation expense is recorded in cost of sales, selling, general and administrative expense and research and development expense in the condensed consolidated statements of operations.

8.    Goodwill and Intangible Assets

Changes in the carrying amount of goodwill for the nine months ended September 30, 2020 and the year ended December 31, 2019 were as follows:

13

Table of Contents

(in thousands)	September 30, 2020		December 31, 2019
Beginning balance	$	6,323	$	6,670
Foreign currency translation	282		(347)
Ending balance	$	6,605	$	6,323

The Company’s intangible assets at September 30, 2020 and December 31, 2019 consisted of the following:

	September 30, 2020								December 31, 2019
(in thousands)	Gross Carrying Amount		Accumulated Amortization		Impairment		Net		Gross Carrying Amount		Accumulated Amortization		Impairment		Net
Other intangible assets:
Developed technology	$	798,240	$	(244,918)	$	—	$	553,322	$	758,760	$	(206,998)	$	—	$	551,762
In-process research and development	—		—		—		—		39,000		(7,222)		—		31,778
Trade name	27,158		—		—		27,158		27,200		—				27,200
Service provider network	2,000		—		—		2,000		2,000		—		—		2,000
Customer relationships	18,551		(3,548)		—		15,003		18,058		(2,993)		—		15,065
Software	10,691		(8,967)		—		1,724		9,861		(5,347)		(992)		3,522
Other	100		(71)		—		29		100		(58)		—		42
Total intangible assets	$	856,740	$	(257,504)	$	—	$	599,236	$	854,979	$	(222,618)	$	(992)	$	631,369

During 2019, the Company recognized an impairment charge of $1.0 million associated with Verigo software following a partnership agreement with a new technology provider. During the Company's annual impairment testing conducted for the year ended December 31, 2019, the Company accelerated the amortization of Ripelock developed technology based on the Company's remaining expected useful life of the technology. This resulted in an increase to amortization expense of $34.0 million.

At September 30, 2020, the weighted-average amortization periods remaining for developed technology, in-process R&D, customer relationships, software and other was 14.8, 14.0, 12.1, 1.0, and 1.8 years, respectively, and the weighted-average amortization period remaining for these finite-lived intangible assets was 14.6 years.

Estimated annual amortization expense for finite-lived intangible assets subsequent to September 30, 2020 is as follows:

(in thousands)	Amount
2020 (remaining)	$	12,045
2021	41,730
2022	40,893
2023	40,791
2024	40,791
Thereafter	393,828
Total	$	570,078

Amortization expense for intangible assets was $11.0 million and $11.8 million for the three months ended September 30, 2020 and 2019, respectively, and $32.9 million and $35.1 million for the nine months ended September 30, 2020 and 2019, respectively.

9.    Other Assets

The Company’s other assets at September 30, 2020 and December 31, 2019 consisted of the following:

14

Table of Contents

(in thousands)	September 30, 2020		December 31, 2019
Right-of-use asset	$	5,657	$	6,599
Long term sales-type lease receivable	2,354		2,501
Other long term receivable	3,438		3,061
Total other assets	$	11,449	$	12,161

10.    Accrued and Other Current Liabilities

The Company’s accrued and other current liabilities at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Accrued compensation and benefits	$	7,111	$	7,307
Accrued taxes	6,501		3,017
Lease liability	1,368		1,493
Accrued rebates payable	3,001		1,377
Insurance premium financing payable	1,151		1,000
Severance	218		444
Deferred revenue	1,373		1,175
Accrued interest	66		71
Interest rate swap	290		—
Other	5,586		8,466
Total accrued and other current liabilities	$	26,665	$	24,350

Other current liabilities include primarily professional services, litigation and research and development accruals.

11.    Debt

The Company’s debt, net of unamortized deferred issuance costs, at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Total term loan outstanding	$	275,000	$	405,875
Unamortized deferred issuance costs	(9,018)		(3,886)
Tecnidex loan outstanding	2,184		750
Less: Amounts due within one year	3,316		4,675
Total long-term debt due after one year	$	264,850	$	398,064

Restated Credit Facility

On July 27, 2020, the Company completed a comprehensive refinancing (the “Refinancing”) by (i) entering into an Amended and Restated Credit Agreement (the “Restated Credit Agreement”) with the other loan parties party thereto, Bank of Montreal, as administrative agent and the lenders party thereto, and (ii) consummating the transactions contemplated by the Investment Agreement (as defined and described in Note 15 – Series B Convertible Preferred Stock and Stockholders’ Equity). The Restated Credit Agreement amends and restates in its entirety the Prior Credit Facility (defined below).

The Restated Credit Agreement provides for a $25.0 million revolving credit facility (the “Restated Revolving Loan”) which matures on June 30, 2024, and a $275.0 million term credit facility (the “Restated Term Loan” and, together with the Restated Revolving Loan, the “Restated Credit Facility”), which matures on December 31, 2024. The Restated Credit Facility includes a $5.0 million swingline commitment and a $10.0 million letter of credit sub-limit. Loans under the Restated Term Loan bear interest at a rate equal to, at the Company’s option, either the Adjusted Eurodollar Rate for the interest period in effect for such borrowing plus an Applicable Rate of 6.25% per annum, or the Alternate Base Rate plus an Applicable Rate of 5.25% per annum. Loans under the Restated Revolving Loan bear interest at a rate equal to, at the Company’s option, the Adjusted Eurodollar Rate for the interest period in effect for such borrowing plus the Applicable Rate ranging from 6.25% to 6.0% per annum, based on

15

Table of Contents

certain ratios. The interest rate was 7.25% for the three months ended September 30, 2020. The Company is also required to pay a commitment fee on the unused portion of the Restated Revolving Loan at a rate ranging from 0.5% to 0.375%, based on certain ratios. The Company is required to make mandatory prepayments of outstanding indebtedness under the Restated Credit Agreement under certain circumstances.

The obligations of AgroFresh Inc., a wholly-owned subsidiary of the Company and the borrower under the Restated Credit Facility, are initially guaranteed by the Company and the Company’s wholly-owned subsidiary, AF Solutions Holdings LLC (together with AgroFresh Inc. and the Company, the “Loan Parties”) and may in the future be guaranteed by certain other domestic subsidiaries of the Company. The obligations of the Loan Parties under the Credit Agreement and other loan documents are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in all tangible and intangible assets of the Loan Parties, except for certain excluded assets, and equity interests of certain foreign subsidiaries of the Loan Parties held by the Loan Parties (subject to certain exclusions and limitations).

The Refinancing was deemed a partial extinguishment of the Term Loan (as defined below) under ASC Topic No. 470-50, “Debt – Modifications and Extinguishments” (Topic No. 470), whereby $107.1 million of the $403.8 million outstanding at the time of the Refinancing was deemed an extinguishment and $296.7 million was deemed a modification of debt. As such, unamortized deferred issuance costs related to the extinguishment of $0.7 million were written off in debt modification and extinguishment expenses and the remaining $1.9 million was deferred and amortized over the term of the Restated Term Loan.

In connection with the Restated Term Loan, expenses incurred related to existing lenders of $4.4 million were recognized in debt modification and extinguishment expenses. Expenses to new lenders of $1.1 million were deferred and amortized over the term of the Restated Term Loan along with $6.4 million of lender fees and issue discounts.

In total, the Company deferred debt issuance costs of $7.5 million related to the Restated Term Loan, $1.9 million related to the modification of the Term Loan and $0.5 million related to the Restated Revolving Loan. The debt issuance costs associated with the Restated Term Loan were capitalized against the principal balance of the debt, and the Restated Revolving Loan costs were capitalized in Other Assets. All issuance costs will be accreted through interest expense using the effective interest method for the duration of each respective debt facility. The interest expense related to the amortization of the Restated Credit Facility debt issuance costs during the three months ended September 30, 2020 was $0.3 million. As of September 30, 2020 there were $9.0 million of unamortized deferred issuance costs.

At September 30, 2020, there was $275.0 million outstanding under the Restated Term Loan and no balance outstanding under the Restated Revolving Loan. At September 30, 2020, the Company evaluated the amount recorded under the Restated Term Loan and determined that the fair value was approximately $267.4 million. The fair value of the debt is based on quoted inactive market prices and is therefore classified as Level 2 within the valuation hierarchy.

Certain restrictive covenants are contained in the Restated Credit Agreement, and the Company was in compliance with these covenants as of September 30, 2020.

Prior Credit Facility

On July 31, 2015, in connection with the consummation of the Business Combination, AgroFresh Inc. as the borrower and AF Solutions Holdings LLC as the guarantor, entered into a Credit Agreement with Bank of Montreal, as administrative agent (as subsequently amended prior to the Refinancing, the “Prior Credit Facility”). The Prior Credit Facility consisted of a $425.0 million term loan (the “Term Loan”), with an amortization equal to 1.00% per year, and a revolving loan facility (the “Revolving Loan”). The net proceeds of the Term Loan were used to fund a portion of the purchase price payable to Dow in connection with the Business Combination.

The Revolving Loan included a $10.0 million letter-of-credit sub-facility, issuances against which reduce the available capacity for borrowing. The Term Loan had a scheduled maturity date of July 31, 2021. As discussed above, the Prior Credit Facility was refinanced on July 27, 2020, and there were no amounts outstanding as of September 30, 2020. The interest rates on borrowings under the facilities were either the alternate base rate plus 3.75% or LIBOR plus 4.75% per annum, with a 1.00% LIBOR floor (with step-downs in respect of borrowings under the Revolving Loan dependent upon the achievement of certain financial ratios).

As of the Closing Date, the Company incurred approximately $12.9 million in debt issuance costs related to the Term Loan and $1.3 million in costs related to the Revolving Loan. The debt issuance costs associated with the Term Loan were capitalized against the principal balance of the debt, and the Revolving Loan costs were capitalized in Other Assets. The interest expense related to the amortization of the Term Loan debt issuance costs during the three months ended September 30, 2020 and 2019, was approximately $0.2 million and $0.6 million, respectively. The interest expense related to the amortization of the Term Loan

16

Table of Contents

debt issuance costs during the nine months ended September 30, 2020 and 2019 was approximately $1.4 million and $1.7 million, respectively.

Tecnidex Debt

On March 23, 2020, Tecnidex entered into a €1.0 million loan agreement with Banco Santander, S.A., which provides funding through March 2023 at a 1.5% interest rate. In May 2020, Tecnidex entered into a €0.3 million loan agreement with BBVA, which provides funding through May 2025 at a 2.2% interest rate. In July 2020, Tecnidex entered into a €0.6 million loan agreement with Banco Santander, S.A., which provides funding through July 2025 at a 2.5% interest rate.

Scheduled principal repayments of debt subsequent to September 30, 2020 are as follows:

(in thousands)	Amount
2020 (remaining)	$	815
2021	3,348
2022	3,390
2023	3,181
2024 and thereafter	$	266,450
Total	$	277,184

Interest Rate Swap

The Company entered into an interest rate swap contract in August 2019 to hedge interest rate risk remaining outstanding with the Restated Credit Facility. During the three and nine months ended September 30, 2020, an unrealized gain of $0.3 million and an unrealized loss of $0.4 million was recognized, respectively, in connection with this swap, which is still outstanding. The interest rate swap contract matures on December 31, 2020.

The Company entered into an interest rate swap contract in January 2018 to hedge interest rate risk associated with the Term Loan. The hedge was settled in September 2018 for $4.0 million, which is being amortized through December 31, 2020, the remaining period of the original hedge.

PPP Loan

As part of the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"), the Company received a Paycheck Protection Program ("PPP") loan to offset eligible costs incurred during the period. Under the terms of the PPP, PPP loans and accrued interest are forgivable after twenty-four weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the forgiveness period.

As of September 30, 2020, the Company has used the entire loan proceeds to fund its eligible payroll expenses and mortgage interest, avoiding furlough of office employees. As a result, the Company believes that it has met the PPP eligibility criteria for forgiveness and has concluded that the loan represents, in substance, a government grant that is expected to be forgiven. As such, in accordance with IAS 20 “Accounting for Government Grants and Disclosure of Government Assistance” the Company has recognized the entire loan amount as Grant Income at September 30, 2020.

The Company does not anticipate taking any action that would cause any portion of the loan to be ineligible for forgiveness. However, to the extent that any amount is deemed unforgivable, such amount is payable over two to five years at an interest rate of 1%, with a deferral of payments for the first six months.

12.    Leases

The Company enters into lease agreements for certain facilities and vehicles that are primarily used in the ordinary course of business. These leases are accounted for as operating leases, whereby lease expense is recognized on a straight-line basis over the term of the lease.

Most leases include an option to extend or renew the lease term. The exercise of the renewal option is at the Company's discretion. The operating lease liability includes lease payments related to options to extend or renew the lease term if the

17

Table of Contents

Company is reasonably certain of exercising those options. The Company, in determining the present value of lease payments, uses the Company’s incremental secured borrowing rate commensurate with the term of the underlying lease.

Lease expense is primarily included in general and administrative expenses in the condensed consolidated statements of operations. Additional information regarding the Company's operating leases is as follows:

(in thousands)	Three months ended September 30, 2020		Three months ended September 30, 2019		Nine months ended September 30, 2020		Nine months ended September 30, 2019
Operating leases	$	662	$	591	$	1,916	$	1,849
Short-term leases (1)	6		5		182		52
Total lease expense	$	668	$	596	$	2,098	$	1,901

(1)    Leases with an initial term of twelve months or less are not recorded on the balance sheet.

Other information on operating leases	Nine months ended September 30, 2020			Nine months ended September 30, 2019
Cash payments included in operating cash flows	$	1,645		$	1,625
Right-of-use assets obtained in exchange for new lease	$	769		$	376
Weighted average discount rate	9.11		%	9.33		%
Weighted average remaining lease term in years	5.09			5.53

The following table presents the contractual maturities of the Company's lease liabilities as of September 30, 2020:

(in thousands)	Lease Liability
Remainder of 2020	$	485
2021	1,784
2022	1,496
2023	1,228
2024 and thereafter	2,290
Total undiscounted lease payments	7,283
Less: present value adjustment	1,450
Operating lease liability	$	5,833

The following table presents the contractual maturities of the Company's lease liabilities as of December 31, 2019:

(in thousands)	Future lease Payments
2020	$	1,939
2021	1,670
2022	1,509
2023	1,294
2024 and thereafter	2,380
Total undiscounted lease payments	8,792
Less: present value adjustment	1,960
Operating lease liability	$	6,832

13.    Other Noncurrent Liabilities

The Company’s other noncurrent liabilities at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Lease liability	$	4,465	$	5,339
Other (1)	1,524		1,907
Total other noncurrent liabilities	$	5,989	$	7,246

18

Table of Contents

(1) Other noncurrent liabilities include long-term rebates and pension liabilities.

14.    Severance

Severance expense was $0.4 million and $0.3 million for the three months ended September 30, 2020 and 2019, respectively, and $0.5 million and $1.0 million for the nine months ended September 30, 2020 and 2019, respectively. These amounts, which do not include stock compensation expense, were recorded in selling, general and administrative expense in the condensed consolidated statements of operations. As of September 30, 2020 and December 31, 2019, the Company had a $0.2 million and $0.4 million severance liability, respectively.

15.    Series B Convertible Preferred Stock and Stockholders’ Equity

Series B Convertible Preferred Stock

On June 13, 2020, the Company entered into an Investment Agreement (the “Investment Agreement”) with the Investor, an affiliate of Paine Schwartz Partners, LLC (“PSP”), pursuant to which, subject to certain closing conditions, the Investor agreed to purchase in a private placement an aggregate of $150,000,000 of convertible preferred equity of the Company. The transaction closed on July 27, 2020 and a total of 150,000 shares of the Company’s newly-designated Series B-1 Convertible Preferred Stock, par value $0.0001 per share (the “Series B-1 Preferred Stock”) were purchased in such transaction (the “Private Placement”). On September 22, 2020, following the approval of the transactions contemplated by the Investment Agreement by the necessary regulatory body, the Company issued to the Investor, for no additional consideration, a total of 150,000 shares of the Company’s newly-designated Series B-2 Convertible Preferred Stock, par value $0.0001 per share (the “Series B-2 Preferred Stock”). On September 25, 2020 (the "Exchange Date"), the Investor elected to exchange the shares of the Company’s Series B-1 Convertible Preferred Stock and Series B-2 Preferred Stock held by it for a total of 150,000 shares of the Company’s newly-designated Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). Accordingly, effective as of the Exchange Date, the Company issued 150,000 shares of Series B Convertible Preferred Stock, par value $0.0001 per share, to the Investor and all of the shares of Series B-1 Preferred Stock and Series B-2 Preferred Stock held by the Investor were cancelled. No shares of Series B-1 Preferred Stock or Series B-2 Preferred Stock are outstanding as of September 30, 2020.

The Series B Preferred Stock ranks senior to the shares of the Company’s common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Series B Preferred Stock has a liquidation preference of $1,000 per share (the “Stated Value”). Holders of the Series B Preferred Stock are entitled to a cumulative dividend at a rate of 16% per annum, of which 50% will be payable in cash and 50% will be payable in kind until the first anniversary of the Closing Date, after which 50% will be payable in cash, 37.5% will be payable in kind, and the remaining 12.5% will be payable in cash or in kind, at the Company’s option, subject in each case to adjustment under certain circumstances. Dividends on the Series B Preferred Stock are cumulative and payable quarterly in arrears. All dividends that are paid in kind will accrete to, and increase, the Stated Value. The applicable dividend rate is subject to increase by 2% per annum during any period that the Company is in breach of certain provisions of the applicable Certificate of Designation of the Preferred Stock. The Series B Preferred Stock has been classified as temporary equity as it may be contingently redeemable in the event of a change of control, which is outside of the Company's control.

Associated with the Series B Preferred Stock, the Company paid $4.4 million of total dividends, of which $2.2 million were in additional preferred shares and $2.2 million were in cash for the three and nine months ended September 30, 2020, respectively. For the three and nine months ended September 30, 2019, the Company paid no dividends. As of September 30, 2020 and December 31, 2019, the Company had no accrued dividends.

The Series B Preferred Stock is convertible into Common Stock at the election of the holder at any time at an initial conversion price of $5.00 (the “Conversion Price”). The Conversion Price is subject to customary adjustments, including for stock splits and other reorganizations affecting the Common Stock and pursuant to certain anti-dilution provisions for below market issuances. As of September 30, 2020 and December 31, 2019, the maximum number of shares of common stock that could be issued upon conversion of the outstanding shares of Series B Preferred Stock was 30,440,000 and 0 shares, respectively.

The below table outlines the change in Series B Preferred Stock during the nine months ended September 30, 2020.

19

Table of Contents

	Series B-1 Convertible Preferred Stock			Series B-2 Convertible Preferred Stock			Series B Convertible Preferred Stock
(in thousands, except share)	Shares	Amount		Shares	Amount		Shares	Amount
Balance at December 31, 2019	—	$	—	—	$	—	—	$	—
Issuance of preferred stock	150,000	150,000		150,000	—		150,000	150,000
Exchange to Series B preferred stock	(150,000)	(150,000)		(150,000)	—		—	—
Issuance-related expenses	—	—		—	—		—	(11,516)
Additional preferred shares	—	—		—	—		—	2,200
Balance at September 30, 2020	—	$	—	—	$	—	150,000	$	140,684

In connection with the consummation of the Investment Agreement, the Company and the Investor entered into a Registration Rights Agreement (the “Registration Rights Agreement”), dated as of July 27, 2020. The Registration Rights Agreement provides that the Company will use its commercially reasonable efforts to prepare and file a shelf registration statement with the SEC no later than the first business day following January 27, 2022, and to use its commercially reasonable efforts to cause such shelf registration statement to be declared effective as promptly as is reasonably practicable after its filing to permit the public resale of registrable securities covered by the Registration Rights Agreement. The registrable securities generally include any shares of the Company’s common stock into which the Series B Preferred Stock is convertible, and any other securities issued or issuable with respect to any such shares of common stock by way of share split, share dividend, distribution, recapitalization, merger, exchange, replacement or similar event or otherwise.

Common Stock

The authorized common stock of the Company consists of 400,000,000 shares with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share of common stock. As of September 30, 2020, there were 52,393,579 shares of common stock outstanding.

Warrants

On July 31, 2020, all outstanding warrants, consisting of warrants to purchase 15,983,072 shares of the Company’s common stock outstanding at a strike price of $11.50, expired. Of the 15,983,072 warrants, 9,823,072 were issued as part of the units sold in the Company's initial public offering in February 2014 (1,201,928 warrants were subsequently repurchased during 2015) and 6,160,000 warrants were sold in a private placement at the time of such public offering.

Series A Preferred Stock

In connection with and as a condition to the consummation of the Business Combination, the Company issued R&H one share of Series A Preferred Stock. R&H, voting as a separate class, is entitled to appoint one director to the Company’s board of directors for so long as R&H beneficially holds 10% or more of the aggregate amount of the outstanding shares of common stock and non-voting common stock of the Company. The Series A Preferred Stock has no other rights.

ATM Facility

In December 2018, the Company filed a shelf registration statement (File No. 333-229002) (the “Form S-3 Shelf”) with the Securities and Exchange Commission, that became effective in February 2019. On June 25, 2020, the Company established an at-the-market offering facility (the “ATM Facility”) under the Form S-3 Shelf, with Virtu Americas LLC, acting as sales agent with support from H.C. Wainwright & Co and Roth Capital Partners. The Company’s board of directors approved sales of up to $30,000,000 maximum aggregate offering of the Company’s common stock under the ATM Facility. Effective as of August 7, 2020, the Company suspended sales under its ATM Facility, in light of the Company’s recent completion of the Refinancing and current market conditions. No sales have been effected pursuant to the ATM Facility to date.

16.    Stock-based Compensation

In July 2015, the Company adopted the 2015 Incentive Compensation Plan (as amended, the “Plan”), pursuant to which the Compensation Committee of the Company is authorized to grant up to 7,150,000 shares to officers and employees of the Company, in the form of equity-based awards, including time or performance based options and restricted stock.

20

Table of Contents

In June 2019, the Company's shareholders approved the 2019 Employee Stock Purchase Plan (the "ESPP"), which became effective July 1, 2019. 500,000 shares of common stock are reserved for issuance under the ESPP. As of September 30, 2020, 253,042 shares had been issued under the ESPP.

Stock compensation expense for equity-classified and liability-classified awards was $0.9 million and $1.0 million for the three months ended September 30, 2020 and 2019, respectively. Stock compensation expense for equity-classified and liability-classified awards was $2.7 million and $2.1 million for the nine months ended September 30, 2020 and 2019, respectively. Stock compensation expense is recognized in cost of goods sold, selling, general and administrative expenses and research and development expenses. At September 30, 2020, there was $5.3 million of unrecognized compensation cost relating to outstanding unvested equity instruments expected to be recognized over the weighted average period of 1.9 years.

17.    Earnings Per Share

Basic (loss) income per share is calculated by dividing net (loss) income by the weighted average number of common shares outstanding for the period. The Company had a loss for the nine months ended September 30, 2020 and 2019. Therefore, the effect of stock-based awards including options, restricted stock, restricted stock units and warrants outstanding at September 30, 2020 and 2019, respectively, have not been included in the computation of diluted loss per share because their inclusion would have been anti-dilutive.

The following is a reconciliation of the weighted-average common shares outstanding used for the computation of basic and diluted net (loss) income per common share:

	Three Months Ended September 30, 2020	Three Months Ended September 30, 2019	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2019
Basic weighted-average common shares outstanding	51,001,852	50,227,590	50,765,829	50,138,835
Effect of dilutive options, performance stock units and restricted stock	—	60,714	—	—
Diluted weighted-average shares outstanding	51,001,852	50,288,304	50,765,829	50,138,835

Securities that could potentially be dilutive are excluded from the computation of diluted (loss) income per share when a loss from continuing operations exists, when the exercise price exceeds the average closing price of the Company's common stock during the period, or for contingently issued shares, if the contingency is not met at the end of the reporting period, because their inclusion would result in an anti-dilutive effect on per share amounts.

The following represents the weighted-average number of shares that could potentially dilute basic earnings per share in the future:

	Three Months Ended September 30, 2020	Three Months Ended September 30, 2019	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2019
Convertible preferred stock	21,526,522	—	7,227,883	—
Stock-based compensation awards(1):
Stock options	799,570	1,028,583	804,267	949,987
Restricted stock to non-directors	1,811,016	749,510	1,079,151	624,930
Warrants:
Private placement warrants	2,075,652	6,160,000	4,788,613	6,160,000
Public warrants	3,309,948	9,823,072	7,636,184	9,823,072

(1)             SARs and Phantom Shares are payable in cash so will have no impact on number of shares.

Warrants and options are considered anti-dilutive and excluded when the exercise price exceeds the average market value of the Company’s common stock price during the applicable period.

18.    Income Taxes

The provision for income taxes consists of provisions for federal, state and foreign incomes taxes. The effective tax rates for the periods ended September 30, 2020 and September 30, 2019, reflect the Company’s expected tax rate on reported income (loss)

21

Table of Contents

from continuing operations before income tax and tax adjustments. The Company operates in a global environment with significant operations in the U.S. and various other jurisdictions outside the U.S. Accordingly, the consolidated income tax rate is a composite rate reflecting the Company’s earnings and the applicable tax rates in the various jurisdictions where the Company operates.

On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act. The CARES Act includes tax changes and financial aid designed to protect the American people from the public health and economic impacts of COVID-19. The tax changes include allowing net operating losses to be carried back five years, suspending the 80% of taxable limitation on the use of net operating losses, an increase of the 30% of EBITDA limitation on the deduction of interest expense to 50%, and acceleration of the refund for alternative minimum tax credits granted under the 2017 Tax Cuts and Jobs Act (“TCJA”). Most significant to the Company are the modifications on the limitation of business interest deductions for tax years beginning in 2019 and 2020. The modifications to Section 163(j) increase the allowable business interest deduction from 30% to 50% of adjusted taxable income.

The Company's U.S. operations have incurred cumulative taxable losses through September 30, 2020. The Company’s U.S. net operating loss carry forwards and carry forwards of other tax attributes are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. The utilization of the tax attributes may become restricted in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, as well as similar state tax provisions. This could limit the amount of the tax attributes that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will generally be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Please refer to Note 4 regarding the ownership change in the quarter ended September 30, 2020. The Company completed a Section 382 study and determined the ownership change gave rise to the restrictions that will limit the realizability of certain U.S. tax attributes.

Typically, the Company has calculated its provision for income taxes during its interim reporting periods by applying an estimate of the annual effective tax rate for the full year "ordinary" income or loss for the respective reporting period. For the nine months ended September 30, 2020, the Company has computed its provision for income taxes under the discrete method which allows the Company to calculate its tax provision based upon the actual effective tax rate for the year-to-date. The discrete method was determined to be an appropriate method for estimating its tax provision for the nine months ended September 30, 2020 as it provides a reliable estimate as opposed to changes in estimated "ordinary" income or loss which would have resulted in significant fluctuations when estimating the annual effective tax rate.

The effective tax rate for the nine months ended September 30, 2020 differs from the U.S. statutory tax rate of 21%, primarily because of changes in valuation allowance positions related to the United States and certain foreign jurisdictions and by foreign exchange currency gains, offset by foreign provision to return tax benefits, primarily in France. The Company recorded an increase of $24.7 million in the valuation allowance for the three months ended September 30, 2020, primarily as a result of the ownership change that will limit the realizability of certain U.S. tax attributes.

The Company's effective tax rate for the three and nine months ended September 30, 2020 was 743.9% and (111.7)%, respectively, compared to the effective tax rate for the three and nine months ended September 30, 2019 of 214.0% and 28.2%, respectively.

19.    Segment Information

The authoritative guidance for disclosures about segments of an enterprise establishes standards for reporting information about segments. It defines operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. We currently operate and manage our business as two operating segments. Our chief operating decision-makers allocate resources and assess performance of the business for each segment. Accordingly, we consider ourselves to have two operating and reportable segments (i) AgroFresh core and (ii) Tecnidex. AgroFresh core business is providing produce preservation and waste prevention solutions for growers and packers. Its products include SmartFresh, Harvista, RipeLock and FreshCloud. Tecnidex is a provider of fungicides, disinfectants, waxes and coatings primarily focused on the citrus market.

Our chief operating decision-maker does not evaluate operating segments using asset or liability information. The following table presents a breakdown of our revenues and gross profit based on reportable segments for the three and nine months ended September 30, 2020 and 2019.

22

Table of Contents

(in thousands)	Three Months Ended September 30, 2020		Three Months Ended September 30, 2019		Nine Months Ended September 30, 2020		Nine Months Ended September 30, 2019
AgroFresh Core
Revenues	$	49,343	$	45,917	$	94,723	$	96,272
Gross Profit	38,283		34,182		73,080		72,679
Tecnidex
Revenues	3,427		3,055		11,052		12,823
Gross Profit	976		898		4,203		4,900
Total Revenues	$	52,770	$	48,972	$	105,775	$	109,095
Total Gross Profit	$	39,259	$	35,080	$	77,283	$	77,579

20.    Commitments and Contingencies

The Company is currently involved in various claims and legal actions that arise in the ordinary course of business. The Company has recorded reserves for loss contingencies based on the specific circumstances of each case. Such reserves are recorded when it is probable that a loss has been incurred as of the balance sheet date and can be reasonably estimated. Although the results of litigation and claims can never be predicted with certainty, the Company does not believe that the ultimate resolution of these actions will have a material adverse effect on the Company’s business, financial condition or results of operations.

On October 14, 2019, the Company was awarded a verdict of $31.1 million in damages, related to, among other things, trade secret misappropriation and willful patent infringement, in its litigation against Decco Post-Harvest, Inc. ("Decco") and Decco's parent company, UPL Limited. The award is subject to post-verdict review by the Court and any appeals that may be taken by the parties in the future.

In July 2020, three separate putative class action lawsuits were filed against the Company, each alleging that the Company’s disclosures regarding the transactions contemplated by the Investment Agreement contained in its proxy statement for the 2020 annual meeting of the Company’s stockholders were inadequate.

Purchase Commitments

The Company has various purchasing contracts for contract manufacturing and research and development services which are based on the requirements of the business. Generally, the contracts are at prices not in excess of current market prices and do not commit the business to obligations outside the normal customary terms for similar contracts.

21.    Fair Value Measurements

Liabilities Measured at Fair Value on a Recurring Basis

The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of September 30, 2020:

(in thousands)	Level 1		Level 2		Level 3		Total
Liability-classified stock compensation (1)	$	—	$	—	$	294	$	294
Interest rate swap	—		—		290		290
Total	$	—	$	—	$	584	$	584

The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2019:

(in thousands)	Level 1		Level 2		Level 3		Total
Liability-classified stock compensation (1)	$	—	$	—	$	218	$	218
Interest rate swap	—		—		(95)		(95)
Total	$	—	$	—	$	123	$	123

23

(1) The fair values of phantom stock units were estimated using a Monte Carlo simulation pricing model with the assumptions described below:

	September 30, 2020
Grant date fair value	$	1.70		—	$7.28
Risk-free interest rate	0.27		%	—	2.39%
Expected life (years)	2.71			—	2.75
Estimated volatility factor	65.1		%	—	69.9%
Expected dividends	None

There were no transfers between Level 1 and Level 2 and no transfers out of Level 3 of the fair value hierarchy during the nine months ended September 30, 2020.

At September 30, 2020, the Company evaluated the amount recorded under the Restated Term Loan and determined that the fair value was approximately $267.4 million. The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value.

Changes in Financial Instruments Measured at Level 3 Fair Value on a Recurring Basis

The following table presents the changes during the period presented in the Company's Level 3 financial instrument liabilities that are measured at fair value on a recurring basis.

(in thousands)	Liability-classified stock compensation		Interest rate swap		Total
Balance, December 31, 2019	$	218	$	(95)	$	123
Stock compensation activity	76		—		76
Mark-to-market adjustment	—		385		385
Balance, September 30, 2020	$	294	$	290	$	584

24

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

As used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), the terms “Company,” “AgroFresh,” “we,” “us” and “our” refer to AgroFresh Solutions, Inc. and its consolidated subsidiaries, unless the context otherwise requires or it is otherwise indicated.

The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto contained elsewhere in this Report.

This MD&A contains the financial measures EBITDA and Adjusted EBITDA, which are not presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). These non-GAAP financial measures are being presented because management believes that they provide readers with additional insight into the Company’s operational performance relative to earlier periods and relative to its competitors and they are key measures used by the Company to evaluate its performance. The Company does not intend for these non-GAAP financial measures to be a substitute for any GAAP financial information. Readers of this MD&A should use these non-GAAP financial measures only in conjunction with the comparable GAAP financial measures. A reconciliation of EBITDA and Adjusted EBITDA to the most comparable GAAP measure is provided in this MD&A.

Note Regarding Forward-Looking Statements

All statements other than statements of historical fact included in this Report including, without limitation, statements in this MD&A regarding the Company's financial position, business strategy and the plans and objectives of management for future operations, are forward looking statements. When used in this Report, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the Company or its management, identify forward looking statements. Such forward looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. Actual results and/or the timing of events could differ materially from those contemplated by these forward-looking statements due to a number of factors, including those discussed under the heading “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019 (the "2019 Form 10-K") as well as the update to those Risk Factors disclosed in Part II, Item 1A of this Report. Any forward-looking statements included in this Report are based only on information currently available to the Company and speak only as of the date on which such statements are made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. All subsequent written or oral forward-looking statements attributable to the Company or persons acting on behalf of the Company are qualified in their entirety by this paragraph.

Business Overview

AgroFresh is a global leader in delivering innovative food quality preservation and waste prevention solutions for fresh produce. The Company is empowering the food industry with a range of integrated solutions designed to help growers, packers and retailers improve produce freshness and quality while reducing waste. AgroFresh has key products registered in over 50 countries and supports customers with over 25,000 storage rooms globally. AgroFresh has an extensive portfolio of freshness solutions ranging from LandSpringTM for transplanted seedlings, near-harvest with HarvistaTM and post-harvest including its flagship SmartFreshTM technology. Additional post-harvest freshness solutions include fungicides that can be applied to meet various customer operational requirements, in either a foggable (ActiMist™) or liquid (ActiSeal™) delivery form. To supplement our near- and post-harvest product solutions, our suite of FreshCloud™ analytical, diagnostic and tracking services provide a range of value-added capabilities that help customers optimize the quality of their produce. Beyond apples, SmartFresh technology can provide ready-to-eat freshness for other fruits and vegetables including avocados, bananas, melons, tomatoes, broccoli and mangos. AgroFresh is also providing customers with packaging-based advisory services and custom packaging solutions including RipeLock, our packaging-based freshness technology solutions for fruits and vegetables.

In December 2017, AgroFresh acquired a controlling interest in Tecnidex. With this acquisition, AgroFresh expanded its post-harvest presence into additional crops, and increased its penetration of the produce market in southern Europe, Latin America and Africa. This acquisition expanded AgroFresh's product portfolio into waxes and coatings and reinforced its position in fungicides. For over 35 years, Tecnidex has been helping fruit and vegetable producers offer clean, safe and high-quality produce to customers, now reaching 18 countries. Through its portfolio of post-harvest fungicides, coatings, waxes, disinfectants, equipment and associated consulting and after-sale services, Tecnidex improves the quality and value of its clients’ fruit and vegetables while respecting the environment. Tecnidex further diversified AgroFresh’s revenue by expanding the Company's ability to provide solutions and service to the citrus industry.

25

Table of Contents

Freshness is the most important driver of consumer satisfaction when it comes to produce and, at the same time, lack of freshness results in waste which is a major issue in the industry. About one third of the total food produced worldwide is lost or wasted each year. Nearly 45% of all fresh fruits and vegetables, 40% of apples and 20% of bananas, are lost to spoilage. AgroFresh plays a key role in the value chain by offering products and services that maintain produce freshness and reduce waste.

AgroFresh’s current flagship product, SmartFresh, regulates the post-harvest ripening effects of ethylene, the naturally occurring plant hormone that triggers ripening in certain fruits and vegetables. SmartFresh is naturally biodegradable, leaves no detectable residue and has been approved for use by many domestic and global regulatory organizations. Harvista extends the Company’s proprietary technology into the field, including treatment of cherries and blueberries early in the growing season and near-harvest management of apples and pears. FreshCloud Storage InsightsTM is an atmospheric monitoring system that leverages the Company's extensive understanding of fruit physiology, fruit respiration, controlled atmosphere technology and new proprietary diagnostic tools to provide improved real-time guidance to producers and packers of fresh produce regarding storage conditions so timely corrective measures can be taken. LandSpringTM is an innovative 1-MCP technology targeted to transplanted vegetable seedlings. It is currently registered for use on tomatoes, peppers and 14 other crops in the U.S. It reduces transplant shock, resulting in less seedling mortality and faster crop establishment, which leads to a healthier crop and improved yields.

AgroFresh’s business is highly seasonal, driven by the timing of harvests in the northern and southern hemispheres. For apples and pears, the first half of the year is when the southern hemisphere harvest occurs and the second half of the year is when the northern hemisphere harvest occurs. Since the northern hemisphere harvest of apples, our primary crop, is typically larger, a significant portion of our sales and profits are historically generated in the second half of the year. In addition to this seasonality, factors such as weather patterns may impact the timing of the harvest within the two halves of the year. Diversifying into other crops is a key strategy to balance seasonality, therefore there is a strategic importance of the Tecnidex acquisition since the citrus harvest in northern hemisphere countries occurs in the last and first quarters of the year.

On July 31, 2015 (the “Closing Date”), we consummated a business combination (the “Business Combination”) pursuant to a Stock Purchase Agreement, dated April 30, 2015 (the “Purchase Agreement”), with Dow, providing for the acquisition by us of the AgroFresh business from Dow. In connection with the closing of the Business Combination, we entered into a tax receivables agreement (the "TRA"), as amended in April 2017, pursuant to which Dow was entitled to receive 50% of the tax savings, if any, that the Company realized as a result of the increase in the tax basis of assets acquired pursuant to the Business Combination. The TRA was terminated in December 2019. Also in connection with the closing of the Business Combination, AgroFresh entered into a transition services agreement with Dow. Under the agreement, Dow provided AgroFresh a suite of services for a period of time ranging from six months to five years depending on the service. While most of the Dow-provided services were complete as of December 31, 2018, certain services are expected to continue through 2020.

Factors Affecting the Company’s Results of Operations

The Company’s results of operations are affected by a number of external factors. Some of the more important factors are briefly discussed below.

Impact of COVID-19

In March 2020, the COVID-19 outbreak was declared a National Public Health Emergency which continues to spread throughout the world and has adversely impacted global activity and contributed to significant declines and volatility in financial markets. The outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. During the three months ended September 30, 2020, as the Company’s primary sales regions moved to the northern hemisphere, the COVID-19 pandemic continued to not have a significant adverse impact on our results of operations. However, there were numerous obstacles presented and some localized financial impacts of the pandemic, including fluctuations in foreign currency exchange rates and customer demand and spending pattern changes. While we are following the requirements of governmental authorities and taking additional preventative and protective measures to ensure the safety of our workforce, including implementing remote working arrangements and varying procedures for essential workforce, we cannot be 100% certain that there will not be any incidents across our global operations that may cause service interruptions. The rapid development and fluidity of this situation precludes any prediction as to the ultimate material adverse impact of the coronavirus outbreak, although the Company operates in an industry that thus far has not been as severely impacted as others. Nevertheless, the outbreak presents some uncertainty and risk with respect to the Company and its performance and financial results.

26

Table of Contents

Demand for the Company’s Offerings

The Company services customers in over 50 countries and derives its revenue by assisting growers and packers to optimize the value of their crops primarily through the post-harvest period. Its products and services add value to customers by reducing food spoilage and extending the life of perishable fruits. The U.S. Food and Agriculture Organization of the United Nations has estimated that a growing global population will require a near doubling of food production in developing countries by 2050 to meet the expected demand of a worldwide population of nine billion people.

This global trend, among others, creates demand for the Company’s solutions. The Company’s offerings are currently protected by patent filings in 51 countries.

The global produce market is a function of both the size and the yield of the crop harvested, and variations in either will affect total production. Given the nature of the agricultural industry, weather patterns may impact total production and the Company's resulting commercial opportunities. The Company supports a diverse customer base whose end markets vary due to the type of fruit and quality of the product demanded in their respective markets. Such variation across end markets also affects demand for the Company’s services.

Customer Pricing

The Company’s service offerings are priced based on the value they provide to the Company’s customers. From time to time, the Company may adjust its pricing policy to incorporate new offerings or address market and volume trends. The Company does not typically price its products in relation to any underlying cost of materials or services; therefore, its margins can fluctuate with changes in these costs. The Company’s pricing may include rebate arrangements with customers in exchange for mutually beneficial long-term relationships and growth.

Integrated Service Model

AgroFresh uses a direct service model to offer the Company’s commercially available products, including SmartFresh and Harvista. Sales and technical support personnel maintain face-to-face relationships with customers year round. Technical sales and support personnel work directly with customers to provide value-added advisory services regarding the application of SmartFresh. The actual application of SmartFresh is performed by service providers that are typically third-party contractors or, for some product variations, made by our customers directly. The Harvista application service, through both aerial and ground application, is also administered by third-party service providers or made by our customers directly.

Most of the Company’s service providers are operating under multi-year contracts. Management believes the quality and experience of its service providers deliver clear commercial benefits.

Seasonality

The Company’s operations are subject to seasonal variation due to the timing of the growing seasons around the world. For our core crops of apples and pears, northern hemisphere growers harvest from August through November, and southern hemisphere growers harvest from late January to early May. As we diversify into other crops, such as citrus, we also anticipate seasonal variations in this business due to the northern hemisphere citrus harvest, which spans from October to March. Since the majority of the Company’s sales are in northern hemisphere countries, a proportionately greater share of its revenue is realized during the second half of the year. There are also variations in the seasonal demands from year to year depending on weather patterns and crop size. This seasonality and variations in seasonal demand could impact the ability to compare results between periods.

Foreign Currency Exchange Rates

With a global customer base and geographic footprint, the Company generates revenue and incurs costs in a number of different currencies, with the Euro comprising the most significant non-U.S. currency. Fluctuations in the value of these currencies relative to the U.S. dollar can increase or decrease the Company’s overall revenue and profitability as stated in U.S. dollars, which is the Company’s reporting currency. In certain instances, if sales in a given geography have been adversely impacted on a long-term basis due to foreign currency depreciation, the Company has been able to adjust its pricing so as to mitigate the impact on profitability.

27

Table of Contents

Domestic and Foreign Operations

The Company has both domestic and foreign operations. Fluctuations in foreign exchange rates, regional growth-related spending in research and development (“R&D”) and marketing expenses, and changes in local selling prices, among other factors, may impact the profitability of foreign operations in the future.

Critical Accounting Policies and Use of Estimates

Critical accounting policies are those accounting policies that can have a significant impact on the presentation of our financial condition and results of operations and that require the use of complex and subjective estimates based upon management’s judgment. Because of the uncertainty inherent in such estimates, actual results may differ materially from these estimates. There have been no material changes to our critical accounting policies and estimates previously disclosed in the 2019 Form 10-K. For a description of our critical accounting policies and estimates as well as a listing of our significant accounting policies, see “Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Use of Estimates” and “Note 2 - Basis of Presentation and Summary of Significant Accounting Policies” in the 2019 Form 10-K. 

28

Table of Contents

Results of Operations

The following table summarizes the results of operations for the three and nine months ended September 30, 2020 and September 30, 2019:

(in thousands)	Three Months Ended September 30, 2020		Three Months Ended September 30, 2019		Nine Months Ended September 30, 2020		Nine Months Ended September 30, 2019
Net sales	$	52,770	$	48,972	$	105,775	$	109,095
Cost of sales (excluding amortization, shown separately below)	13,511		13,892		28,492		31,516
Gross profit	39,259		35,080		77,283		77,579
Research and development expenses	2,852		2,566		8,389		9,720
Selling, general and administrative expenses	13,494		14,998		39,925		47,044
Amortization of intangibles	10,973		11,754		32,866		35,136
Impairment of long lived assets	—		—		—		992
Change in fair value of contingent consideration	—		(229)		—		128
Grant income	—		—		(2,974)		—
Operating income (loss)	11,940		5,991		(923)		(15,441)
Other income (expense)	96		(81)		1,596		(119)
Debt modification and extinguishment expenses	(5,028)		—		(5,028)		—
Gain (loss) on foreign currency exchange	1,390		54		2,466		(2,884)
Interest expense, net	(4,922)		(8,606)		(18,401)		(26,021)
Gain (loss) before income taxes	3,476		(2,642)		(20,290)		(44,465)
Income taxes expense (benefit)	25,857		(5,653)		22,656		(12,530)
Net (loss) income including non-controlling interests	(22,381)		3,011		(42,946)		(31,935)
Less: Net loss attributable to non-controlling interests	(494)		(278)		(857)		(336)
Net (loss) income attributable to AgroFresh Solutions, Inc	(21,887)		3,289		(42,089)		(31,599)
Less: Dividends on convertible preferred stock	4,400		—		4,400		—
(Loss) income attributable to AgroFresh Solutions, Inc. common stockholders	$	(26,287)	$	3,289	$	(46,489)	$	(31,599)

Comparison of Results of Operations for the three months ended September 30, 2020 versus the three months ended September 30, 2019.

Net Sales

Net sales were $52.8 million for the three months ended September 30, 2020, as compared to net sales of $49.0 million for the three months ended September 30, 2019, an increase of 7.8%. The impact of the change in foreign currency exchange rates compared to the third quarter of 2019 increased revenue by $1.1 million. Excluding this impact, revenue increased approximately 5.6%. The net sales increase was primarily the result of SmartFresh growth in Europe due in part to the normalization of harvest seasonality versus prior year, increased traction of Harvista in European markets, and positive contributions from Tecnidex.

Cost of Sales

Cost of sales was $13.5 million for the three months ended September 30, 2020, as compared to $13.9 million for the three months ended September 30, 2019. Gross profit margin was 74.4% for the three months ended September 30, 2020 versus 71.6% for the three months ended September 30, 2019. The higher gross margin was primarily the result of the Company's supply chain efficiencies and further supported by price discipline.

29

Table of Contents

Research and Development Expenses

Research and development expenses were $2.9 million and $2.6 million, respectively, for the three months ended September 30, 2020 and September 30, 2019.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $13.5 million for the three months ended September 30, 2020, compared to $15.0 million for the three months ended September 30, 2019, a decrease of 10.0%. Included in selling, general and administrative expenses were $0.4 million in the current year and $1.6 million in the prior year of costs associated with non-recurring items that included M&A, litigation, refinancing and severance costs. Excluding these items, selling general and administrative expenses decreased approximately 1.6% in the third quarter versus the prior year period, which reflects the Company's ongoing cost optimization initiatives, as well as a temporary decrease in travel and other miscellaneous expenses as a result of the global pandemic.

Amortization of Intangibles

Amortization of intangible assets was $11.0 million for the three months ended September 30, 2020, compared to $11.8 million for the three months ended September 30, 2019. The reduction in the amortization expense for the three months ended September 30, 2020 is due to the accelerated amortization of RipeLock in December 2019 of $38.0 million, which resulted in lower quarterly amortization of $0.6 million.

Impairment of Intangibles

There were no indicators of impairment during the three months ended September 30, 2020 and September 30, 2019.

Change in Fair Value of Contingent Consideration

The Company recorded no gain or loss for the three months ended September 30, 2020 related to a change in the fair value of contingent consideration, as compared to a $0.2 million gain in the three months ended September 30, 2019. As discussed in Note 3 - Business Combinations and Asset Acquisition of the unaudited condensed consolidated financial statements, pursuant to the Business Combination the Company entered into various forms of contingent consideration, including the tax amortization benefit contingency. These liabilities are measured at fair value each reporting date and any mark-to-market fluctuations are recognized in earnings. In December 2019, the TRA with Dow was terminated, and the Company paid to Dow an aggregate of $16 million in settlement of all past and estimated future liabilities that would have been owed under the TRA. The fair value adjustment of the contingent consideration related to the Tecnidex acquisition was settled in 2019.

Other Income (Expense)

Other income was $0.1 million for the three months ended September 30, 2020, as compared to expense of $0.1 million for the three months ended September 30, 2019.

Debt Modification and Extinguishment Expenses

The Company recognized debt modification and extinguishment expense of $5.0 million for the three months ended September 30, 2020 as a result of closing the Restated Credit Facility as discussed in Note 11 - Debt of the unaudited condensed consolidated financial statements and below. There was no such expense recognized during the three months ended September 30, 2019.

Interest Expense, Net

Interest expense was $4.9 million for the three months ended September 30, 2020, as compared to $8.6 million for the three months ended September 30, 2019. The decrease was primarily due to $1.9 million lower interest on the long-term debt due to a lower variable rate and principal balance and $0.9 million lower accretion on the TRA due to the settlement of the TRA in December 2019 and an increase in hedge income of $0.7 million.

Gain (loss) on Foreign Currency

Gain on foreign currency was $1.4 million for the three months ended September 30, 2020, as compared to a gain of $0.1 million for the three months ended September 30, 2019.

30

Table of Contents

During the three months ended September 30, 2020, foreign currency gains were recognized related to U.S. dollar intercompany payables to the Brazilian real and Turkish lira, which grew weaker relative to the U.S. dollar.

Income Taxes

Income tax expense was $25.9 million for the three months ended September 30, 2020, compared to income tax benefit of $5.7 million for the three months ended September 30, 2019. During the three months ended September 30, 2020, the Company recorded a valuation allowance of $24.7 million, primarily as a result of the ownership change (related to the new preferred stock investment) that will limit the realizability of certain U.S. tax attributes. For the three months ended September 30, 2019, the quarter’s largest effective tax rate modification related to the elimination of intercompany profits resulted in an income tax benefit.

Comparison of Results of Operations for the nine months ended September 30, 2020 versus the nine months ended September 30, 2019.

Net Sales

Net sales were $105.8 million for the nine months ended September 30, 2020, as compared to net sales of $109.1 million for the nine months ended September 30, 2019, a decrease of 3.0%. The impacts of the change in foreign currency rates reduced revenue by $2.7 million for the nine months ended September 30, 2020. Excluding this impact, revenue decreased approximately 0.5%. The slight decrease in net sales on a constant currency basis was primarily the result of geographic mix, where the relatively strong sales in the EMEA and APAC regions were more than offset by relatively weaker sales in the North America and Latin America regions.

Cost of Sales

Cost of sales was $28.5 million for the nine months ended September 30, 2020, as compared to $31.5 million for the nine months ended September 30, 2019. Gross profit margin was 73.1% for the nine months ended September 30, 2020 versus 71.1% for the nine months ended September 30, 2019. The year over year improvement was a result of the supply chain cost optimizations that were implemented at the end of 2019 and are expected to carry through the balance of 2020.

Research and Development Expenses

Research and development expenses were $8.4 million and $9.7 million, respectively, for the nine months ended September 30, 2020 and September 30, 2019. The decrease in research and development expenses for the nine months ended September 30, 2020 was partially driven by the timing of projects.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $39.9 million for the nine months ended September 30, 2020 compared to $47.0 million for the nine months ended September 30, 2019, a decrease of 15.1%. There were non-recurring costs associated with M&A, litigation, refinancing and severance in the amount of $2.8 million in the current year and $6.9 million in the prior year period. Excluding these items, selling general and administrative expenses decreased approximately 7.6% over the same period last year driven by ongoing cost optimization initiatives, and to a lesser extent, the temporary decrease in travel and other miscellaneous expenses as a result of the global pandemic.

Amortization of Intangibles

Amortization of intangible assets was $32.9 million for the nine months ended September 30, 2020, compared to $35.1 million for the nine months ended September 30, 2019. The reduction in the amortization expense for the nine months ended September 30, 2020 is due to the accelerated amortization of RipeLock in December 2019 of $38.0 million, which resulted in lower amortization of $1.9 million during the period.

31

Table of Contents

Impairment of Intangibles

There were no indicators of impairment during the nine months ended September 30, 2020. The Company recorded an impairment charge of $1.0 million during the nine months ended September 30, 2019 associated with the Verigo software following a partnership agreement with a new technology provider.

Change in Fair Value of Contingent Consideration

The Company recorded no gain or loss for the nine months ended September 30, 2020, as compared to a $0.1 million loss in the nine months ended September 30, 2019. As discussed in Note 3 - Business Combinations and Asset Acquisition of the unaudited condensed consolidated financial statements, pursuant to the Business Combination the Company entered into various forms of contingent consideration, including the tax amortization benefit contingency. These liabilities are measured at fair value each reporting date and any mark-to-market fluctuations are recognized in earnings. In December 2019, the TRA with Dow was terminated, and the Company paid to Dow an aggregate of $16 million in settlement of all past and estimated future liabilities that would have been owed under the TRA. The fair value adjustment of the contingent consideration related to the Tecnidex acquisition was settled in 2019.

Grant Income

The Company recorded income of $3.0 million in the nine months ended September 30, 2020. Pursuant to the CARES Act, the Company received a Paycheck Protection Program loan to offset eligible costs incurred during the period. As the Company believes it is in compliance with the forgiveness criteria under this loan program, the full amount was recognized as grant income.

Other Income (Expense)

Other income was $1.6 million for the nine months ended September 30, 2020, as compared to $0.1 million expense for the nine months ended September 30, 2019. The Company received $1.6 million in cash from settlement of a litigation matter during the nine months ended September 30, 2020.

Debt Modification and Extinguishment Expenses

The Company recognized debt modification and extinguishment expenses of $5.0 million for the nine months ended September 30, 2020 as a result of closing the Restated Term Facility as discussed in Note 11 - Debt of the unaudited condensed consolidated financial statements and below. There was no such expense recognized during the nine months ended September 30, 2019.

Interest Expense, Net

Interest expense was $18.4 million for the nine months ended September 30, 2020, as compared to $26.0 million for the nine months ended September 30, 2019. The decrease was primarily due to $4.9 million lower interest on long-term debt due to a lower variable rate and principal balance and $2.6 million lower accretion on the TRA due to the settlement of the TRA in December 2019.

Gain (loss) on Foreign Currency

Gain on foreign currency was $2.5 million for the nine months ended September 30, 2020, as compared to a loss of $2.9 million for the nine months ended September 30, 2019.

During the nine months ended September 30, 2020, foreign currency gains were recognized related to the U.S. dollar and euro intercompany payables to Turkish lira, South African rand and Brazilian real, which experienced inflation during the period, offset by foreign currency losses recognized in Argentina due to inflation during the period and hyperinflationary accounting. During the nine months ended September 30, 2019, the loss was primarily related to foreign currency losses in Argentina due to inflation during the period and hyperinflationary accounting.

Income Taxes

Income tax expense was $22.7 million for the nine months ended September 30, 2020, compared to income tax benefit of $12.5 million for the nine months ended September 30, 2019. During the nine months ended September 30, 2020, there was an increase in the valuation allowance, primarily as a result of the ownership change that will limit the realizability of certain U.S. tax

32

Table of Contents

attributes. For the nine months ended September 30, 2019, the period’s largest effective tax rate modification related to the elimination of intercompany profits resulted in an income tax benefit.

33

Table of Contents

Non-GAAP Measures

The following table sets forth the non-GAAP financial measures of EBITDA and Adjusted EBITDA. The Company believes these non-GAAP financial measures provide meaningful supplemental information as they are used by the Company’s management to evaluate the Company’s performance (including incentive bonuses and for bank covenant reporting), are more indicative of future operating performance of the Company, and facilitate a better comparison among fiscal periods. These non-GAAP results are presented for supplemental informational purposes only and should not be considered a substitute for the financial information presented in accordance with GAAP.

The following is a reconciliation between the non-GAAP financial measures of EBITDA and Adjusted EBITDA to their most directly comparable GAAP financial measure, net loss:

(in thousands)	Three Months Ended September 30, 2020		Three Months Ended September 30, 2019		Nine Months Ended September 30, 2020		Nine Months Ended September 30, 2019
GAAP net (loss) income including non-controlling interests	$	(22,381)	$	3,011	$	(42,946)	$	(31,935)
Expense (benefit) for income taxes	25,857		(5,653)		22,656		(12,530)
Interest expense (1)	4,922		8,606		18,401		26,021
Depreciation and amortization	11,630		12,356		34,775		36,692
Non-GAAP EBITDA	$	20,028	$	18,320	$	32,886	$	18,248
Share-based compensation	943		959		2,705		2,111
Severance related costs (2)	356		344		430		1,040
Other non-recurring costs (3)	—		1,297		2,383		6,305
(Gain) loss on foreign currency exchange (4)	(1,390)		(54)		(2,466)		2,884
Debt modification and extinguishment costs	5,028		—		5,028		—
Mark-to-market adjustments, net (5)	—		(229)		—		128
Impairment of intangible assets (6)	—		—		—		992
Grant income	—		—		(2,974)		—
Litigation recovery	—		—		(1,600)		—
Non-GAAP Adjusted EBITDA	$	24,965	$	20,637	$	36,392	$	31,708

(1)    Interest on debt, accretion for debt discounts, debt issuance costs and contingent consideration.

(2)     Severance costs related to ongoing cost optimization initiatives.

(3)    Costs related to certain professional and other infrequent or non-recurring fees, including those associated with refinancing, litigation and M&A related fees.

(4)    (Gain) loss on foreign currency exchange relates to net losses and gains resulting from transactions denominated in a currency other than the entity's functional currency.

(5)    Non-cash adjustment to the fair value of contingent consideration, including the TRA and contingent payment related to the Tecnidex acquisition.

(6)    Impairment of intangible assets related to software.

The following is a reconciliation between net sales on a non-GAAP constant currency basis to GAAP net sales:

(in thousands)	Three Months Ended September 30, 2020		Three Months Ended September 30, 2019		Nine Months Ended September 30, 2020		Nine Months Ended September 30, 2019
GAAP net sales	$	52,770	$	48,972	$	105,775	$	109,095
Impact from changes in foreign currency exchange rates	(1,064)		—		2,738		—
Non-GAAP constant currency net sales (1)	$	51,706	$	48,972	$	108,513	$	109,095

(1)     The company provides net sales on a constant currency basis to enhance investors’ understanding of underlying business trends and operating performance, by removing the impact of foreign currency exchange rate fluctuations. The impact from foreign currency, calculated on a constant currency basis, is determined by applying prior period average exchange rates to current year results.

34

Table of Contents

Liquidity and Capital Resources

Cash Flow

(in thousands)	Nine Months Ended September 30, 2020		Nine Months Ended September 30, 2019
Net cash used in operating activities	$	(359)	$	(8,684)
Net cash used in investing activities	$	(2,131)	$	(3,521)
Net cash used in financing activities	$	(1,002)	$	(5,056)

Cash used in operating activities was ($0.4) million for the nine months ended September 30, 2020, as compared to cash used in operating activities of ($8.7) million for the nine months ended September 30, 2019. In 2020, net income before non-cash depreciation and amortization was ($8.2) million. Other non-cash charges included stock-based compensation of $2.5 million, $2.3 million of deferred financing costs, a $18.1 million increase in net deferred taxes and interest income recognized on the interest rate swap of ($1.8) million. Additionally, the change in net operating assets was ($13.3) million in 2020. For the nine months ended September 30, 2019, net loss before non-cash depreciation and amortization and changes in fair value of contingent consideration (including accretion) was $7.6 million. Other non-cash charges included interest income recognized on the interest rate swap of ($1.1) million, stock-based compensation of $2.3 million, $2.0 million of deferred financing costs, a ($14.5) million increase in net deferred tax assets, impairment of $1.0 million and other non-cash items of $0.2 million. Additionally, the change in net operating assets was ($6.2) million for the nine months ended September 30, 2019.

Cash used in investing activities was ($2.1) million for the nine months ended September 30, 2020, as compared to ($3.5) million for the nine months ended September 30, 2019. Cash used in investing activities in 2020 was for the purchase of fixed assets and leasehold improvements of ($2.1) million. Cash used in 2019 was for the purchase of fixed assets and leasehold improvements of ($3.3) million and other investments of ($0.3) million.

Cash used in financing activities was ($1.0) million for the nine months ended September 30, 2020, as compared to ($5.1) million for the nine months ended September 30, 2019. Cash used in financing activities in 2020 was for the repayment of debt in the amount of ($131.6) million, payment of deferred financing costs of ($8.0) million, payment of preferred stock costs of ($7.0) million and payment of dividends of ($2.2) million, offset by proceeds from the issuance of preferred stock, net of issuance costs of $145.5 million, long-term borrowings of $2.0 million and proceeds from the issuance of stock of $0.3 million. Cash used in 2019 was for the repayment of debt in the amount of ($5.1) million.

Liquidity

At September 30, 2020, we had $25.1 million of cash and cash equivalents, compared to $29.3 million at December 31, 2019.

Restated Credit Facility

On July 27, 2020, the Company completed a comprehensive refinancing (the “Refinancing”) by (i) entering into an Amended and Restated Credit Agreement (the “Restated Credit Agreement”) with the other loan parties party thereto, Bank of Montreal, as administrative agent and the lenders party thereto, and (ii) consummating the transactions contemplated by the Investment Agreement (as defined and described below). The Restated Credit Agreement amends and restates in its entirety the Prior Credit Facility (defined below).

The Restated Credit Agreement provides for a $25.0 million revolving credit facility (the “Restated Revolving Loan”) which matures on June 30, 2024, and a $275.0 million term credit facility (the “Restated Term Loan” and, together with the Restated Revolving Loan, the “Restated Credit Facility”), which matures on December 31, 2024. The Restated Credit Facility includes a $5.0 million swingline commitment and a $10.0 million letter of credit sub-limit. Loans under the Restated Term Loan bear interest at a rate equal to, at the Company’s option, either the Adjusted Eurodollar Rate for the interest period in effect for such borrowing plus an Applicable Rate of 6.25% per annum, or the Alternate Base Rate plus an Applicable Rate of 5.25% per annum. Loans under the Restated Revolving Loan bear interest at a rate equal to, at the Company’s option, the Adjusted Eurodollar Rate for the interest period in effect for such borrowing plus the Applicable Rate ranging from 6.25% to 6.0% per annum, based on certain ratios. The interest rate was 7.25% for the three months ended September 30, 2020. The Company is also required to pay a commitment fee on the unused portion of the Restated Revolving Loan at a rate ranging from 0.5% to 0.375%, based on certain ratios. The Company is required to make mandatory prepayments of outstanding indebtedness under the Restated Credit Agreement under certain circumstances.

35

Table of Contents

The obligations of AgroFresh Inc., a wholly-owned subsidiary of the Company and the borrower under the Restated Credit Facility, are initially guaranteed by the Company and the Company’s wholly-owned subsidiary, AF Solutions Holdings LLC (together with AgroFresh Inc. and the Company, the “Loan Parties”) and may in the future be guaranteed by certain other domestic subsidiaries of the Company. The obligations of the Loan Parties under the Credit Agreement and other loan documents are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in all tangible and intangible assets of the Loan Parties, except for certain excluded assets, and equity interests of certain foreign subsidiaries of the Loan Parties held by the Loan Parties (subject to certain exclusions and limitations).

The Refinancing was deemed a partial extinguishment of the Term Loan (as defined below) under ASC Topic No. 470-50, “Debt – Modifications and Extinguishments” (Topic No. 470), whereby $107.1 million of the $403.8 million outstanding at the time of the Refinancing was deemed an extinguishment and $296.7 million was deemed a modification of debt. As such, unamortized deferred issuance costs related to the extinguishment of $0.7 million were written off in debt modification and extinguishment expenses and the remaining $1.9 million was deferred and amortized over the term of the Restated Term Loan.

In connection with the Restated Term Loan, third-party expenses to existing lenders of $4.4 million were recognized in debt modification and extinguishment expenses. Expenses to new lenders of $1.1 million were deferred and amortized over the term of the Restated Term Loan along with $6.4 million of lender fees and issue discounts.

In total, the Company deferred debt issuance costs of $7.5 million related to the Restated Term Loan, $1.9 million related to the modification of the Term Loan and $0.5 million related to the Restated Revolving Loan. The debt issuance costs associated with the Restated Term Loan were capitalized against the principal balance of the debt, and the Restated Revolving Loan costs were capitalized in Other Assets. All issuance costs will be accreted through interest expense using the effective interest method for the duration of each respective debt facility. The interest expense related to the amortization of the Restated Credit Facility debt issuance costs during the three months ended September 30, 2020 was $0.3 million. As of September 30, 2020 there were $9.0 million of unamortized deferred issuance costs.

At September 30, 2020, there was $275.0 million outstanding under the Restated Term Loan and no balance outstanding under the Restated Revolving Loan. At September 30, 2020, the Company evaluated the amount recorded under the Restated Term Loan and determined that the fair value was approximately $267.4 million. The fair value of the debt is based on quoted inactive market prices and is therefore classified as Level 2 within the valuation hierarchy.

Certain restrictive covenants are contained in the Restated Credit Agreement, and the Company was in compliance with these covenants as of September 30, 2020.

Prior Credit Facility

On July 31, 2015, in connection with the consummation of the Business Combination, AgroFresh Inc. as the borrower and AF Solutions Holdings LLC as the guarantor, entered into a Credit Agreement with Bank of Montreal, as administrative agent (as subsequently amended prior to the Refinancing, the “Prior Credit Facility”). The Prior Credit Facility consisted of a $425.0 million term loan (the “Term Loan”), with an amortization equal to 1.00% per year, and a revolving loan facility (the “Revolving Loan”). The net proceeds of the Term Loan were used to fund a portion of the purchase price payable to Dow in connection with the Business Combination.

The Revolving Loan included a $10.0 million letter-of-credit sub-facility, issuances against which reduce the available capacity for borrowing. The Term Loan had a scheduled maturity date of July 31, 2021. As discussed above, the Prior Credit Facility was refinanced on July 27, 2020, and there were no amounts outstanding as of September 30, 2020. The interest rates on borrowings under the facilities were either the alternate base rate plus 3.75% or LIBOR plus 4.75% per annum, with a 1.00% LIBOR floor (with step-downs in respect of borrowings under the Revolving Loan dependent upon the achievement of certain financial ratios).

As of the Closing Date, the Company incurred approximately $12.9 million in debt issuance costs related to the Term Loan and $1.3 million in costs related to the Revolving Loan. The debt issuance costs associated with the Term Loan were capitalized against the principal balance of the debt, and the Revolving Loan costs were capitalized in Other Assets. The interest expense related to the amortization of the Term Loan debt issuance costs during the three months ended September 30, 2020 and 2019, was approximately $0.2 million and $0.6 million, respectively. The interest expense related to the amortization of the Term Loan debt issuance costs during the nine months ended September 30, 2020 and 2019 was approximately $1.4 million and $1.7 million, respectively.

36

Table of Contents

Tecnidex Debt

On March 23, 2020, Tecnidex entered into a €1.0 million loan agreement with Banco Santander, S.A., which provides funding through March 2023 at a 1.5% interest rate. In May 2020, Tecnidex entered into a €0.3 million loan agreement with BBVA, which provides funding through May 2025 at a 2.2% interest rate. In July 2020, Tecnidex entered into a €0.6 million loan agreement with Banco Santander, S.A., which provides funding through July 2025 at a 2.5% interest rate.

Preferred Stock Financing

On June 13, 2020, the Company entered into an Investment Agreement (the “Investment Agreement”) with the Investor, an affiliate of Paine Schwartz Partners, LLC (“PSP”), pursuant to which, subject to certain closing conditions, the Investor agreed to purchase in a private placement an aggregate of $150,000,000 of convertible preferred equity of the Company. The transaction closed on July 27, 2020 and a total of 150,000 shares of the Company’s newly-designated Series B-1 Convertible Preferred Stock, par value $0.0001 per share (the “Series B-1 Preferred Stock”) were purchased in such transaction (the “Private Placement”). On September 22, 2020, following the approval of the transactions contemplated by the Investment Agreement by the necessary regulatory body, the Company issued to the Investor, for no additional consideration, a total of 150,000 shares of the Company’s newly-designated Series B-2 Convertible Preferred Stock, par value $0.0001 per share (the “Series B-2 Preferred Stock”). On September 25, 2020 (the "Exchange Date"), the Investor elected to exchange the shares of the Company’s Series B-1 Convertible Preferred Stock and Series B-2 Preferred Stock held by it for a total of 150,000 shares of the Company’s newly-designated Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). Accordingly, effective as of the Exchange Date, the Company issued 150,000 shares of Series B Convertible Preferred Stock, par value $0.0001 per share, to the Investor and all of the shares of Series B-1 Preferred Stock and Series B-2 Preferred Stock held by the Investor were cancelled. No shares of Series B-1 Preferred Stock or Series B-2 Preferred Stock are outstanding as of September 30, 2020.

The Series B Preferred Stock ranks senior to the shares of the Company’s common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Series B Preferred Stock has a liquidation preference of $1,000 per share (the “Stated Value”). Holders of the Series B Preferred Stock are entitled to a cumulative dividend at a rate of 16% per annum, of which 50% will be payable in cash and 50% will be payable in kind until the first anniversary of the Closing Date, after which 50% will be payable in cash, 37.5% will be payable in kind, and the remaining 12.5% will be payable in cash or in kind, at the Company’s option, subject in each case to adjustment under certain circumstances. Dividends on the Series B Preferred Stock are cumulative and payable quarterly in arrears. All dividends that are paid in kind will accrete to, and increase, the Stated Value. The applicable dividend rate is subject to increase by 2% per annum during any period that the Company is in breach of certain provisions of the applicable Certificate of Designation of the Preferred Stock. The Series B Preferred Stock has been classified as temporary equity as it may be contingently redeemable in the event of a change of control, which is outside of the Company's control.

Associated with the Series B Preferred Stock, the Company paid $4.4 million of total dividends, of which $2.2 million were in additional preferred shares and $2.2 million were in cash for the three and nine months ended September 30, 2020, respectively. For the three and nine months ended September 30, 2019, the Company paid no dividends. As of September 30, 2020 and December 31, 2019, the Company had no accrued dividends.

The Series B Preferred Stock is convertible into Common Stock at the election of the holder at any time at an initial conversion price of $5.00 (the “Conversion Price”). The Conversion Price is subject to customary adjustments, including for stock splits and other reorganizations affecting the Common Stock and pursuant to certain anti-dilution provisions for below market issuances. As of September 30, 2020 and December 31, 2019, the maximum number of shares of common stock that could be issued upon conversion of the outstanding shares of Series B Convertible Preferred Stock was 30,440,000 and 0 shares, respectively.

Off-Balance Sheet Arrangements

As of September 30, 2020, the Company did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any commitments or contractual obligations other than as disclosed in Note 20 of the unaudited condensed consolidated financial statements. The Company has not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.

37

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

An evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information required to be disclosed is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Changes in Internal Controls

There were no changes in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

38

Table of Contents

PART II- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time we are named as a defendant in legal actions arising from our normal business activities. Although we cannot predict with certainty the ultimate resolution of lawsuits, investigations and claims asserted against us, we do not believe any currently pending legal proceeding to which we are a party will have a material adverse effect on our business, prospects, financial condition, cash flows or results of operations.

ITEM 1A. RISK FACTORS

Ownership of our securities involves a high degree of risk. Holders of our securities should carefully consider, in addition to the historical financial statements and related notes and other information set forth in this Report, the risk factors discussed in Part I - Item 1A - Risk Factors included in our 2019 Form 10-K, all of which could materially affect our business or future results. Other than the amended and restated risk factors and the additional risk factors set forth below, we are not currently aware of any material changes to the risk factors disclosed in our 2019 Form 10-K. If any of the risks or uncertainties described in any of such risk factors actually occur, our business, financial condition and operating results could be adversely affected in a material way. This could cause the trading prices of our securities to decline, perhaps significantly, and you may lose part or all of your investment.

The Investor and The Dow Chemical Company (“Dow”) have significant influence over us, which could limit your ability to influence the outcome of key transactions, including a change of control.

As of September 30, 2020, the Investor owned 150,000 shares of our Series B preferred stock (the “Series B Preferred Stock”), which is currently convertible into approximately 30.4 million shares of our outstanding common stock representing approximately 36% of our outstanding common stock on an as-converted basis (and which votes with our common stock on an as-converted basis), and Dow owned approximately 21 million shares of our outstanding common stock. In addition, we will issue additional shares of Preferred Stock to the Investor as dividends payable-in-kind on the Series B Preferred Stock. Because of the degree of concentration of voting power (and the potential for such power to increase upon the purchase of additional stock and/or the payment of dividends-in-kind), your ability to elect members of our board of directors and influence our business and affairs, including any determinations with respect to mergers or other business combinations, the acquisition or disposition of assets, the incurrence of indebtedness, the issuance of any additional common stock or other equity securities, the repurchase or redemption of common stock and the payment of dividends, may be diminished.

In addition, the Investor and Dow have representation on the Company’s board of directors and have significant control over the management and affairs of the Company. The Investor currently has two designees on the board of directors, and commencing on July 27, 2021 (or earlier under certain circumstances) will have the right to appoint additional directors to the board, such that the total number of its designees would be proportionate to its ownership of common stock, on an as-converted basis. Dow (or an affiliate) has one designee on the board of directors and would have the right to appoint an additional director in the future under certain circumstances. The Investor also has class approval rights over certain specified actions that would affect the holders of the Preferred Stock, and has the right to approve certain corporate actions for so long as it continues to hold at least 10% of the shares of common stock outstanding (on an as-converted basis).

Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.

As of December 31, 2019, we had aggregate U.S. net operating loss carryforwards of approximately $102.6 million, These net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Tax Cuts and Jobs Act, federal net operating losses incurred in taxable years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of federal net operating losses generated in tax years beginning after December 31, 2017 is limited. It is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change” (which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We experienced an ownership change as a result of the consummation of the sale of the Preferred Stock to the Investor. Such ownership change may materially limit certain U.S. tax attributes, which may harm our future operating results by effectively increasing our future tax obligations. The Company will continue to review the realizability of the net operating losses and other tax attributes and may make additional adjustments to the valuation allowance.

39

Table of Contents

Risks associated with the current uncertainty with respect to rapid expansion of the COVID-19 pandemic

We are cognizant of the rapid expansion of the COVID-19 pandemic and the resulting global implications. To date, we have been able to manage our day-to-day operations without significant disruptions. However, there continues to be a possibility for potential developments that could adversely affect our operations, research and development and marketing plans. The impact of these restrictions on the results of our business, if implemented, is currently unknown but could be significant.

40

Table of Contents

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

41

Table of Contents

ITEM 6. EXHIBITS

Exhibit No.		Description
3.1	(1)	Second Amended and Restated Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on July 31, 2015.
3.2	(4)	Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation.
3.3	(1)	Series A Certificate of Designation.
3.4	(6)	Certificate of Designation of Series B Convertible Preferred Stock.
3.5	(2)	Amended and Restated Bylaws.
3.6	(3)	Amendment to the Amended and Restated Bylaws of AgroFresh Solutions, Inc., effective as of September 3, 2015.
3.7	(5)	Amendment to the Amended and Restated Bylaws of AgroFresh Solutions, Inc., effective as of November 2, 2017.
4.1	(1)	Specimen Common Stock Certificate.
4.2	(1)	Specimen Warrant Certificate.
10.1	(7)	Amended and Restated Credit Agreement, dated July 27, 2020.
10.2	(7)	Registration Rights Agreement, dated July 27, 2020, between the Company and PSP AGFS Holdings, L.P.
31.1	*	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended.
31.2	*	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Act of 1934, as amended.
32.1	*	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	*	XBRL Instance Document
101.SCH	*	XBRL Taxonomy Extension Schema Document
101.CAL	*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	*	XBRL Taxonomy Extension Presentation Linkbase Document

———————————————————————————————

*    Filed herewith.

(1)    Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on August 6, 2015.

(2)    Incorporated by reference to Annex A to the Company’s definitive proxy statement (File No. 001-36197) filed with the Securities and Exchange Commission on July 16, 2015.

(3)    Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on September 10, 2015.

(4)    Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on June 7, 2017.

(5)    Incorporated by reference to an exhibit to the Quarterly Report on Form 10-Q of the Company filed with the Securities and Exchange Commission on November 9, 2017.

(6)    Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on September 28, 2020.

(7) Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on July 29, 2020.

42

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AgroFresh Solutions, Inc.
Date:	November 5, 2020
/s/ Jordi Ferre
By:	Jordi Ferre
Title:	Chief Executive Officer
/s/ Graham Miao
By:	Graham Miao
Title:	Chief Financial Officer

43

EX-31.1

EXHIBIT 31.1

CERTIFICATE PURSUANT TO

RULES 13a-14(a) and 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jordi Ferre, certify that:

1.    I have reviewed this quarterly report on Form 10-Q of AgroFresh Solutions, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	November 5, 2020
/s/ Jordi Ferre
By:	Jordi Ferre
Title:	Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATE PURSUANT TO

RULES 13a-14(a) and 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Graham Miao, certify that:

1.    I have reviewed this quarterly report on Form 10-Q of AgroFresh Solutions, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	November 5, 2020
/s/ Graham Miao
By:	Graham Miao
Title:	Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

AND CHIEF FINANCIAL OFFICER PURSUANT TO

18 USC. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AgroFresh Solutions, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Jordi Ferre, President and Chief Executive Officer, and Graham Miao, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

AgroFresh Solutions, Inc.
Date:	November 5, 2020
/s/ Jordi Ferre
By:	Jordi Ferre
Title:	Chief Executive Officer
/s/ Graham Miao
By:	Graham Miao
Title:	Chief Financial Officer

XML

Cover Page - shares	9 Months Ended
	Sep. 30, 2020	Oct. 22, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-36316
Entity Registrant Name	AgroFresh Solutions, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-4007249
Entity Address, Address Line One	510-530 Walnut Street, Suite 1350
Entity Address, City or Town	Philadelphia
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19106
City Area Code	267
Local Phone Number	317-9139
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AGFS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		53,054,960
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001592016

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 25,149	$ 29,288
Accounts receivable, net of allowance for doubtful accounts of $2,025 and $2,232, respectively	69,580	68,634
Inventories	24,444	22,621
Other current assets	17,265	11,802
Total Current Assets	136,438	132,345
Property and equipment, net	13,275	13,177
Goodwill	6,605	6,323
Intangible assets, net	599,236	631,369
Deferred income tax assets	10,502	10,317
Other assets	11,449	12,161
TOTAL ASSETS	777,505	805,692
Current Liabilities:
Accounts payable	13,784	15,105
Current portion of long-term debt	3,316	4,675
Income taxes payable	7,629	5,648
Accrued expenses and other current liabilities	26,665	24,350
Total Current Liabilities	51,394	49,778
Long-term debt	264,850	398,064
Other noncurrent liabilities	5,989	7,246
Deferred income tax liabilities	35,577	16,574
Total Liabilities	357,810	471,662
Commitments and contingencies (see Note 20)
Series B convertible preferred stock, par value $0.0001; 150,000 and 0 shares authorized, 150,000 and 0 shares designated and outstanding at September 30, 2020 and December 31, 2019, respectively	140,684	0
Stockholders’ Equity:
Common stock, par value $0.0001; 400,000,000 shares authorized, 53,054,960 and 51,839,527 shares issued and 52,393,579 and 51,178,146 outstanding at September 30, 2020 and December 31, 2019, respectively	5	5
Preferred stock, par value $0.0001; 1 share authorized and outstanding at September 30, 2020 and December 31, 2019, respectively	0	0
Treasury stock, par value $0.0001; 661,381 shares at September 30, 2020 and December 31, 2019, respectively	(3,885)	(3,885)
Additional paid-in capital	559,037	561,006
Accumulated deficit	(241,710)	(199,621)
Accumulated other comprehensive loss	(41,164)	(31,060)
Total AgroFresh Stockholders’ Equity	272,283	326,445
Non-controlling interest	6,728	7,585
Total Stockholders' Equity	279,011	334,030
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY	$ 777,505	$ 805,692

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Allowance for doubtful accounts	$ 2,025	$ 2,232
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	53,054,960	51,839,527
Common stock, shares outstanding (in shares)	52,393,579	51,178,146
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	1	1
Preferred stock, shares outstanding (in shares)	1	1
Treasury stock (in shares)	661,381	661,381
Treasury Stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Series B Convertible Stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	150,000	0
Preferred stock, shares outstanding (in shares)	150,000	0

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Net sales	$ 52,770	$ 48,972	$ 105,775	$ 109,095
Cost of sales (excluding amortization, shown separately below)	13,511	13,892	28,492	31,516
Gross Profit	39,259	35,080	77,283	77,579
Research and development expenses	2,852	2,566	8,389	9,720
Selling, general and administrative expenses	13,494	14,998	39,925	47,044
Amortization of intangibles	10,973	11,754	32,866	35,136
Impairment of long lived assets	0	0	0	992
Change in fair value of contingent consideration	0	(229)	0	128
Grant income	0	0	(2,974)	0
Operating income (loss)	11,940	5,991	(923)	(15,441)
Other income (expense)	96	(81)	1,596	(119)
Debt modification and extinguishment expenses	(5,028)	0	(5,028)	0
Gain (loss) on foreign currency exchange	1,390	54	2,466	(2,884)
Interest expense, net	(4,922)	(8,606)	(18,401)	(26,021)
Gain (loss) before income taxes	3,476	(2,642)	(20,290)	(44,465)
Income taxes expense (benefit)	25,857	(5,653)	22,656	(12,530)
Net (loss) income including non-controlling interests	(22,381)	3,011	(42,946)	(31,935)
Less: Net loss attributable to non-controlling interests	(494)	(278)	(857)	(336)
Net (loss) income attributable to AgroFresh Solutions, Inc	(21,887)	3,289	(42,089)	(31,599)
Less: Dividends on convertible preferred stock	4,400	0	4,400	0
(Loss) income attributable to AgroFresh Solutions, Inc. common stockholders	$ (26,287)	$ 3,289	$ (46,489)	$ (31,599)
Net (loss) income per share:
Basic (in dollars per share)	$ (0.52)	$ 0.06	$ (0.92)	$ (0.64)
Diluted (in dollars per share)	$ (0.52)	$ 0.06	$ (0.92)	$ (0.64)
Weighted average shares outstanding:
Basic (in shares)	51,001,852	50,227,590	50,765,829	50,138,835
Diluted (in shares)	51,001,852	50,288,304	50,765,829	50,138,835

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (22,381)	$ 3,011	$ (42,946)	$ (31,935)
Other comprehensive (loss) income:
Unrealized gain (loss) on hedging activity, net of tax of $61, $24, ($81) and $24, respectively	229	83	(304)	83
Recognition of gain on hedging activity reclassified to net loss, net of tax of ($239), ($78), ($398) and ($235), respectively	(857)	(278)	(1,411)	(834)
Foreign currency translation adjustments	296	(3,823)	(8,389)	(903)
Comprehensive loss, net of tax	$ (22,714)	$ (1,007)	$ (53,050)	$ (33,589)

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Unrealized gain on hedging activity, tax expense (benefit)	$ 61	$ 24	$ (81)	$ 24
Realized gain on hedging activity reclassified to net loss, tax	$ (239)	$ (78)	$ (398)	$ (235)

XML

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Non-Controlling Interest
Beginning balance (in shares) at Dec. 31, 2018		1	51,071,573
Beginning balance at Dec. 31, 2018	$ 372,576	$ 0	$ 5	$ (3,885)	$ 535,819	$ (138,789)	$ (28,837)	$ 8,263
Increase (Decrease) in Stockholders' Equity
Stock-based compensation	2,256				2,256
Issuance of stock, net of forfeitures (in shares)			521,386
Comprehensive loss	(33,589)					(31,599)	(1,654)	(336)
Ending balance (in shares) at Sep. 30, 2019		1	51,592,959
Ending balance at Sep. 30, 2019	341,243	$ 0	$ 5	(3,885)	538,075	(170,388)	(30,491)	7,927
Beginning balance (in shares) at Jun. 30, 2019		1	51,620,770
Beginning balance at Jun. 30, 2019	341,434	$ 0	$ 5	(3,885)	537,259	(173,677)	(26,473)	8,205
Increase (Decrease) in Stockholders' Equity
Stock-based compensation	816				816
Forfeiture of stock, net of issuances (in shares)			(27,811)
Comprehensive loss	(1,007)					3,289	(4,018)	(278)
Ending balance (in shares) at Sep. 30, 2019		1	51,592,959
Ending balance at Sep. 30, 2019	341,243	$ 0	$ 5	(3,885)	538,075	(170,388)	(30,491)	7,927
Beginning balance (in shares) at Dec. 31, 2019		1	51,839,527
Beginning balance at Dec. 31, 2019	334,030	$ 0	$ 5	(3,885)	561,006	(199,621)	(31,060)	7,585
Increase (Decrease) in Stockholders' Equity
Stock-based compensation	2,473				2,473
Issuance of stock, net of forfeitures (in shares)			1,178,663
Shares withheld for taxes (in shares)			(47,599)
Shares withheld for taxes	(239)				(239)
Issuance of common stock under employee stock purchase plan (in shares)			84,369
Issuance of common stock under employee stock purchase plan	197				197
Convertible preferred dividend	(4,400)				(4,400)
Comprehensive loss	(53,050)					(42,089)	(10,104)	(857)
Ending balance (in shares) at Sep. 30, 2020		1	53,054,960
Ending balance at Sep. 30, 2020	279,011	$ 0	$ 5	(3,885)	559,037	(241,710)	(41,164)	6,728
Beginning balance (in shares) at Jun. 30, 2020		1	52,875,089
Beginning balance at Jun. 30, 2020	305,272	$ 0	$ 5	(3,885)	562,584	(219,823)	(40,831)	7,222
Increase (Decrease) in Stockholders' Equity
Stock-based compensation	872				872
Issuance of stock, net of forfeitures (in shares)			187,302
Shares withheld for taxes (in shares)			(7,431)
Shares withheld for taxes	(19)				(19)
Issuance of common stock under employee stock purchase plan (in shares)			0
Issuance of common stock under employee stock purchase plan	0				0
Convertible preferred dividend	(4,400)				(4,400)
Comprehensive loss	(22,714)					(21,887)	(333)	(494)
Ending balance (in shares) at Sep. 30, 2020		1	53,054,960
Ending balance at Sep. 30, 2020	$ 279,011	$ 0	$ 5	$ (3,885)	$ 559,037	$ (241,710)	$ (41,164)	$ 6,728

XML

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net loss	$ (42,946)	$ (31,935)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	34,775	36,692
(Benefit) provision for bad debts	(124)	215
Stock-based compensation	2,473	2,256
Impairment of intangible assets	0	992
Amortization of deferred financing costs	2,342	2,032
Interest income on interest rate swap	(1,809)	(1,070)
Accretion of contingent consideration	0	2,669
Change in fair value of contingent consideration	0	128
Deferred income taxes	18,086	(14,499)
Loss on sales of property and equipment	155	2
Changes in operating assets and liabilities:
Accounts receivable	(4,297)	(1,499)
Inventories	(2,281)	(4,424)
Prepaid expenses and other current assets	(6,784)	(1,429)
Accounts payable	(1,274)	3,855
Accrued expenses and other liabilities	2,344	(2,958)
Income taxes payable	2,846	(95)
Other assets and liabilities	(3,865)	384
Net cash used in operating activities	(359)	(8,684)
Cash flows from investing activities:
Cash paid for property and equipment	(2,131)	(3,271)
Other investments	0	(250)
Net cash used in investing activities	(2,131)	(3,521)
Cash flows from financing activities:
Net proceeds from issuance of convertible preferred stock	145,490	0
Costs associated with issuance of convertible preferred stock	(7,006)	0
Payment of preferred dividends	(2,200)	0
Proceeds from long-term debt	2,042	0
Repayment of long-term debt	(131,599)	(5,056)
Payment of deferred financing costs	(7,988)	0
Proceeds from issuance of stock under employee stock purchase plan	259	0
Net cash used in financing activities	(1,002)	(5,056)
Effect of exchange rate changes on cash and cash equivalents and restricted cash	(1,176)	1,682
Net decrease in cash and cash equivalents and restricted cash	(4,668)	(15,579)
Cash and cash equivalents and restricted cash, beginning of period	29,817	34,852
Cash and cash equivalents, end of period	25,149	19,273
Cash paid for:
Cash paid for interest	18,381	18,007
Cash paid for income taxes	1,733	2,469
Supplemental schedule of non-cash investing and financing activities:
Accrued purchases of property and equipment	$ 146	$ 62

XML

Description of Business

9 Months Ended

Sep. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business

Description of Business

AgroFresh Solutions, Inc. (the “Company”) is a global leader in delivering innovative food preservation and waste prevention solutions for fresh produce. The Company is empowering the food industry with a range of integrated solutions designed to help growers, packers and retailers improve produce freshness and quality while preventing waste. The Company has an extensive portfolio of solutions to extend freshness across the produce supply chain from near-harvest up to the point-of-sale. These include HarvistaTM for near-harvest optimization and the SmartFreshTM Quality System, the Company's flagship post-harvest freshness solution. Additional post-harvest freshness solutions include fungicides that can be applied to meet various customer operational requirements in both foggable (ActiMist™) and liquid (ActiSeal™) delivery options. The Company has a controlling interest in Tecnidex Fruit Protection, S.A. (“Tecnidex”), a leading regional provider of post-harvest fungicides, waxes, disinfectants and packinghouse equipment for the citrus market. Beyond apples, SmartFresh technology can provide ready-to-eat freshness for other fruits and vegetables including avocados, bananas, melons, tomatoes, broccoli and mangos. Additionally, LandSpringTM eases transplant shock for higher potential yields. RipeLockTM is the Company's modified atmosphere packaging technology for fruits and vegetables. The Company has key products registered in over 50 countries and supports customers with over 25,000 storage rooms globally.

The end-markets that the Company serves are seasonal and are generally aligned with the seasonal growing patterns of the Company’s customers. For those customers growing, harvesting or storing apples and pears, the Company’s core crops, the peak season in the southern hemisphere is the first and second quarters of each year, while the peak season in the northern hemisphere is the third and fourth quarters of each year. Within each half-year period (i.e., January through June for the southern hemisphere, and July through December for the northern hemisphere) the growing season has historically occurred during both quarters. A variety of factors, including weather and fruit quality, may affect the timing of the growing, harvesting and storing patterns of the Company’s customers and therefore shift consumption of the Company’s services and products between the first and second quarters primarily in the southern hemisphere or between the third and fourth quarters primarily in the northern hemisphere.

XML

Basis of Presentation and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. These financial statements include all adjustments that are necessary for a fair presentation of the Company's condensed consolidated results of operations, financial condition and cash flows for the periods shown, including normal, recurring accruals and other items. The condensed consolidated results of operations for the interim periods presented are not necessarily indicative of results for the full year. For additional information, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report filed on Form 10-K for the year ended December 31, 2019.

COVID-19

In March 2020, the World Health Organization characterized the coronavirus ("COVID-19") a pandemic, and the President of the United States declared the COVID-19 outbreak a national emergency. The rapid spread of the pandemic and the continuously evolving responses to combat it have had an increasingly negative impact on the global economy. During the three months ended September 30, 2020, as the Company’s primary sales regions moved to the northern hemisphere, the COVID-19 pandemic continued to not have a significant adverse impact on the Company’s results of operations. However, there were numerous obstacles presented and some localized financial impacts of the pandemic, including fluctuations in foreign currency exchange rates and customer demand and spending pattern changes. While the Company is following the requirements of governmental authorities and taking additional preventative and protective measures to ensure the safety of its workforce, including implementing remote working arrangements and varying procedures for essential workforce, the Company cannot be 100% certain there will not be any incidents across its global operations that may cause service interruptions. The rapid development and fluidity of this situation precludes any prediction as to the ultimate material adverse impact of the coronavirus outbreak, although the Company operates in an industry that thus far has not been as severely impacted as others. Nevertheless, the outbreak presents some uncertainty and risk with respect to the Company and its performance and financial results.

Adoption of Highly Inflationary Accounting in Argentina

GAAP requires the use of highly inflationary accounting for countries whose cumulative three-year inflation rate exceeds 100 percent. The Company closely monitors the inflation data and currency volatility in Argentina, where there are multiple data sources for measuring and reporting inflation. In the second quarter of 2018, the Argentine peso rapidly devalued relative to the

U.S. dollar, which along with increased inflation, indicated that the three-year cumulative inflation rate in that country exceeded 100 percent as of June 30, 2018. As a result, the Company adopted highly inflationary accounting as of July 1, 2018 for its subsidiary in Argentina. Under highly inflationary accounting, the functional currency of the Company's subsidiary in Argentina became the U.S. dollar, and its income statement and balance sheet are measured in U.S. dollars using both current and historical rates of exchange. The effect of changes in exchange rates on Argentine peso-denominated monetary assets and liabilities are reflected in earnings. As the three-year cumulative inflation rate exceeded 100 percent as of September 30, 2020, there is no change to highly inflationary accounting. As of September 30, 2020, the Company’s subsidiary in Argentina had a net asset position of $3.0 million. Net sales attributable to Argentina were approximately 6% and 6% of the Company’s consolidated net sales for each of the nine months ended September 30, 2020 and 2019, respectively.

Disaggregation of Revenue

The Company disaggregates revenue from contracts with customers into geographic region, product and timing of transfer of goods and services. The Company determined that disaggregating revenue into these categories achieves the disclosure objective of depicting how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

Revenues for the three months ended September 30, 2020

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	17,122	$	28,906	$	845	$	1,165	$	48,038
Fungicides, waxes, coatings and disinfectants	534		3,011		575		—		4,120
Other*	190		115		210		97		612
	$	17,846	$	32,032	$	1,630	$	1,262	$	52,770
Pattern of Revenue Recognition
Products transferred at a point in time	$	17,663	$	31,921	$	1,420	$	1,165	$	52,169
Services transferred over time	183		111		210		97		601
	$	17,846	$	32,032	$	1,630	$	1,262	$	52,770

Revenues for the three months ended September 30, 2019

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	19,726	$	22,377	$	1,680	$	1,605	$	45,388
Fungicides, waxes, coatings and disinfectants	—		2,857		198		—		3,055
Other*	218		86		108		117		529
	$	19,944	$	25,320	$	1,986	$	1,722	$	48,972
Pattern of Revenue Recognition
Products transferred at a point in time	$	19,802	$	25,238	$	1,877	$	1,605	$	48,522
Services transferred over time	142		82		109		117		450
	$	19,944	$	25,320	$	1,986	$	1,722	$	48,972

Revenues for the nine months ended September 30, 2020

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	19,264	$	37,223	$	23,217	$	11,538	$	91,242
Fungicides, waxes, coatings and disinfectants	534		9,650		1,750		—		11,934
Other*	722		700		938		239		2,599
	$	20,520	$	47,573	$	25,905	$	11,777	$	105,775
Pattern of Revenue Recognition
Products transferred at a point in time	$	19,823	$	46,887	$	25,338	$	11,538	$	103,586
Services transferred over time	697		686		567		239		2,189
	$	20,520	$	47,573	$	25,905	$	11,777	$	105,775

Revenues for the nine months ended September 30, 2019

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	23,084	$	31,965	$	27,503	$	11,287	$	93,839
Fungicides, waxes, coatings and disinfectants	—		11,365		1,458		—		12,823
Other*	954		927		381		171		2,433
	$	24,038	$	44,257	$	29,342	$	11,458	$	109,095
Pattern of Revenue Recognition
Products transferred at a point in time	$	23,380	$	43,374	$	29,159	$	11,309	$	107,222
Services transferred over time	658		883		183		149		1,873
	$	24,038	$	44,257	$	29,342	$	11,458	$	109,095

*Other includes FreshCloud, technical services and sales-type leases related to Tecnidex.

———————————————————————————————————

(1)            North America includes the United States and Canada.

(2)             EMEA includes Europe, the Middle East and Africa.

(3)             Latin America includes Argentina, Brazil, Chile, Costa Rica, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Peru and Uruguay.

(4)             Asia Pacific includes Australia, China, India, Japan, New Zealand, the Philippines, South Korea, Taiwan and Thailand.

Contract Assets and Liabilities

ASC 606 requires an entity to present a revenue contract as a contract asset when the entity performs its obligations under the contract by transferring goods or services to a customer before the customer pays consideration or before payment is due. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g., receivable), before the entity transfers a good or service to the customer. The following table presents changes in the Company’s contract assets and liabilities during the nine months ended September 30, 2020 and the year ended December 31, 2019:

(in thousands)	Balance at January 1, 2020		Additions	Deductions	Balance at September 30, 2020
Contract assets:
Unbilled revenue	$	1,666	11,670	(9,423)	$	3,913
Contract liabilities:
Deferred revenue	$	1,175	4,437	(4,239)	$	1,373

(in thousands)	Balance at January 1, 2019		Additions	Deductions	Balance at December 31, 2019
Contract assets:
Unbilled revenue	$	1,956	10,029	(10,319)	$	1,666
Contract liabilities:
Deferred revenue	$	1,280	3,032	(3,137)	$	1,175

The Company recognizes contract assets in the form of unbilled revenue in instances where services are performed by the Company but not billed by period end. The Company recognizes contract liabilities in the form of deferred revenue in instances where a customer pays in advance for future services to be performed by the Company. The Company generally receives payments from its customers based on standard terms and conditions. No significant changes or impairment losses occurred to contract balances during the nine months ended September 30, 2020. Amounts reclassified from unbilled revenue to accounts receivable for the nine months ended September 30, 2020 and for the year ended December 31, 2019 were $9.4 million and $10.3 million, respectively. Amounts reclassified from deferred revenue to revenue for the nine months ended September 30, 2020 and for the year ended December 31, 2019 were $4.2 million and $3.1 million, respectively.

Recently Issued Accounting Standards and Pronouncements

In January 2017, the Financial Accounting Standards Board ("FASB") issued ASU No. 2017-04, "Intangibles - Goodwill and Other", which simplifies the test for goodwill impairment. The guidance was effective for the Company beginning in the first quarter of fiscal year 2020. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the condensed consolidated financial statements of the Company.

In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments”, which introduces a new

current expense credit loss model to measure impairment on certain types of financial instruments. This update requires an entity to use a forward-looking expected credit loss model for accounts receivable, loans, and other financial instruments. In addition, the FASB issued various amendments during 2018 and 2019 to clarify the provisions of ASU 2016-13. The standard was effective for fiscal years beginning January 1, 2020, including interim periods. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the financial statements of the Company.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify and add

certain disclosure requirements related to fair value measurements covered in Topic 820. The new standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the notes to condensed consolidated financial statements of the Company.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments simplify the accounting for income taxes by removing certain exceptions to the general principles of Topic 740, "Income Taxes" and also improve consistent application by clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted, with the amendments to be applied on a retrospective, modified retrospective or prospective basis, depending on the specific amendment. The Company is currently evaluating the impact of adopting this guidance.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments are intended to ease the potential burden in accounting for, or recognizing the effects of, reference rate

reform on financial reporting. The new standard is effective on a date selected by the Company between March 12, 2020 and December 31, 2022. The Company is currently evaluating the impact of adopting this guidance.

XML

Business Combinations and Asset Acquisition

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

Business Combinations and Asset Acquisition

Business Combinations and Asset Acquisition

Business Combination with Dow

On July 31, 2015 (the "Closing Date"), the Company consummated a business combination (the “Business Combination”) pursuant to the Stock Purchase Agreement, dated April 30, 2015 (the “Purchase Agreement”), by and between the Company and The Dow Chemical Company ("Dow") providing for the acquisition by the Company of the AgroFresh business from Dow, resulting in AgroFresh Inc. becoming a wholly-owned, indirect subsidiary of the Company. Pursuant to the Purchase Agreement, the Company paid the following consideration to Rohm and Haas Company (“R&H”), a subsidiary of Dow: (i) 17.5 million shares of common stock and (ii) $635 million in cash.

Pursuant to a Tax Receivables Agreement among the Company, Dow, R&H and AgroFresh Inc. entered into in connection with the consummation of the Business Combination, as amended on April 4, 2017 (as so amended, the “Tax Receivables Agreement”), the Company was required to pay to Dow 50% of the annual tax savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realized as a result of the increase in tax basis of the AgroFresh assets resulting from a Section 338(h)(10) election that the Company and Dow made in connection with the Business Combination. In December 2019, the Tax Receivables Agreement was terminated, and the Company paid to Dow an aggregate of $16 million in settlement of all past and estimated future liabilities that would have been owed under the Tax Receivables Agreement. Based on this termination, the Company recorded a reduction of liabilities of $27.9 million. This reduction, net of deferred income taxes of $5.9 million, has been recorded to additional paid-in capital since the Tax Receivable Agreement was with a related party and is treated as a capital transaction.

Acquisition of Tecnidex

On November 7, 2017, the Company entered into a definitive agreement to acquire a controlling interest in Tecnidex. The transaction was closed on December 1, 2017. Tecnidex is a leading regional provider of post-harvest fungicides, waxes, coatings, and disinfectants for the citrus market, with clients in 18 countries. For over 35 years, Tecnidex has been helping fruit and vegetable producers offer clean, safe and high-quality products to their regional clients. The acquisition was accounted for as a purchase in accordance with ASC 805, Business Combination.

At the effective date of the acquisition, the Company agreed to pay holders of Tecnidex an estimated $25.0 million in cash for 75% of the outstanding capital stock, of which $20.0 million was paid on December 1, 2017. In 2018, the purchase price was finalized as $22.3 million after giving effect to working capital, net debt and other adjustments. The remaining $2.3 million was paid during 2018.

In accordance with the acquisition method of accounting, the Company has allocated the purchase price to the estimated fair values of the identifiable assets acquired and liabilities assumed, with any excess allocated to goodwill. The preliminary assessment of fair value of the contingent consideration payments on the acquisition date was approximately $0.7 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. During the year ended December 31, 2019 there was a final adjustment made to consideration payable to holders of Tecnidex which resulted in a fair value adjustment of $0.4 million.

XML

Related Party Transactions

9 Months Ended

Sep. 30, 2020

Related Party Transactions [Abstract]

Related Party Transactions

Related Party Transactions

The Company is a party to an ongoing transition services agreement with Dow, a related party. The Company incurred expenses for such transition services for the nine months ended September 30, 2020 and 2019 of $0.04 million and $0.09 million, respectively. As of September 30, 2020 and December 31, 2019, the Company had outstanding amounts payable to Dow of $0.0 million and $0.1 million, respectively.

On June 13, 2020, in connection with the execution of the Investment Agreement (as defined in Note 15- Series B Convertible Preferred Stock and Stockholders’ Equity), the Company, PSP AGFS Holdings, L.P. (the “Investor”) and R&H entered into a side agreement, pursuant to which the parties agreed that if the Investor or its affiliates has the right to designate at least 50% of the total directors on the Company’s board of directors pursuant to the Investment Agreement, so long as R&H or its affiliates beneficially owns at least 20% of the Company’s outstanding common stock (on a fully diluted, “as converted” basis), the Company and the board of directors will increase the size of the board of directors by one member and the board will elect a

designee selected by R&H to fill the newly-created vacancy. Such right is in addition to any right that R&H has to appoint a member of the board pursuant to its ownership of the Company’s Series A preferred stock (see Note 15- Series B Convertible Preferred Stock and Stockholders’ Equity).

Refer to Note 3 - Business Combinations and Asset Acquisition regarding the contingent consideration owed to Dow as part of the Business Combination, as well as certain other agreements entered into in connection with the Business Combination, including the termination of the Tax Receivables Agreement in 2019.

During 2016, the Company made a minority investment in RipeLocker, LLC ("RipeLocker"), a company led by George Lobisser, a director of the Company. In February 2019, the Company made a further minority investment in RipeLocker. As of and for the nine months ended September 30, 2020, there were no material amounts paid or owed to RipeLocker or Mr. Lobisser.

XML

Inventories

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Inventories

Inventories

Inventories at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Raw material	$	3,026	$	3,401
Work-in-process	8,575		7,278
Finished goods	11,619		10,974
Supplies	1,224		968
Total inventories	$	24,444	$	22,621

XML

Other Current Assets

9 Months Ended

Sep. 30, 2020

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Current Assets

Other Current Assets

The Company's other current assets at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
VAT receivable	$	7,627	$	4,925
Prepaid income tax asset	5,349		3,616
Prepaid and other current assets	4,289		3,261
Total other current assets	$	17,265	$	11,802

XML

Property and Equipment

9 Months Ended

Sep. 30, 2020

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and Equipment

Property and equipment at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands, except for useful life data)	Useful life (years)	September 30, 2020		December 31, 2019
Buildings and leasehold improvements	7-20	$	7,032	$	6,508
Machinery & equipment	1-12	11,953		10,954
Furniture	1-12	2,944		2,681
Construction in progress		1,149		902
		23,078		21,045
Less: accumulated depreciation		(9,803)		(7,868)
Total property and equipment, net		$	13,275	$	13,177

Depreciation expense was $0.7 million and $0.6 million for the three months ended September 30, 2020 and 2019, respectively, and $1.9 million and $1.6 million for the nine months ended September 30, 2020 and 2019, respectively. Depreciation expense is recorded in cost of sales, selling, general and administrative expense and research and development expense in the condensed consolidated statements of operations.

XML

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill and Intangible AssetsChanges in the carrying amount of goodwill for the nine months ended September 30, 2020 and the year ended December 31, 2019 were as follows:

(in thousands)	September 30, 2020		December 31, 2019
Beginning balance	$	6,323	$	6,670
Foreign currency translation	282		(347)
Ending balance	$	6,605	$	6,323

The Company’s intangible assets at September 30, 2020 and December 31, 2019 consisted of the following:

	September 30, 2020								December 31, 2019
(in thousands)	Gross Carrying Amount		Accumulated Amortization		Impairment		Net		Gross Carrying Amount		Accumulated Amortization		Impairment		Net
Other intangible assets:
Developed technology	$	798,240	$	(244,918)	$	—	$	553,322	$	758,760	$	(206,998)	$	—	$	551,762
In-process research and development	—		—		—		—		39,000		(7,222)		—		31,778
Trade name	27,158		—		—		27,158		27,200		—				27,200
Service provider network	2,000		—		—		2,000		2,000		—		—		2,000
Customer relationships	18,551		(3,548)		—		15,003		18,058		(2,993)		—		15,065
Software	10,691		(8,967)		—		1,724		9,861		(5,347)		(992)		3,522
Other	100		(71)		—		29		100		(58)		—		42
Total intangible assets	$	856,740	$	(257,504)	$	—	$	599,236	$	854,979	$	(222,618)	$	(992)	$	631,369

During 2019, the Company recognized an impairment charge of $1.0 million associated with Verigo software following a partnership agreement with a new technology provider. During the Company's annual impairment testing conducted for the year ended December 31, 2019, the Company accelerated the amortization of Ripelock developed technology based on the Company's remaining expected useful life of the technology. This resulted in an increase to amortization expense of $34.0 million.

At September 30, 2020, the weighted-average amortization periods remaining for developed technology, in-process R&D, customer relationships, software and other was 14.8, 14.0, 12.1, 1.0, and 1.8 years, respectively, and the weighted-average amortization period remaining for these finite-lived intangible assets was 14.6 years.

Estimated annual amortization expense for finite-lived intangible assets subsequent to September 30, 2020 is as follows:

(in thousands)	Amount
2020 (remaining)	$	12,045
2021	41,730
2022	40,893
2023	40,791
2024	40,791
Thereafter	393,828
Total	$	570,078

Amortization expense for intangible assets was $11.0 million and $11.8 million for the three months ended September 30, 2020 and 2019, respectively, and $32.9 million and $35.1 million for the nine months ended September 30, 2020 and 2019, respectively.

XML

Other Assets

9 Months Ended

Sep. 30, 2020

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Assets

Other AssetsThe Company’s other assets at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Right-of-use asset	$	5,657	$	6,599
Long term sales-type lease receivable	2,354		2,501
Other long term receivable	3,438		3,061
Total other assets	$	11,449	$	12,161

XML

Accrued and Other Current Liabilities

9 Months Ended

Sep. 30, 2020

Payables and Accruals [Abstract]

Accrued and Other Current Liabilities

Accrued and Other Current Liabilities

The Company’s accrued and other current liabilities at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Accrued compensation and benefits	$	7,111	$	7,307
Accrued taxes	6,501		3,017
Lease liability	1,368		1,493
Accrued rebates payable	3,001		1,377
Insurance premium financing payable	1,151		1,000
Severance	218		444
Deferred revenue	1,373		1,175
Accrued interest	66		71
Interest rate swap	290		—
Other	5,586		8,466
Total accrued and other current liabilities	$	26,665	$	24,350

Other current liabilities include primarily professional services, litigation and research and development accruals.

XML

Debt

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Debt

Debt

The Company’s debt, net of unamortized deferred issuance costs, at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Total term loan outstanding	$	275,000	$	405,875
Unamortized deferred issuance costs	(9,018)		(3,886)
Tecnidex loan outstanding	2,184		750
Less: Amounts due within one year	3,316		4,675
Total long-term debt due after one year	$	264,850	$	398,064

Restated Credit Facility

On July 27, 2020, the Company completed a comprehensive refinancing (the “Refinancing”) by (i) entering into an Amended and Restated Credit Agreement (the “Restated Credit Agreement”) with the other loan parties party thereto, Bank of Montreal, as administrative agent and the lenders party thereto, and (ii) consummating the transactions contemplated by the Investment Agreement (as defined and described in Note 15 – Series B Convertible Preferred Stock and Stockholders’ Equity). The Restated Credit Agreement amends and restates in its entirety the Prior Credit Facility (defined below).

The Restated Credit Agreement provides for a $25.0 million revolving credit facility (the “Restated Revolving Loan”) which matures on June 30, 2024, and a $275.0 million term credit facility (the “Restated Term Loan” and, together with the Restated Revolving Loan, the “Restated Credit Facility”), which matures on December 31, 2024. The Restated Credit Facility includes a $5.0 million swingline commitment and a $10.0 million letter of credit sub-limit. Loans under the Restated Term Loan bear interest at a rate equal to, at the Company’s option, either the Adjusted Eurodollar Rate for the interest period in effect for such borrowing plus an Applicable Rate of 6.25% per annum, or the Alternate Base Rate plus an Applicable Rate of 5.25% per annum. Loans under the Restated Revolving Loan bear interest at a rate equal to, at the Company’s option, the Adjusted Eurodollar Rate for the interest period in effect for such borrowing plus the Applicable Rate ranging from 6.25% to 6.0% per annum, based on

certain ratios. The interest rate was 7.25% for the three months ended September 30, 2020. The Company is also required to pay a commitment fee on the unused portion of the Restated Revolving Loan at a rate ranging from 0.5% to 0.375%, based on certain ratios. The Company is required to make mandatory prepayments of outstanding indebtedness under the Restated Credit Agreement under certain circumstances.

The obligations of AgroFresh Inc., a wholly-owned subsidiary of the Company and the borrower under the Restated Credit Facility, are initially guaranteed by the Company and the Company’s wholly-owned subsidiary, AF Solutions Holdings LLC (together with AgroFresh Inc. and the Company, the “Loan Parties”) and may in the future be guaranteed by certain other domestic subsidiaries of the Company. The obligations of the Loan Parties under the Credit Agreement and other loan documents are secured, subject to customary permitted liens and other agreed upon exceptions, by a perfected security interest in all tangible and intangible assets of the Loan Parties, except for certain excluded assets, and equity interests of certain foreign subsidiaries of the Loan Parties held by the Loan Parties (subject to certain exclusions and limitations).

The Refinancing was deemed a partial extinguishment of the Term Loan (as defined below) under ASC Topic No. 470-50, “Debt – Modifications and Extinguishments” (Topic No. 470), whereby $107.1 million of the $403.8 million outstanding at the time of the Refinancing was deemed an extinguishment and $296.7 million was deemed a modification of debt. As such, unamortized deferred issuance costs related to the extinguishment of $0.7 million were written off in debt modification and extinguishment expenses and the remaining $1.9 million was deferred and amortized over the term of the Restated Term Loan.

In connection with the Restated Term Loan, expenses incurred related to existing lenders of $4.4 million were recognized in debt modification and extinguishment expenses. Expenses to new lenders of $1.1 million were deferred and amortized over the term of the Restated Term Loan along with $6.4 million of lender fees and issue discounts.

In total, the Company deferred debt issuance costs of $7.5 million related to the Restated Term Loan, $1.9 million related to the modification of the Term Loan and $0.5 million related to the Restated Revolving Loan. The debt issuance costs associated with the Restated Term Loan were capitalized against the principal balance of the debt, and the Restated Revolving Loan costs were capitalized in Other Assets. All issuance costs will be accreted through interest expense using the effective interest method for the duration of each respective debt facility. The interest expense related to the amortization of the Restated Credit Facility debt issuance costs during the three months ended September 30, 2020 was $0.3 million. As of September 30, 2020 there were $9.0 million of unamortized deferred issuance costs.

At September 30, 2020, there was $275.0 million outstanding under the Restated Term Loan and no balance outstanding under the Restated Revolving Loan. At September 30, 2020, the Company evaluated the amount recorded under the Restated Term Loan and determined that the fair value was approximately $267.4 million. The fair value of the debt is based on quoted inactive market prices and is therefore classified as Level 2 within the valuation hierarchy.

Certain restrictive covenants are contained in the Restated Credit Agreement, and the Company was in compliance with these covenants as of September 30, 2020.

Prior Credit Facility

On July 31, 2015, in connection with the consummation of the Business Combination, AgroFresh Inc. as the borrower and AF Solutions Holdings LLC as the guarantor, entered into a Credit Agreement with Bank of Montreal, as administrative agent (as subsequently amended prior to the Refinancing, the “Prior Credit Facility”). The Prior Credit Facility consisted of a $425.0 million term loan (the “Term Loan”), with an amortization equal to 1.00% per year, and a revolving loan facility (the “Revolving Loan”). The net proceeds of the Term Loan were used to fund a portion of the purchase price payable to Dow in connection with the Business Combination.

The Revolving Loan included a $10.0 million letter-of-credit sub-facility, issuances against which reduce the available capacity for borrowing. The Term Loan had a scheduled maturity date of July 31, 2021. As discussed above, the Prior Credit Facility was refinanced on July 27, 2020, and there were no amounts outstanding as of September 30, 2020. The interest rates on borrowings under the facilities were either the alternate base rate plus 3.75% or LIBOR plus 4.75% per annum, with a 1.00% LIBOR floor (with step-downs in respect of borrowings under the Revolving Loan dependent upon the achievement of certain financial ratios).

As of the Closing Date, the Company incurred approximately $12.9 million in debt issuance costs related to the Term Loan and $1.3 million in costs related to the Revolving Loan. The debt issuance costs associated with the Term Loan were capitalized against the principal balance of the debt, and the Revolving Loan costs were capitalized in Other Assets. The interest expense related to the amortization of the Term Loan debt issuance costs during the three months ended September 30, 2020 and 2019, was approximately $0.2 million and $0.6 million, respectively. The interest expense related to the amortization of the Term Loan

debt issuance costs during the nine months ended September 30, 2020 and 2019 was approximately $1.4 million and $1.7 million, respectively.

Tecnidex Debt

On March 23, 2020, Tecnidex entered into a €1.0 million loan agreement with Banco Santander, S.A., which provides funding through March 2023 at a 1.5% interest rate. In May 2020, Tecnidex entered into a €0.3 million loan agreement with BBVA, which provides funding through May 2025 at a 2.2% interest rate. In July 2020, Tecnidex entered into a €0.6 million loan agreement with Banco Santander, S.A., which provides funding through July 2025 at a 2.5% interest rate.

Scheduled principal repayments of debt subsequent to September 30, 2020 are as follows:

(in thousands)	Amount
2020 (remaining)	$	815
2021	3,348
2022	3,390
2023	3,181
2024 and thereafter	$	266,450
Total	$	277,184

Interest Rate Swap

The Company entered into an interest rate swap contract in August 2019 to hedge interest rate risk remaining outstanding with the Restated Credit Facility. During the three and nine months ended September 30, 2020, an unrealized gain of $0.3 million and an unrealized loss of $0.4 million was recognized, respectively, in connection with this swap, which is still outstanding. The interest rate swap contract matures on December 31, 2020.

The Company entered into an interest rate swap contract in January 2018 to hedge interest rate risk associated with the Term Loan. The hedge was settled in September 2018 for $4.0 million, which is being amortized through December 31, 2020, the remaining period of the original hedge.

PPP Loan

As part of the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"), the Company received a Paycheck Protection Program ("PPP") loan to offset eligible costs incurred during the period. Under the terms of the PPP, PPP loans and accrued interest are forgivable after twenty-four weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the forgiveness period.

As of September 30, 2020, the Company has used the entire loan proceeds to fund its eligible payroll expenses and mortgage interest, avoiding furlough of office employees. As a result, the Company believes that it has met the PPP eligibility criteria for forgiveness and has concluded that the loan represents, in substance, a government grant that is expected to be forgiven. As such, in accordance with IAS 20 “Accounting for Government Grants and Disclosure of Government Assistance” the Company has recognized the entire loan amount as Grant Income at September 30, 2020.

The Company does not anticipate taking any action that would cause any portion of the loan to be ineligible for forgiveness. However, to the extent that any amount is deemed unforgivable, such amount is payable over two to five years at an interest rate of 1%, with a deferral of payments for the first six months.

XML

Leases

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Leases

Leases

The Company enters into lease agreements for certain facilities and vehicles that are primarily used in the ordinary course of business. These leases are accounted for as operating leases, whereby lease expense is recognized on a straight-line basis over the term of the lease.

Most leases include an option to extend or renew the lease term. The exercise of the renewal option is at the Company's discretion. The operating lease liability includes lease payments related to options to extend or renew the lease term if the

Company is reasonably certain of exercising those options. The Company, in determining the present value of lease payments, uses the Company’s incremental secured borrowing rate commensurate with the term of the underlying lease.

Lease expense is primarily included in general and administrative expenses in the condensed consolidated statements of operations. Additional information regarding the Company's operating leases is as follows:

(in thousands)	Three months ended September 30, 2020		Three months ended September 30, 2019		Nine months ended September 30, 2020		Nine months ended September 30, 2019
Operating leases	$	662	$	591	$	1,916	$	1,849
Short-term leases (1)	6		5		182		52
Total lease expense	$	668	$	596	$	2,098	$	1,901

(1)    Leases with an initial term of twelve months or less are not recorded on the balance sheet.

Other information on operating leases	Nine months ended September 30, 2020			Nine months ended September 30, 2019
Cash payments included in operating cash flows	$	1,645		$	1,625
Right-of-use assets obtained in exchange for new lease	$	769		$	376
Weighted average discount rate	9.11		%	9.33		%
Weighted average remaining lease term in years	5.09			5.53

The following table presents the contractual maturities of the Company's lease liabilities as of September 30, 2020:

(in thousands)	Lease Liability
Remainder of 2020	$	485
2021	1,784
2022	1,496
2023	1,228
2024 and thereafter	2,290
Total undiscounted lease payments	7,283
Less: present value adjustment	1,450
Operating lease liability	$	5,833

The following table presents the contractual maturities of the Company's lease liabilities as of December 31, 2019:

(in thousands)	Future lease Payments
2020	$	1,939
2021	1,670
2022	1,509
2023	1,294
2024 and thereafter	2,380
Total undiscounted lease payments	8,792
Less: present value adjustment	1,960
Operating lease liability	$	6,832

XML

Other Noncurrent Liabilities

9 Months Ended

Sep. 30, 2020

Liabilities, Other than Long-term Debt, Noncurrent [Abstract]

Other Noncurrent Liabilities

Other Noncurrent Liabilities

The Company’s other noncurrent liabilities at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Lease liability	$	4,465	$	5,339
Other (1)	1,524		1,907
Total other noncurrent liabilities	$	5,989	$	7,246

(1) Other noncurrent liabilities include long-term rebates and pension liabilities.

XML

Severance	9 Months Ended
	Sep. 30, 2020
Compensation Related Costs [Abstract]
Severance	SeveranceSeverance expense was $0.4 million and $0.3 million for the three months ended September 30, 2020 and 2019, respectively, and $0.5 million and $1.0 million for the nine months ended September 30, 2020 and 2019, respectively. These amounts, which do not include stock compensation expense, were recorded in selling, general and administrative expense in the condensed consolidated statements of operations. As of September 30, 2020 and December 31, 2019, the Company had a $0.2 million and $0.4 million severance liability, respectively.

XML

Series B Convertible Preferred Stock and Stockholders' Equity

9 Months Ended

Sep. 30, 2020

Stockholders' Equity Note [Abstract]

Series B Convertible Preferred Stock and Stockholders' Equity

Series B Convertible Preferred Stock and Stockholders’ Equity

Series B Convertible Preferred Stock

On June 13, 2020, the Company entered into an Investment Agreement (the “Investment Agreement”) with the Investor, an affiliate of Paine Schwartz Partners, LLC (“PSP”), pursuant to which, subject to certain closing conditions, the Investor agreed to purchase in a private placement an aggregate of $150,000,000 of convertible preferred equity of the Company. The transaction closed on July 27, 2020 and a total of 150,000 shares of the Company’s newly-designated Series B-1 Convertible Preferred Stock, par value $0.0001 per share (the “Series B-1 Preferred Stock”) were purchased in such transaction (the “Private Placement”). On September 22, 2020, following the approval of the transactions contemplated by the Investment Agreement by the necessary regulatory body, the Company issued to the Investor, for no additional consideration, a total of 150,000 shares of the Company’s newly-designated Series B-2 Convertible Preferred Stock, par value $0.0001 per share (the “Series B-2 Preferred Stock”). On September 25, 2020 (the "Exchange Date"), the Investor elected to exchange the shares of the Company’s Series B-1 Convertible Preferred Stock and Series B-2 Preferred Stock held by it for a total of 150,000 shares of the Company’s newly-designated Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). Accordingly, effective as of the Exchange Date, the Company issued 150,000 shares of Series B Convertible Preferred Stock, par value $0.0001 per share, to the Investor and all of the shares of Series B-1 Preferred Stock and Series B-2 Preferred Stock held by the Investor were cancelled. No shares of Series B-1 Preferred Stock or Series B-2 Preferred Stock are outstanding as of September 30, 2020.

The Series B Preferred Stock ranks senior to the shares of the Company’s common stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Series B Preferred Stock has a liquidation preference of $1,000 per share (the “Stated Value”). Holders of the Series B Preferred Stock are entitled to a cumulative dividend at a rate of 16% per annum, of which 50% will be payable in cash and 50% will be payable in kind until the first anniversary of the Closing Date, after which 50% will be payable in cash, 37.5% will be payable in kind, and the remaining 12.5% will be payable in cash or in kind, at the Company’s option, subject in each case to adjustment under certain circumstances. Dividends on the Series B Preferred Stock are cumulative and payable quarterly in arrears. All dividends that are paid in kind will accrete to, and increase, the Stated Value. The applicable dividend rate is subject to increase by 2% per annum during any period that the Company is in breach of certain provisions of the applicable Certificate of Designation of the Preferred Stock. The Series B Preferred Stock has been classified as temporary equity as it may be contingently redeemable in the event of a change of control, which is outside of the Company's control.

Associated with the Series B Preferred Stock, the Company paid $4.4 million of total dividends, of which $2.2 million were in additional preferred shares and $2.2 million were in cash for the three and nine months ended September 30, 2020, respectively. For the three and nine months ended September 30, 2019, the Company paid no dividends. As of September 30, 2020 and December 31, 2019, the Company had no accrued dividends.

The Series B Preferred Stock is convertible into Common Stock at the election of the holder at any time at an initial conversion price of $5.00 (the “Conversion Price”). The Conversion Price is subject to customary adjustments, including for stock splits and other reorganizations affecting the Common Stock and pursuant to certain anti-dilution provisions for below market issuances. As of September 30, 2020 and December 31, 2019, the maximum number of shares of common stock that could be issued upon conversion of the outstanding shares of Series B Preferred Stock was 30,440,000 and 0 shares, respectively.

The below table outlines the change in Series B Preferred Stock during the nine months ended September 30, 2020.

	Series B-1 Convertible Preferred Stock			Series B-2 Convertible Preferred Stock			Series B Convertible Preferred Stock
(in thousands, except share)	Shares	Amount		Shares	Amount		Shares	Amount
Balance at December 31, 2019	—	$	—	—	$	—	—	$	—
Issuance of preferred stock	150,000	150,000		150,000	—		150,000	150,000
Exchange to Series B preferred stock	(150,000)	(150,000)		(150,000)	—		—	—
Issuance-related expenses	—	—		—	—		—	(11,516)
Additional preferred shares	—	—		—	—		—	2,200
Balance at September 30, 2020	—	$	—	—	$	—	150,000	$	140,684

In connection with the consummation of the Investment Agreement, the Company and the Investor entered into a Registration Rights Agreement (the “Registration Rights Agreement”), dated as of July 27, 2020. The Registration Rights Agreement provides that the Company will use its commercially reasonable efforts to prepare and file a shelf registration statement with the SEC no later than the first business day following January 27, 2022, and to use its commercially reasonable efforts to cause such shelf registration statement to be declared effective as promptly as is reasonably practicable after its filing to permit the public resale of registrable securities covered by the Registration Rights Agreement. The registrable securities generally include any shares of the Company’s common stock into which the Series B Preferred Stock is convertible, and any other securities issued or issuable with respect to any such shares of common stock by way of share split, share dividend, distribution, recapitalization, merger, exchange, replacement or similar event or otherwise.

Common Stock

The authorized common stock of the Company consists of 400,000,000 shares with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share of common stock. As of September 30, 2020, there were 52,393,579 shares of common stock outstanding.

Warrants

On July 31, 2020, all outstanding warrants, consisting of warrants to purchase 15,983,072 shares of the Company’s common stock outstanding at a strike price of $11.50, expired. Of the 15,983,072 warrants, 9,823,072 were issued as part of the units sold in the Company's initial public offering in February 2014 (1,201,928 warrants were subsequently repurchased during 2015) and 6,160,000 warrants were sold in a private placement at the time of such public offering.

Series A Preferred Stock

In connection with and as a condition to the consummation of the Business Combination, the Company issued R&H one share of Series A Preferred Stock. R&H, voting as a separate class, is entitled to appoint one director to the Company’s board of directors for so long as R&H beneficially holds 10% or more of the aggregate amount of the outstanding shares of common stock and non-voting common stock of the Company. The Series A Preferred Stock has no other rights.

ATM Facility

In December 2018, the Company filed a shelf registration statement (File No. 333-229002) (the “Form S-3 Shelf”) with the Securities and Exchange Commission, that became effective in February 2019. On June 25, 2020, the Company established an at-the-market offering facility (the “ATM Facility”) under the Form S-3 Shelf, with Virtu Americas LLC, acting as sales agent with support from H.C. Wainwright & Co and Roth Capital Partners. The Company’s board of directors approved sales of up to $30,000,000 maximum aggregate offering of the Company’s common stock under the ATM Facility. Effective as of August 7, 2020, the Company suspended sales under its ATM Facility, in light of the Company’s recent completion of the Refinancing and current market conditions. No sales have been effected pursuant to the ATM Facility to date.

XML

Stock-based Compensation

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Stock-based Compensation

Stock-based CompensationIn July 2015, the Company adopted the 2015 Incentive Compensation Plan (as amended, the “Plan”), pursuant to which the Compensation Committee of the Company is authorized to grant up to 7,150,000 shares to officers and employees of the Company, in the form of equity-based awards, including time or performance based options and restricted stock.

In June 2019, the Company's shareholders approved the 2019 Employee Stock Purchase Plan (the "ESPP"), which became effective July 1, 2019. 500,000 shares of common stock are reserved for issuance under the ESPP. As of September 30, 2020, 253,042 shares had been issued under the ESPP.

Stock compensation expense for equity-classified and liability-classified awards was $0.9 million and $1.0 million for the three months ended September 30, 2020 and 2019, respectively. Stock compensation expense for equity-classified and liability-classified awards was $2.7 million and $2.1 million for the nine months ended September 30, 2020 and 2019, respectively. Stock compensation expense is recognized in cost of goods sold, selling, general and administrative expenses and research and development expenses. At September 30, 2020, there was $5.3 million of unrecognized compensation cost relating to outstanding unvested equity instruments expected to be recognized over the weighted average period of 1.9 years.

XML

Earnings Per Share

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Earnings Per Share

Earnings Per Share

Basic (loss) income per share is calculated by dividing net (loss) income by the weighted average number of common shares outstanding for the period. The Company had a loss for the nine months ended September 30, 2020 and 2019. Therefore, the effect of stock-based awards including options, restricted stock, restricted stock units and warrants outstanding at September 30, 2020 and 2019, respectively, have not been included in the computation of diluted loss per share because their inclusion would have been anti-dilutive.

The following is a reconciliation of the weighted-average common shares outstanding used for the computation of basic and diluted net (loss) income per common share:

	Three Months Ended September 30, 2020	Three Months Ended September 30, 2019	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2019
Basic weighted-average common shares outstanding	51,001,852	50,227,590	50,765,829	50,138,835
Effect of dilutive options, performance stock units and restricted stock	—	60,714	—	—
Diluted weighted-average shares outstanding	51,001,852	50,288,304	50,765,829	50,138,835

Securities that could potentially be dilutive are excluded from the computation of diluted (loss) income per share when a loss from continuing operations exists, when the exercise price exceeds the average closing price of the Company's common stock during the period, or for contingently issued shares, if the contingency is not met at the end of the reporting period, because their inclusion would result in an anti-dilutive effect on per share amounts.

The following represents the weighted-average number of shares that could potentially dilute basic earnings per share in the future:

	Three Months Ended September 30, 2020	Three Months Ended September 30, 2019	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2019
Convertible preferred stock	21,526,522	—	7,227,883	—
Stock-based compensation awards(1):
Stock options	799,570	1,028,583	804,267	949,987
Restricted stock to non-directors	1,811,016	749,510	1,079,151	624,930
Warrants:
Private placement warrants	2,075,652	6,160,000	4,788,613	6,160,000
Public warrants	3,309,948	9,823,072	7,636,184	9,823,072

(1)             SARs and Phantom Shares are payable in cash so will have no impact on number of shares.

Warrants and options are considered anti-dilutive and excluded when the exercise price exceeds the average market value of the Company’s common stock price during the applicable period.

XML

Income Taxes

9 Months Ended

Sep. 30, 2020

Income Tax Disclosure [Abstract]

Income Taxes

Income TaxesThe provision for income taxes consists of provisions for federal, state and foreign incomes taxes. The effective tax rates for the periods ended September 30, 2020 and September 30, 2019, reflect the Company’s expected tax rate on reported income (loss)

from continuing operations before income tax and tax adjustments. The Company operates in a global environment with significant operations in the U.S. and various other jurisdictions outside the U.S. Accordingly, the consolidated income tax rate is a composite rate reflecting the Company’s earnings and the applicable tax rates in the various jurisdictions where the Company operates.

On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act. The CARES Act includes tax changes and financial aid designed to protect the American people from the public health and economic impacts of COVID-19. The tax changes include allowing net operating losses to be carried back five years, suspending the 80% of taxable limitation on the use of net operating losses, an increase of the 30% of EBITDA limitation on the deduction of interest expense to 50%, and acceleration of the refund for alternative minimum tax credits granted under the 2017 Tax Cuts and Jobs Act (“TCJA”). Most significant to the Company are the modifications on the limitation of business interest deductions for tax years beginning in 2019 and 2020. The modifications to Section 163(j) increase the allowable business interest deduction from 30% to 50% of adjusted taxable income.

The Company's U.S. operations have incurred cumulative taxable losses through September 30, 2020. The Company’s U.S. net operating loss carry forwards and carry forwards of other tax attributes are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. The utilization of the tax attributes may become restricted in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, as well as similar state tax provisions. This could limit the amount of the tax attributes that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will generally be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. Please refer to Note 4 regarding the ownership change in the quarter ended September 30, 2020. The Company completed a Section 382 study and determined the ownership change gave rise to the restrictions that will limit the realizability of certain U.S. tax attributes.

Typically, the Company has calculated its provision for income taxes during its interim reporting periods by applying an estimate of the annual effective tax rate for the full year "ordinary" income or loss for the respective reporting period. For the nine months ended September 30, 2020, the Company has computed its provision for income taxes under the discrete method which allows the Company to calculate its tax provision based upon the actual effective tax rate for the year-to-date. The discrete method was determined to be an appropriate method for estimating its tax provision for the nine months ended September 30, 2020 as it provides a reliable estimate as opposed to changes in estimated "ordinary" income or loss which would have resulted in significant fluctuations when estimating the annual effective tax rate.

The effective tax rate for the nine months ended September 30, 2020 differs from the U.S. statutory tax rate of 21%, primarily because of changes in valuation allowance positions related to the United States and certain foreign jurisdictions and by foreign exchange currency gains, offset by foreign provision to return tax benefits, primarily in France. The Company recorded an increase of $24.7 million in the valuation allowance for the three months ended September 30, 2020, primarily as a result of the ownership change that will limit the realizability of certain U.S. tax attributes.

The Company's effective tax rate for the three and nine months ended September 30, 2020 was 743.9% and (111.7)%, respectively, compared to the effective tax rate for the three and nine months ended September 30, 2019 of 214.0% and 28.2%, respectively.

XML

Segment Information

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Segment Information

Segment Information

The authoritative guidance for disclosures about segments of an enterprise establishes standards for reporting information about segments. It defines operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. We currently operate and manage our business as two operating segments. Our chief operating decision-makers allocate resources and assess performance of the business for each segment. Accordingly, we consider ourselves to have two operating and reportable segments (i) AgroFresh core and (ii) Tecnidex. AgroFresh core business is providing produce preservation and waste prevention solutions for growers and packers. Its products include SmartFresh, Harvista, RipeLock and FreshCloud. Tecnidex is a provider of fungicides, disinfectants, waxes and coatings primarily focused on the citrus market.

Our chief operating decision-maker does not evaluate operating segments using asset or liability information. The following table presents a breakdown of our revenues and gross profit based on reportable segments for the three and nine months ended September 30, 2020 and 2019.

(in thousands)	Three Months Ended September 30, 2020		Three Months Ended September 30, 2019		Nine Months Ended September 30, 2020		Nine Months Ended September 30, 2019
AgroFresh Core
Revenues	$	49,343	$	45,917	$	94,723	$	96,272
Gross Profit	38,283		34,182		73,080		72,679
Tecnidex
Revenues	3,427		3,055		11,052		12,823
Gross Profit	976		898		4,203		4,900
Total Revenues	$	52,770	$	48,972	$	105,775	$	109,095
Total Gross Profit	$	39,259	$	35,080	$	77,283	$	77,579

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Commitments and Contingencies

The Company is currently involved in various claims and legal actions that arise in the ordinary course of business. The Company has recorded reserves for loss contingencies based on the specific circumstances of each case. Such reserves are recorded when it is probable that a loss has been incurred as of the balance sheet date and can be reasonably estimated. Although the results of litigation and claims can never be predicted with certainty, the Company does not believe that the ultimate resolution of these actions will have a material adverse effect on the Company’s business, financial condition or results of operations.

On October 14, 2019, the Company was awarded a verdict of $31.1 million in damages, related to, among other things, trade secret misappropriation and willful patent infringement, in its litigation against Decco Post-Harvest, Inc. ("Decco") and Decco's parent company, UPL Limited. The award is subject to post-verdict review by the Court and any appeals that may be taken by the parties in the future.

In July 2020, three separate putative class action lawsuits were filed against the Company, each alleging that the Company’s disclosures regarding the transactions contemplated by the Investment Agreement contained in its proxy statement for the 2020 annual meeting of the Company’s stockholders were inadequate.

Purchase Commitments

The Company has various purchasing contracts for contract manufacturing and research and development services which are based on the requirements of the business. Generally, the contracts are at prices not in excess of current market prices and do not commit the business to obligations outside the normal customary terms for similar contracts.

XML

Fair Value Measurements

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

Fair Value Measurements

Liabilities Measured at Fair Value on a Recurring Basis

The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of September 30, 2020:

(in thousands)	Level 1		Level 2		Level 3		Total
Liability-classified stock compensation (1)	$	—	$	—	$	294	$	294
Interest rate swap	—		—		290		290
Total	$	—	$	—	$	584	$	584

The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2019:

(in thousands)	Level 1		Level 2		Level 3		Total
Liability-classified stock compensation (1)	$	—	$	—	$	218	$	218
Interest rate swap	—		—		(95)		(95)
Total	$	—	$	—	$	123	$	123

(1) The fair values of phantom stock units were estimated using a Monte Carlo simulation pricing model with the assumptions described below:

	September 30, 2020
Grant date fair value	$	1.70		—	$7.28
Risk-free interest rate	0.27		%	—	2.39%
Expected life (years)	2.71			—	2.75
Estimated volatility factor	65.1		%	—	69.9%
Expected dividends	None

There were no transfers between Level 1 and Level 2 and no transfers out of Level 3 of the fair value hierarchy during the nine months ended September 30, 2020.

At September 30, 2020, the Company evaluated the amount recorded under the Restated Term Loan and determined that the fair value was approximately $267.4 million. The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value.

Changes in Financial Instruments Measured at Level 3 Fair Value on a Recurring Basis

The following table presents the changes during the period presented in the Company's Level 3 financial instrument liabilities that are measured at fair value on a recurring basis.

(in thousands)	Liability-classified stock compensation		Interest rate swap		Total
Balance, December 31, 2019	$	218	$	(95)	$	123
Stock compensation activity	76		—		76
Mark-to-market adjustment	—		385		385
Balance, September 30, 2020	$	294	$	290	$	584

XML

Basis of Presentation and Summary of Significant Accounting Policies (Policy)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. These financial statements include all adjustments that are necessary for a fair presentation of the Company's condensed consolidated results of operations, financial condition and cash flows for the periods shown, including normal, recurring accruals and other items. The condensed consolidated results of operations for the interim periods presented are not necessarily indicative of results for the full year. For additional information, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report filed on Form 10-K for the year ended December 31, 2019.

Revenue Recognition

Adoption of Highly Inflationary Accounting in Argentina

GAAP requires the use of highly inflationary accounting for countries whose cumulative three-year inflation rate exceeds 100 percent. The Company closely monitors the inflation data and currency volatility in Argentina, where there are multiple data sources for measuring and reporting inflation. In the second quarter of 2018, the Argentine peso rapidly devalued relative to the

U.S. dollar, which along with increased inflation, indicated that the three-year cumulative inflation rate in that country exceeded 100 percent as of June 30, 2018. As a result, the Company adopted highly inflationary accounting as of July 1, 2018 for its subsidiary in Argentina. Under highly inflationary accounting, the functional currency of the Company's subsidiary in Argentina became the U.S. dollar, and its income statement and balance sheet are measured in U.S. dollars using both current and historical rates of exchange. The effect of changes in exchange rates on Argentine peso-denominated monetary assets and liabilities are reflected in earnings. As the three-year cumulative inflation rate exceeded 100 percent as of September 30, 2020, there is no change to highly inflationary accounting. As of September 30, 2020, the Company’s subsidiary in Argentina had a net asset position of $3.0 million. Net sales attributable to Argentina were approximately 6% and 6% of the Company’s consolidated net sales for each of the nine months ended September 30, 2020 and 2019, respectively.

Disaggregation of Revenue

The Company disaggregates revenue from contracts with customers into geographic region, product and timing of transfer of goods and services. The Company determined that disaggregating revenue into these categories achieves the disclosure objective of depicting how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

Revenues for the three months ended September 30, 2020

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	17,122	$	28,906	$	845	$	1,165	$	48,038
Fungicides, waxes, coatings and disinfectants	534		3,011		575		—		4,120
Other*	190		115		210		97		612
	$	17,846	$	32,032	$	1,630	$	1,262	$	52,770
Pattern of Revenue Recognition
Products transferred at a point in time	$	17,663	$	31,921	$	1,420	$	1,165	$	52,169
Services transferred over time	183		111		210		97		601
	$	17,846	$	32,032	$	1,630	$	1,262	$	52,770

Revenues for the three months ended September 30, 2019

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	19,726	$	22,377	$	1,680	$	1,605	$	45,388
Fungicides, waxes, coatings and disinfectants	—		2,857		198		—		3,055
Other*	218		86		108		117		529
	$	19,944	$	25,320	$	1,986	$	1,722	$	48,972
Pattern of Revenue Recognition
Products transferred at a point in time	$	19,802	$	25,238	$	1,877	$	1,605	$	48,522
Services transferred over time	142		82		109		117		450
	$	19,944	$	25,320	$	1,986	$	1,722	$	48,972

Revenues for the nine months ended September 30, 2020

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	19,264	$	37,223	$	23,217	$	11,538	$	91,242
Fungicides, waxes, coatings and disinfectants	534		9,650		1,750		—		11,934
Other*	722		700		938		239		2,599
	$	20,520	$	47,573	$	25,905	$	11,777	$	105,775
Pattern of Revenue Recognition
Products transferred at a point in time	$	19,823	$	46,887	$	25,338	$	11,538	$	103,586
Services transferred over time	697		686		567		239		2,189
	$	20,520	$	47,573	$	25,905	$	11,777	$	105,775

Revenues for the nine months ended September 30, 2019

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	23,084	$	31,965	$	27,503	$	11,287	$	93,839
Fungicides, waxes, coatings and disinfectants	—		11,365		1,458		—		12,823
Other*	954		927		381		171		2,433
	$	24,038	$	44,257	$	29,342	$	11,458	$	109,095
Pattern of Revenue Recognition
Products transferred at a point in time	$	23,380	$	43,374	$	29,159	$	11,309	$	107,222
Services transferred over time	658		883		183		149		1,873
	$	24,038	$	44,257	$	29,342	$	11,458	$	109,095

*Other includes FreshCloud, technical services and sales-type leases related to Tecnidex.

———————————————————————————————————

(1)            North America includes the United States and Canada.

(2)             EMEA includes Europe, the Middle East and Africa.

(3)             Latin America includes Argentina, Brazil, Chile, Costa Rica, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Peru and Uruguay.

(4)             Asia Pacific includes Australia, China, India, Japan, New Zealand, the Philippines, South Korea, Taiwan and Thailand.

Contract Assets and Liabilities

ASC 606 requires an entity to present a revenue contract as a contract asset when the entity performs its obligations under the contract by transferring goods or services to a customer before the customer pays consideration or before payment is due. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g., receivable), before the entity transfers a good or service to the customer. The following table presents changes in the Company’s contract assets and liabilities during the nine months ended September 30, 2020 and the year ended December 31, 2019:

(in thousands)	Balance at January 1, 2020		Additions	Deductions	Balance at September 30, 2020
Contract assets:
Unbilled revenue	$	1,666	11,670	(9,423)	$	3,913
Contract liabilities:
Deferred revenue	$	1,175	4,437	(4,239)	$	1,373

(in thousands)	Balance at January 1, 2019		Additions	Deductions	Balance at December 31, 2019
Contract assets:
Unbilled revenue	$	1,956	10,029	(10,319)	$	1,666
Contract liabilities:
Deferred revenue	$	1,280	3,032	(3,137)	$	1,175

The Company recognizes contract assets in the form of unbilled revenue in instances where services are performed by the Company but not billed by period end. The Company recognizes contract liabilities in the form of deferred revenue in instances where a customer pays in advance for future services to be performed by the Company. The Company generally receives payments from its customers based on standard terms and conditions.

Recently Issued Accounting Standards and Pronouncements

Recently Issued Accounting Standards and Pronouncements

In January 2017, the Financial Accounting Standards Board ("FASB") issued ASU No. 2017-04, "Intangibles - Goodwill and Other", which simplifies the test for goodwill impairment. The guidance was effective for the Company beginning in the first quarter of fiscal year 2020. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the condensed consolidated financial statements of the Company.

In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments”, which introduces a new

current expense credit loss model to measure impairment on certain types of financial instruments. This update requires an entity to use a forward-looking expected credit loss model for accounts receivable, loans, and other financial instruments. In addition, the FASB issued various amendments during 2018 and 2019 to clarify the provisions of ASU 2016-13. The standard was effective for fiscal years beginning January 1, 2020, including interim periods. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the financial statements of the Company.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify and add

certain disclosure requirements related to fair value measurements covered in Topic 820. The new standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the notes to condensed consolidated financial statements of the Company.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments simplify the accounting for income taxes by removing certain exceptions to the general principles of Topic 740, "Income Taxes" and also improve consistent application by clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted, with the amendments to be applied on a retrospective, modified retrospective or prospective basis, depending on the specific amendment. The Company is currently evaluating the impact of adopting this guidance.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments are intended to ease the potential burden in accounting for, or recognizing the effects of, reference rate

reform on financial reporting. The new standard is effective on a date selected by the Company between March 12, 2020 and December 31, 2022. The Company is currently evaluating the impact of adopting this guidance.

XML

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Schedule of disaggregated revenue

Revenues for the three months ended September 30, 2020

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	17,122	$	28,906	$	845	$	1,165	$	48,038
Fungicides, waxes, coatings and disinfectants	534		3,011		575		—		4,120
Other*	190		115		210		97		612
	$	17,846	$	32,032	$	1,630	$	1,262	$	52,770
Pattern of Revenue Recognition
Products transferred at a point in time	$	17,663	$	31,921	$	1,420	$	1,165	$	52,169
Services transferred over time	183		111		210		97		601
	$	17,846	$	32,032	$	1,630	$	1,262	$	52,770

Revenues for the three months ended September 30, 2019

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	19,726	$	22,377	$	1,680	$	1,605	$	45,388
Fungicides, waxes, coatings and disinfectants	—		2,857		198		—		3,055
Other*	218		86		108		117		529
	$	19,944	$	25,320	$	1,986	$	1,722	$	48,972
Pattern of Revenue Recognition
Products transferred at a point in time	$	19,802	$	25,238	$	1,877	$	1,605	$	48,522
Services transferred over time	142		82		109		117		450
	$	19,944	$	25,320	$	1,986	$	1,722	$	48,972

Revenues for the nine months ended September 30, 2020

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	19,264	$	37,223	$	23,217	$	11,538	$	91,242
Fungicides, waxes, coatings and disinfectants	534		9,650		1,750		—		11,934
Other*	722		700		938		239		2,599
	$	20,520	$	47,573	$	25,905	$	11,777	$	105,775
Pattern of Revenue Recognition
Products transferred at a point in time	$	19,823	$	46,887	$	25,338	$	11,538	$	103,586
Services transferred over time	697		686		567		239		2,189
	$	20,520	$	47,573	$	25,905	$	11,777	$	105,775

Revenues for the nine months ended September 30, 2019

(in thousands)
Region	North America (1)		EMEA (2)		Latin America (3)		Asia Pacific (4)		Total Revenues
Product
1-MCP based	$	23,084	$	31,965	$	27,503	$	11,287	$	93,839
Fungicides, waxes, coatings and disinfectants	—		11,365		1,458		—		12,823
Other*	954		927		381		171		2,433
	$	24,038	$	44,257	$	29,342	$	11,458	$	109,095
Pattern of Revenue Recognition
Products transferred at a point in time	$	23,380	$	43,374	$	29,159	$	11,309	$	107,222
Services transferred over time	658		883		183		149		1,873
	$	24,038	$	44,257	$	29,342	$	11,458	$	109,095

*Other includes FreshCloud, technical services and sales-type leases related to Tecnidex.

———————————————————————————————————

(1)            North America includes the United States and Canada.

(2)             EMEA includes Europe, the Middle East and Africa.

(3)             Latin America includes Argentina, Brazil, Chile, Costa Rica, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Peru and Uruguay.

(4)             Asia Pacific includes Australia, China, India, Japan, New Zealand, the Philippines, South Korea, Taiwan and Thailand.

Schedule of changes in contract assets and liabilities

The following table presents changes in the Company’s contract assets and liabilities during the nine months ended September 30, 2020 and the year ended December 31, 2019:

(in thousands)	Balance at January 1, 2020		Additions	Deductions	Balance at September 30, 2020
Contract assets:
Unbilled revenue	$	1,666	11,670	(9,423)	$	3,913
Contract liabilities:
Deferred revenue	$	1,175	4,437	(4,239)	$	1,373

(in thousands)	Balance at January 1, 2019		Additions	Deductions	Balance at December 31, 2019
Contract assets:
Unbilled revenue	$	1,956	10,029	(10,319)	$	1,666
Contract liabilities:
Deferred revenue	$	1,280	3,032	(3,137)	$	1,175

XML

Inventories (Tables)

9 Months Ended

Sep. 30, 2020

Inventory Disclosure [Abstract]

Schedule of inventories

Inventories at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Raw material	$	3,026	$	3,401
Work-in-process	8,575		7,278
Finished goods	11,619		10,974
Supplies	1,224		968
Total inventories	$	24,444	$	22,621

XML

Other Current Assets (Tables)

9 Months Ended

Sep. 30, 2020

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of other current assets

The Company's other current assets at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
VAT receivable	$	7,627	$	4,925
Prepaid income tax asset	5,349		3,616
Prepaid and other current assets	4,289		3,261
Total other current assets	$	17,265	$	11,802

XML

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2020

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

Property and equipment at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands, except for useful life data)	Useful life (years)	September 30, 2020		December 31, 2019
Buildings and leasehold improvements	7-20	$	7,032	$	6,508
Machinery & equipment	1-12	11,953		10,954
Furniture	1-12	2,944		2,681
Construction in progress		1,149		902
		23,078		21,045
Less: accumulated depreciation		(9,803)		(7,868)
Total property and equipment, net		$	13,275	$	13,177

XML

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of changes in the carrying amount of goodwill

Changes in the carrying amount of goodwill for the nine months ended September 30, 2020 and the year ended December 31, 2019 were as follows:

(in thousands)	September 30, 2020		December 31, 2019
Beginning balance	$	6,323	$	6,670
Foreign currency translation	282		(347)
Ending balance	$	6,605	$	6,323

Schedule of other intangible assets

The Company’s intangible assets at September 30, 2020 and December 31, 2019 consisted of the following:

	September 30, 2020								December 31, 2019
(in thousands)	Gross Carrying Amount		Accumulated Amortization		Impairment		Net		Gross Carrying Amount		Accumulated Amortization		Impairment		Net
Other intangible assets:
Developed technology	$	798,240	$	(244,918)	$	—	$	553,322	$	758,760	$	(206,998)	$	—	$	551,762
In-process research and development	—		—		—		—		39,000		(7,222)		—		31,778
Trade name	27,158		—		—		27,158		27,200		—				27,200
Service provider network	2,000		—		—		2,000		2,000		—		—		2,000
Customer relationships	18,551		(3,548)		—		15,003		18,058		(2,993)		—		15,065
Software	10,691		(8,967)		—		1,724		9,861		(5,347)		(992)		3,522
Other	100		(71)		—		29		100		(58)		—		42
Total intangible assets	$	856,740	$	(257,504)	$	—	$	599,236	$	854,979	$	(222,618)	$	(992)	$	631,369

Schedule of estimated annual amortization expense for finite-lived intangible assets

Estimated annual amortization expense for finite-lived intangible assets subsequent to September 30, 2020 is as follows:

(in thousands)	Amount
2020 (remaining)	$	12,045
2021	41,730
2022	40,893
2023	40,791
2024	40,791
Thereafter	393,828
Total	$	570,078

XML

Other Assets (Tables)

9 Months Ended

Sep. 30, 2020

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Assets

The Company’s other assets at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Right-of-use asset	$	5,657	$	6,599
Long term sales-type lease receivable	2,354		2,501
Other long term receivable	3,438		3,061
Total other assets	$	11,449	$	12,161

XML

Accrued and Other Current Liabilities (Tables)

9 Months Ended

Sep. 30, 2020

Payables and Accruals [Abstract]

Accrued and other current liabilities

The Company’s accrued and other current liabilities at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Accrued compensation and benefits	$	7,111	$	7,307
Accrued taxes	6,501		3,017
Lease liability	1,368		1,493
Accrued rebates payable	3,001		1,377
Insurance premium financing payable	1,151		1,000
Severance	218		444
Deferred revenue	1,373		1,175
Accrued interest	66		71
Interest rate swap	290		—
Other	5,586		8,466
Total accrued and other current liabilities	$	26,665	$	24,350

XML

Debt (Tables)

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Schedule of debt, net of unamortized discount and deferred financing fees

The Company’s debt, net of unamortized deferred issuance costs, at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Total term loan outstanding	$	275,000	$	405,875
Unamortized deferred issuance costs	(9,018)		(3,886)
Tecnidex loan outstanding	2,184		750
Less: Amounts due within one year	3,316		4,675
Total long-term debt due after one year	$	264,850	$	398,064

Schedule of principal repayments under the term loan

Scheduled principal repayments of debt subsequent to September 30, 2020 are as follows:

(in thousands)	Amount
2020 (remaining)	$	815
2021	3,348
2022	3,390
2023	3,181
2024 and thereafter	$	266,450
Total	$	277,184

XML

Leases (Tables)

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Schedule of Additional Information of Operating Leases

Additional information regarding the Company's operating leases is as follows:

(in thousands)	Three months ended September 30, 2020		Three months ended September 30, 2019		Nine months ended September 30, 2020		Nine months ended September 30, 2019
Operating leases	$	662	$	591	$	1,916	$	1,849
Short-term leases (1)	6		5		182		52
Total lease expense	$	668	$	596	$	2,098	$	1,901

(1)    Leases with an initial term of twelve months or less are not recorded on the balance sheet.

Other information on operating leases	Nine months ended September 30, 2020			Nine months ended September 30, 2019
Cash payments included in operating cash flows	$	1,645		$	1,625
Right-of-use assets obtained in exchange for new lease	$	769		$	376
Weighted average discount rate	9.11		%	9.33		%
Weighted average remaining lease term in years	5.09			5.53

Schedule of Maturities of Lease Liabilities

The following table presents the contractual maturities of the Company's lease liabilities as of September 30, 2020:

(in thousands)	Lease Liability
Remainder of 2020	$	485
2021	1,784
2022	1,496
2023	1,228
2024 and thereafter	2,290
Total undiscounted lease payments	7,283
Less: present value adjustment	1,450
Operating lease liability	$	5,833

The following table presents the contractual maturities of the Company's lease liabilities as of December 31, 2019:

(in thousands)	Future lease Payments
2020	$	1,939
2021	1,670
2022	1,509
2023	1,294
2024 and thereafter	2,380
Total undiscounted lease payments	8,792
Less: present value adjustment	1,960
Operating lease liability	$	6,832

XML

Other Noncurrent Liabilities (Tables)

9 Months Ended

Sep. 30, 2020

Liabilities, Other than Long-term Debt, Noncurrent [Abstract]

Other noncurrent liabilities

The Company’s other noncurrent liabilities at September 30, 2020 and December 31, 2019 consisted of the following:

(in thousands)	September 30, 2020		December 31, 2019
Lease liability	$	4,465	$	5,339
Other (1)	1,524		1,907
Total other noncurrent liabilities	$	5,989	$	7,246

(1) Other noncurrent liabilities include long-term rebates and pension liabilities.

XML

Series B Convertible Preferred Stock and Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Change in Series B Preferred Stock

The below table outlines the change in Series B Preferred Stock during the nine months ended September 30, 2020.

	Series B-1 Convertible Preferred Stock			Series B-2 Convertible Preferred Stock			Series B Convertible Preferred Stock
(in thousands, except share)	Shares	Amount		Shares	Amount		Shares	Amount
Balance at December 31, 2019	—	$	—	—	$	—	—	$	—
Issuance of preferred stock	150,000	150,000		150,000	—		150,000	150,000
Exchange to Series B preferred stock	(150,000)	(150,000)		(150,000)	—		—	—
Issuance-related expenses	—	—		—	—		—	(11,516)
Additional preferred shares	—	—		—	—		—	2,200
Balance at September 30, 2020	—	$	—	—	$	—	150,000	$	140,684

XML

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Schedule of weighted average common shares outstanding

The following is a reconciliation of the weighted-average common shares outstanding used for the computation of basic and diluted net (loss) income per common share:

	Three Months Ended September 30, 2020	Three Months Ended September 30, 2019	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2019
Basic weighted-average common shares outstanding	51,001,852	50,227,590	50,765,829	50,138,835
Effect of dilutive options, performance stock units and restricted stock	—	60,714	—	—
Diluted weighted-average shares outstanding	51,001,852	50,288,304	50,765,829	50,138,835

Amounts that could potentially dilute basic earnings per share

The following represents the weighted-average number of shares that could potentially dilute basic earnings per share in the future:

	Three Months Ended September 30, 2020	Three Months Ended September 30, 2019	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2019
Convertible preferred stock	21,526,522	—	7,227,883	—
Stock-based compensation awards(1):
Stock options	799,570	1,028,583	804,267	949,987
Restricted stock to non-directors	1,811,016	749,510	1,079,151	624,930
Warrants:
Private placement warrants	2,075,652	6,160,000	4,788,613	6,160,000
Public warrants	3,309,948	9,823,072	7,636,184	9,823,072

(1)             SARs and Phantom Shares are payable in cash so will have no impact on number of shares.

XML

Segment Information (Tables)

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Schedule of revenue by segment

The following table presents a breakdown of our revenues and gross profit based on reportable segments for the three and nine months ended September 30, 2020 and 2019.

(in thousands)	Three Months Ended September 30, 2020		Three Months Ended September 30, 2019		Nine Months Ended September 30, 2020		Nine Months Ended September 30, 2019
AgroFresh Core
Revenues	$	49,343	$	45,917	$	94,723	$	96,272
Gross Profit	38,283		34,182		73,080		72,679
Tecnidex
Revenues	3,427		3,055		11,052		12,823
Gross Profit	976		898		4,203		4,900
Total Revenues	$	52,770	$	48,972	$	105,775	$	109,095
Total Gross Profit	$	39,259	$	35,080	$	77,283	$	77,579

XML

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Tabular disclosure of financial instruments measured at fair value on a recurring basis

The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of September 30, 2020:

(in thousands)	Level 1		Level 2		Level 3		Total
Liability-classified stock compensation (1)	$	—	$	—	$	294	$	294
Interest rate swap	—		—		290		290
Total	$	—	$	—	$	584	$	584

The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2019:

(in thousands)	Level 1		Level 2		Level 3		Total
Liability-classified stock compensation (1)	$	—	$	—	$	218	$	218
Interest rate swap	—		—		(95)		(95)
Total	$	—	$	—	$	123	$	123

(1) The fair values of phantom stock units were estimated using a Monte Carlo simulation pricing model with the assumptions described below:

	September 30, 2020
Grant date fair value	$	1.70		—	$7.28
Risk-free interest rate	0.27		%	—	2.39%
Expected life (years)	2.71			—	2.75
Estimated volatility factor	65.1		%	—	69.9%
Expected dividends	None

Changes in financial instruments measured at level 3 fair value on a recurring basis

The following table presents the changes during the period presented in the Company's Level 3 financial instrument liabilities that are measured at fair value on a recurring basis.

(in thousands)	Liability-classified stock compensation		Interest rate swap		Total
Balance, December 31, 2019	$	218	$	(95)	$	123
Stock compensation activity	76		—		76
Mark-to-market adjustment	—		385		385
Balance, September 30, 2020	$	294	$	290	$	584

XML

Description of Business (Details) storage_room in Thousands	9 Months Ended
	Sep. 30, 2020 storage_room country
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating countries (over) | country	50
Number of storage rooms (over) | storage_room	25

XML

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - Argentina - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Subsidiaries
Concentration Risk [Line Items]
Net assets	$ 3.0
Revenue from Contract with Customer | Geographic Concentration Risk
Concentration Risk [Line Items]
Concentration risk percentage	6.00%	6.00%
Revenue Benchmark | Geographic Concentration Risk
Concentration Risk [Line Items]
Concentration risk percentage		6.00%

XML

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Total Revenues	$ 52,770	$ 48,972	$ 105,775	$ 109,095
North America
Disaggregation of Revenue [Line Items]
Total Revenues	17,846	19,944	20,520	24,038
EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	32,032	25,320	47,573	44,257
Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	1,630	1,986	25,905	29,342
Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	1,262	1,722	11,777	11,458
Products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total Revenues	52,169	48,522	103,586	107,222
Products transferred at a point in time | North America
Disaggregation of Revenue [Line Items]
Total Revenues	17,663	19,802	19,823	23,380
Products transferred at a point in time | EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	31,921	25,238	46,887	43,374
Products transferred at a point in time | Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	1,420	1,877	25,338	29,159
Products transferred at a point in time | Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	1,165	1,605	11,538	11,309
Services transferred over time
Disaggregation of Revenue [Line Items]
Total Revenues	601	450	2,189	1,873
Services transferred over time | North America
Disaggregation of Revenue [Line Items]
Total Revenues	183	142	697	658
Services transferred over time | EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	111	82	686	883
Services transferred over time | Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	210	109	567	183
Services transferred over time | Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	97	117	239	149
1-MCP based
Disaggregation of Revenue [Line Items]
Total Revenues	48,038	45,388	91,242	93,839
1-MCP based | North America
Disaggregation of Revenue [Line Items]
Total Revenues	17,122	19,726	19,264	23,084
1-MCP based | EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	28,906	22,377	37,223	31,965
1-MCP based | Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	845	1,680	23,217	27,503
1-MCP based | Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	1,165	1,605	11,538	11,287
Fungicides, waxes, coatings and disinfectants
Disaggregation of Revenue [Line Items]
Total Revenues	4,120	3,055	11,934	12,823
Fungicides, waxes, coatings and disinfectants | North America
Disaggregation of Revenue [Line Items]
Total Revenues	534	0	534	0
Fungicides, waxes, coatings and disinfectants | EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	3,011	2,857	9,650	11,365
Fungicides, waxes, coatings and disinfectants | Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	575	198	1,750	1,458
Fungicides, waxes, coatings and disinfectants | Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	0	0	0	0
Other
Disaggregation of Revenue [Line Items]
Total Revenues	612	529	2,599	2,433
Other | North America
Disaggregation of Revenue [Line Items]
Total Revenues	190	218	722	954
Other | EMEA
Disaggregation of Revenue [Line Items]
Total Revenues	115	86	700	927
Other | Latin America
Disaggregation of Revenue [Line Items]
Total Revenues	210	108	938	381
Other | Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenues	$ 97	$ 117	$ 239	$ 171

XML

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Contract assets:
Beginning balance	$ 1,666	$ 1,666	$ 1,956
Additions	10,029	11,670
Deductions	(10,319)	(9,423)	(10,300)
Ending balance		3,913	1,666
Contract liabilities:
Beginning balance	1,175	1,175	1,280
Additions	3,032	4,437
Deductions	$ (3,137)	(4,239)	(3,100)
Ending balance		1,373	$ 1,175
Amounts reclassified from unbilled revenue to accounts receivable		(9,400)
Amounts reclassified from deferred revenue to revenue		$ (4,200)

XML

Business Combinations and Asset Acquisition (Details) $ in Millions				1 Months Ended	12 Months Ended
	Dec. 01, 2017 USD ($)	Apr. 04, 2017	Jul. 31, 2015 USD ($) shares	Dec. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2020 country	Nov. 07, 2017 country
Class of Warrant or Right [Line Items]
Number of operating countries | country							50
Tax receivables agreement (TRA)
Class of Warrant or Right [Line Items]
Settlement of preexisting relationship, amount				$ 16.0
Settlement with related party, liability				27.9
Settlement with related party, deferred income taxes				$ 5.9
Tax receivables agreement (TRA) | Dow
Class of Warrant or Right [Line Items]
Rate of tax receivable agreement		50.00%
AgroFresh Inc.
Class of Warrant or Right [Line Items]
Cash consideration			$ 635.0
Tecnidex Fruit Protection, S.A.U.
Class of Warrant or Right [Line Items]
Cash consideration	$ 20.0					$ 2.3
Purchase price	$ 22.3
Percentage of voting interests acquired	75.00%
Tecnidex Fruit Protection, S.A.U. | Previously Reported
Class of Warrant or Right [Line Items]
Purchase price	$ 25.0
Common Stock | AgroFresh Inc.
Class of Warrant or Right [Line Items]
Number of shares issued as consideration (in shares) | shares			17,500,000
Level 3 | Tecnidex Fruit Protection, S.A.U.
Class of Warrant or Right [Line Items]
Contingent consideration	$ 0.7
Adjustment to purchase price allocation					$ 0.4
Tecnidex Fruit Protection, S.A.U. | Tecnidex Fruit Protection, S.A.U.
Class of Warrant or Right [Line Items]
Number of operating countries | country								18

XML

Related Party Transactions (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Jun. 13, 2020
Dow
Related party transactions
Outstanding payable to related party	$ 0.0	$ 100,000
Other Affiliates | Investment Agreement
Related party transactions
Percent of board required for right to designate directors			50.00%
Percent ownership interest required to designate directors			20.00%
Director | Mutal services agreement
Related party transactions
Expenses paid per service agreement	0
Dow | Dow | Ongoing costs of transition services agreement
Related party transactions
Payment amount for services	$ 40,000.00	$ 90,000.00

XML

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw material	$ 3,026	$ 3,401
Work-in-process	8,575	7,278
Finished goods	11,619	10,974
Supplies	1,224	968
Total inventories	$ 24,444	$ 22,621

XML

Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
VAT receivable	$ 7,627	$ 4,925
Prepaid income tax asset	5,349	3,616
Prepaid and other current assets	4,289	3,261
Total other current assets	$ 17,265	$ 11,802

XML

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 23,078		$ 23,078		$ 21,045
Less: accumulated depreciation	(9,803)		(9,803)		(7,868)
Total property and equipment, net	13,275		13,275		13,177
Depreciation expense	700	$ 600	1,900	$ 1,600
Buildings and leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,032		$ 7,032		6,508
Buildings and leasehold improvements | Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)			7 years
Buildings and leasehold improvements | Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)			20 years
Machinery & equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	11,953		$ 11,953		10,954
Machinery & equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)			1 year
Machinery & equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)			12 years
Furniture
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,944		$ 2,944		2,681
Furniture | Minimum
Property, Plant and Equipment [Line Items]
Useful life (years)			1 year
Furniture | Maximum
Property, Plant and Equipment [Line Items]
Useful life (years)			12 years
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,149		$ 1,149		$ 902

XML

Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Goodwill [Roll Forward]
Beginning balance	$ 6,323	$ 6,670
Foreign currency translation	282	(347)
Ending balance	$ 6,605	$ 6,323

XML

Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Other intangible assets:
Total intangible assets	$ 856,740		$ 856,740		$ 854,979
Accumulated Amortization	(257,504)		(257,504)		(222,618)
Impairment	0		0		(992)
Total	570,078		570,078
Total intangible assets, net	599,236		599,236		631,369
Amortization of intangibles	10,973	$ 11,754	$ 32,866	$ 35,136
Weighted average
Other intangible assets:
Useful life			14 years 7 months 6 days
Trade name
Other intangible assets:
Gross carrying amount, indefinite-lived	27,158		$ 27,158		27,200
Net, indefinite-lived intangible assets	27,158		27,158		27,200
Service provider network
Other intangible assets:
Gross carrying amount, indefinite-lived	2,000		2,000		2,000
Net, indefinite-lived intangible assets	2,000		2,000		2,000
Developed technology
Other intangible assets:
Gross carrying amount, finite-lived	798,240		798,240		758,760
Accumulated Amortization	(244,918)		(244,918)		(206,998)
Total	553,322		$ 553,322		551,762
Amortization of intangibles					34,000
Developed technology | Weighted average
Other intangible assets:
Useful life			14 years 9 months 18 days
In-process research and development
Other intangible assets:
Gross carrying amount, finite-lived	0		$ 0		39,000
Accumulated Amortization	0		0		(7,222)
Total	0		$ 0		31,778
In-process research and development | Weighted average
Other intangible assets:
Useful life			14 years
Customer relationships
Other intangible assets:
Gross carrying amount, finite-lived	18,551		$ 18,551		18,058
Accumulated Amortization	(3,548)		(3,548)		(2,993)
Total	15,003		$ 15,003		15,065
Customer relationships | Weighted average
Other intangible assets:
Useful life			12 years 1 month 6 days
Software
Other intangible assets:
Gross carrying amount, finite-lived	10,691		$ 10,691		9,861
Accumulated Amortization	(8,967)		(8,967)		(5,347)
Impairment	0		0		(992)
Total	1,724		$ 1,724		3,522
Software | Weighted average
Other intangible assets:
Useful life			1 year
Other
Other intangible assets:
Gross carrying amount, finite-lived	100		$ 100		100
Accumulated Amortization	(71)		(71)		(58)
Total	$ 29		$ 29		$ 42
Other | Weighted average
Other intangible assets:
Useful life			1 year 9 months 18 days

XML

Goodwill and Intangible Assets - Future Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Estimated annual amortization expense
2020 (remaining)	$ 12,045		$ 12,045
2021	41,730		41,730
2022	40,893		40,893
2023	40,791		40,791
2024	40,791		40,791
Thereafter	393,828		393,828
Total	570,078		570,078
Amortization of intangibles	$ 10,973	$ 11,754	$ 32,866	$ 35,136

XML

Other Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Right-of-use asset	$ 5,657	$ 6,599
Long term sales-type lease receivable	2,354	2,501
Other long term receivable	3,438	3,061
Total other assets	$ 11,449	$ 12,161

XML

Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued compensation and benefits	$ 7,111	$ 7,307
Accrued taxes	6,501	3,017
Lease liability	1,368	1,493
Accrued rebates payable	3,001	1,377
Insurance premium financing payable	1,151	1,000
Severance	218	444
Deferred revenue	1,373	1,175
Accrued interest	66	71
Interest rate swap	290	0
Other	5,586	8,466
Total accrued and other current liabilities	$ 26,665	$ 24,350

XML

Debt - Net of Unamortized Discounts and Deferred Financing Fees (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Jul. 27, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Less: Amounts due within one year	$ 3,316		$ 4,675
Total long-term debt due after one year	264,850		398,064
Loans Payable
Debt Instrument [Line Items]
Loans outstanding	2,184		750
Term loan
Debt Instrument [Line Items]
Loans outstanding	275,000	$ 403,800	405,875
Unamortized deferred issuance costs	$ (9,018)		$ (3,886)

XML

Debt - Narrative (Details)			1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 27, 2020 USD ($)	Jul. 31, 2015 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Jul. 31, 2020 EUR (€)	May 31, 2020 EUR (€)	Mar. 23, 2020 EUR (€)	Dec. 31, 2019 USD ($)	Jan. 31, 2019 USD ($)
Credit facility
Interest rate				7.25%		7.25%
Long term debt, gross				$ 277,184,000		$ 277,184,000
Amortization of deferred financing costs						$ 2,342,000	$ 2,032,000
Payment Protection Program, CARES Act
Credit facility
Forgiveness ineligibility, interest rate				100.00%		100.00%
Forgiveness ineligibility, payment deferral period						6 months
Interest rate swap
Credit facility
Cash flow hedge, gain (loss)			$ 4,000,000.0
Interest rate swap | Derivative financial instruments, liabilities
Credit facility
Mark-to-market adjustment				$ (300,000)		$ 400,000
Minimum
Credit facility
Commitment fee percentage	0.375%
Minimum | Payment Protection Program, CARES Act
Credit facility
Debt instrument, term						2 years
Maximum
Credit facility
Commitment fee percentage	0.50%
Maximum | Payment Protection Program, CARES Act
Credit facility
Debt instrument, term						5 years
Eurodollar
Credit facility
Margin of interest (as a percent)	6.25%
Eurodollar | Minimum
Credit facility
Margin of interest (as a percent)	6.00%
Eurodollar | Maximum
Credit facility
Margin of interest (as a percent)	6.25%
Base Rate
Credit facility
Margin of interest (as a percent)	5.25%
Term loan
Credit facility
Face amount	$ 275,000,000.0	$ 425,000,000.0		275,000,000.0		$ 275,000,000.0		€ 600,000	€ 300,000	€ 1,000,000.0
Interest rate								2.50%	2.20%	1.50%
Extinguishment of debt	107,100,000
Loan balance	403,800,000			275,000,000		275,000,000					$ 405,875,000
Modification of debt	296,700,000
Write off of deferred debt issuance cost	700,000
Unamortized issuance costs	1,900,000
Long term debt, gross				0		0
Debt issuance costs incurred	7,500,000	$ 12,900,000
Amortization of deferred financing costs				200,000	$ 600,000	1,400,000	$ 1,700,000
Deferred issuance costs, net				9,018,000		9,018,000					$ 3,886,000
Fair value of debt				267,400,000		267,400,000
Amortization per year (as a percent)		1.00%
Term loan | Restated Credit Facility
Credit facility
Debt issuance costs incurred	6,400,000
Amortization of deferred financing costs				300,000
Term loan | Existing Lenders
Credit facility
Write off of deferred debt issuance cost	4,400,000
Term loan | New Lenders
Credit facility
Debt issuance costs incurred	1,100,000
Revolving loan
Credit facility
Maximum borrowing available	25,000,000.0
Long term debt, gross				$ 0		$ 0
Debt issuance costs incurred	500,000	$ 1,300,000
Letter-of-credit sub-facility
Credit facility
Maximum borrowing available	10,000,000.0											$ 10,000,000.0
Credit Facility | Alternate base rate
Credit facility
Margin of interest (as a percent)		3.75%
Credit Facility | LIBOR
Credit facility
Margin of interest (as a percent)		4.75%
Variable rate base minimum (as a percent)		1.00%
Bridge Loan
Credit facility
Maximum borrowing available	$ 5,000,000.0

XML

Debt - Principal Repayments (Details) $ in Thousands	Sep. 30, 2020 USD ($)
Schedule of principal repayments under the Term Loan
2020 (remaining)	$ 815
2021	3,348
2022	3,390
2023	3,181
2024 and thereafter	266,450
Total	$ 277,184

XML

Leases - Additional Information on Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Lease, Cost [Abstract]
Operating leases	$ 662	$ 591	$ 1,916	$ 1,849
Short-term lease	6	5	182	52
Total lease expense	$ 668	$ 596	2,098	1,901
Cash payments included in operating cash flows			1,645	1,625
Right-of-use assets obtained in exchange for new lease			$ 769	$ 376
Weighted average discount rate	9.11%	9.33%	9.11%	9.33%
Weighted average remaining lease term in years	5 years 1 month 2 days	5 years 6 months 10 days	5 years 1 month 2 days	5 years 6 months 10 days

XML

Leases - Maturities of Lease Liabilities: Current Period (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Remainder of 2020	$ 485
2021	1,784	$ 1,939
2022	1,496	1,670
2023	1,228	1,509
2024 and thereafter	2,290
Total undiscounted lease payments	7,283	8,792
Less: present value adjustment	1,450	1,960
Operating lease liability	$ 5,833	$ 6,832

XML

Leases - Maturities of Lease Liabilities: Prior Period (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Leases [Abstract]
2020	$ 1,784	$ 1,939
2021	1,496	1,670
2022	1,228	1,509
2023		1,294
2024 and thereafter		2,380
Total undiscounted lease payments	7,283	8,792
Less: present value adjustment	1,450	1,960
Operating lease liability	$ 5,833	$ 6,832

XML

Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Liabilities, Other than Long-term Debt, Noncurrent [Abstract]
Lease liability	$ 4,465	$ 5,339
Other	1,524	1,907
Total other noncurrent liabilities	$ 5,989	$ 7,246

XML

Severance (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Compensation Related Costs [Abstract]
Severance expense	$ 0.4	$ 0.3	$ 0.5	$ 1.0
Severance liability, current	$ 0.2		$ 0.2		$ 0.4

XML

Series B Convertible Preferred Stock and Stockholders' Equity (Details)			1 Months Ended	3 Months Ended		5 Months Ended	9 Months Ended		12 Months Ended
	Jun. 13, 2020 $ / shares	Jul. 31, 2015 director shares	Jul. 27, 2020 shares	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2019 USD ($)	Dec. 31, 2020 USD ($) shares	Sep. 30, 2020 USD ($) vote $ / shares shares	Sep. 30, 2019 USD ($)	Dec. 31, 2015 shares	Jun. 25, 2020 shares	Dec. 31, 2019 USD ($) $ / shares shares	Feb. 28, 2014 shares
Class of Warrant or Right [Line Items]
Authorized common stock (in shares)				400,000,000			400,000,000				400,000,000
Par value of common stock (in dollars per share) | $ / shares				$ 0.0001			$ 0.0001				$ 0.0001
Number of votes entitled by holders of common stock for each share of common stock | vote							1
Common stock, shares outstanding (in shares)				52,393,579			52,393,579				51,178,146
Number of shares issuable upon exercise of warrants (in shares)				15,983,072			15,983,072
Exercise price (in dollars per share) | $ / shares				$ 11.50			$ 11.50
Number of warrants outstanding (in shares)				15,983,072			15,983,072
Preferred stock, par value (in dollars per share) | $ / shares				$ 0.0001			$ 0.0001				$ 0.0001
Rohm and Haas
Class of Warrant or Right [Line Items]
Number of shares of Series A Preferred Stock issued as condition to consummation of business combination (in shares)		1
Number of directors preferred stockholder is entitled to appoint if minimum ownership percentage of common stock is maintained | director		1
Minimum percentage of outstanding shares of voting and non-voting common stock to be held to entitle preferred stockholder to appoint director		10.00%
Series B Convertible Stock
Class of Warrant or Right [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares				$ 0.0001			$ 0.0001				$ 0.0001
Dividends | $				$ 4,400,000	$ 0		$ 4,400,000	$ 0
Accrued dividends | $				$ 0			$ 0				$ 0
Preferred stock, convertible, conversion price (in dollars per share) | $ / shares	$ 5.00
Series B Convertible Stock | Maximum
Class of Warrant or Right [Line Items]
Preferred stock issued (in shares)				30,440,000			30,440,000				0
Series B Convertible Stock | Paid In-Kind
Class of Warrant or Right [Line Items]
Dividends | $				$ 2,200,000			$ 2,200,000
Series B Convertible Stock | Cash
Class of Warrant or Right [Line Items]
Dividends | $				$ 2,200,000			$ 2,200,000
Public warrants
Class of Warrant or Right [Line Items]
Number of warrants outstanding (in shares)												9,823,072
Number of warrants repurchased (in shares)									1,201,928
Private placement warrants
Class of Warrant or Right [Line Items]
Number of warrants outstanding (in shares)												6,160,000
Dividend rate increase	2.00%
Private placement warrants | Dividends Within First Anniversary
Class of Warrant or Right [Line Items]
Percentage payable in cash	50.00%
Percentage payable in kind	50.00%
Private placement warrants | Dividends After First Anniversary
Class of Warrant or Right [Line Items]
Percentage payable in cash	50.00%
Percentage payable in kind	37.50%
Percentage payable in cash or kind	12.50%
Private placement warrants | Convertible Preferred Stock | Forecast
Class of Warrant or Right [Line Items]
Sale of stock, consideration received on transaction | $						$ 150,000,000
Private placement warrants | Series B Convertible Stock
Class of Warrant or Right [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
Liquidation preference (in dollars per share) | $ / shares	1,000
Private placement warrants | Series B Convertible Stock | Forecast
Class of Warrant or Right [Line Items]
Preferred stock issued (in shares)						150,000
Convertible preferred stock, shares issued upon conversion (in shares)						150,000
Cumulative dividend rate						16.00%
Private placement warrants | Series B-1 Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Preferred stock issued (in shares)			150,000
Preferred stock, par value (in dollars per share) | $ / shares	0.0001
Liquidation preference (in dollars per share) | $ / shares	1,000
Private placement warrants | Series B-1 Convertible Preferred Stock | Forecast
Class of Warrant or Right [Line Items]
Cumulative dividend rate						16.00%
Private placement warrants | Series B-2 Convertible Preferred Stock
Class of Warrant or Right [Line Items]
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001
ATM Facility
Class of Warrant or Right [Line Items]
Authorized common stock (in shares)										30,000,000

XML

Series B Convertible Preferred Stock and Stockholders' Equity - Temporary Equity (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($) shares
Series B Convertible Stock
Temporary Equity [Line Items]
Balance at beginning of period (in shares) | shares	0
Balance at beginning of period	$ 0
Issuance of preferred stock (in shares) | shares	150,000
Issuance of preferred stock	$ 150,000
Exchange to Series B preferred stock (in shares) | shares	0
Exchange to Series B preferred stock	$ 0
Issuance-related expenses	$ (11,516)
Additional preferred shares (in shares) | shares	0
Additional preferred shares	$ 2,200
Balance at end of period (in shares) | shares	150,000
Balance at end of period	$ 140,684
Series B-1 Convertible Preferred Stock
Temporary Equity [Line Items]
Balance at beginning of period (in shares) | shares	0
Balance at beginning of period	$ 0
Issuance of preferred stock (in shares) | shares	150,000
Issuance of preferred stock	$ 150,000
Exchange to Series B preferred stock (in shares) | shares	(150,000)
Exchange to Series B preferred stock	$ (150,000)
Issuance-related expenses	$ 0
Additional preferred shares (in shares) | shares	0
Additional preferred shares	$ 0
Balance at end of period (in shares) | shares	0
Balance at end of period	$ 0
Series B-2 Convertible Preferred Stock
Temporary Equity [Line Items]
Balance at beginning of period (in shares) | shares	0
Balance at beginning of period	$ 0
Issuance of preferred stock (in shares) | shares	150,000
Issuance of preferred stock	$ 0
Exchange to Series B preferred stock (in shares) | shares	(150,000)
Exchange to Series B preferred stock	$ 0
Issuance-related expenses	$ 0
Additional preferred shares (in shares) | shares	0
Additional preferred shares	$ 0
Balance at end of period (in shares) | shares	0
Balance at end of period	$ 0

XML

Stock-based Compensation - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2019	Jul. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized (in shares)						7,150,000
Stock-based compensation expense	$ 0.9	$ 1.0	$ 2.7	$ 2.1
Share-based compensation, nonvested awards, compensation cost not yet recognized	$ 5.3		$ 5.3
Period for recognition of compensation on unvested stock option (in years)			1 year 10 months 24 days
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized (in shares)					500,000
Shares issued (in shares)			253,042

XML

Earnings Per Share - Schedule of Weighted Average Common Shares Outstanding (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Basic weighted-average common shares outstanding (in shares)	51,001,852	50,227,590	50,765,829	50,138,835
Effect of dilutive options, performance stock units and restricted stock (in shares)	0	60,714	0	0
Dilute weighted-average shares outstanding (in shares)	51,001,852	50,288,304	50,765,829	50,138,835

XML

Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stock options
Earnings Per Share [Line Items]
Antidilutive securities (in shares)	799,570	1,028,583	804,267	949,987
Warrants | Private placement warrants
Earnings Per Share [Line Items]
Antidilutive securities (in shares)	2,075,652	6,160,000	4,788,613	6,160,000
Warrants | Public warrants
Earnings Per Share [Line Items]
Antidilutive securities (in shares)	3,309,948	9,823,072	7,636,184	9,823,072
Non-Director | Restricted stock
Earnings Per Share [Line Items]
Antidilutive securities (in shares)	1,811,016	749,510	1,079,151	624,930

XML

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Valuation allowance	$ 24.7		$ 24.7
Effective tax rate (as a percent)	743.90%	214.00%	(111.70%)	28.20%

XML

Segment Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) segment	Sep. 30, 2019 USD ($)
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of operating segments | segment			2
Number of reportable segments | segment			2
Net sales	$ 52,770	$ 48,972	$ 105,775	$ 109,095
Gross Profit	39,259	35,080	77,283	77,579
AgroFresh Core
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Net sales	49,343	45,917	94,723	96,272
Gross Profit	38,283	34,182	73,080	72,679
Tecnidex
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Net sales	3,427	3,055	11,052	12,823
Gross Profit	$ 976	$ 898	$ 4,203	$ 4,900

XML

Commitment and Contingencies (Details) $ in Millions		1 Months Ended
	Oct. 14, 2019 USD ($)	Jul. 31, 2020 numberOfLawsuits
Loss Contingencies [Line Items]
Number of class action lawsuits filed | numberOfLawsuits		3
Unfavorable Regulatory Action
Loss Contingencies [Line Items]
Damages awarded | $	$ 31.1

XML

Fair Value Measurements - Financial Instruments Measured on a Recurring Basis (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Phantom Stock Units
Financial instruments measured at fair value on a recurring basis
Expected dividends	$ 0
Minimum | Phantom Stock Units
Financial instruments measured at fair value on a recurring basis
Grant date fair value (in dollars per share)	$ 1.70
Risk-free interest rate	0.27%
Expected life (years)	2 years 8 months 15 days
Estimated volatility factor (percent)	65.10%
Maximum | Phantom Stock Units
Financial instruments measured at fair value on a recurring basis
Grant date fair value (in dollars per share)	$ 7.28
Risk-free interest rate	2.39%
Expected life (years)	2 years 9 months
Estimated volatility factor (percent)	69.90%
Recurring
Financial instruments measured at fair value on a recurring basis
Fair value of liability	$ 584,000	$ 123,000
Recurring | Level 1
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Recurring | Level 2
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Recurring | Level 3
Financial instruments measured at fair value on a recurring basis
Fair value of liability	584,000	123,000
Liability-classified stock compensation | Recurring
Financial instruments measured at fair value on a recurring basis
Fair value of liability	294,000	218,000
Liability-classified stock compensation | Recurring | Level 1
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Liability-classified stock compensation | Recurring | Level 2
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Liability-classified stock compensation | Recurring | Level 3
Financial instruments measured at fair value on a recurring basis
Fair value of liability	294,000	218,000
Derivative financial instruments, liabilities | Recurring | Interest rate swap
Financial instruments measured at fair value on a recurring basis
Fair value of liability	290,000	(95,000)
Derivative financial instruments, liabilities | Recurring | Level 1 | Interest rate swap
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Derivative financial instruments, liabilities | Recurring | Level 2 | Interest rate swap
Financial instruments measured at fair value on a recurring basis
Fair value of liability	0	0
Derivative financial instruments, liabilities | Recurring | Level 3 | Interest rate swap
Financial instruments measured at fair value on a recurring basis
Fair value of liability	$ 290,000	$ (95,000)

XML

Fair Value Measurements - Changes of Level 3 Financial Instruments (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020 USD ($)	Sep. 30, 2020 USD ($)
Level 3
Financial instruments measured at Level 3 fair value on a recurring basis rollforward
Balance, beginning period		$ 123
Stock compensation activity		76
Mark-to-market adjustment		385
Balance, ending period	$ 584	584
Liability-classified stock compensation | Level 3
Financial instruments measured at Level 3 fair value on a recurring basis rollforward
Balance, beginning period		218
Stock compensation activity		76
Mark-to-market adjustment		0
Balance, ending period	294	294
Derivative financial instruments, liabilities | Interest rate swap
Financial instruments measured at Level 3 fair value on a recurring basis rollforward
Mark-to-market adjustment	300	(400)
Derivative financial instruments, liabilities | Interest rate swap | Level 3
Financial instruments measured at Level 3 fair value on a recurring basis rollforward
Balance, beginning period		(95)
Stock compensation activity		0
Mark-to-market adjustment		385
Balance, ending period	290	290
Term loan
Financial instruments measured at Level 3 fair value on a recurring basis
Fair value of debt	$ 267,400	$ 267,400